Announcements
10 April 2024
Meet Us at the 48th FEBS Congress, 29 June–3 July 2024, Milan, Italy
9 April 2024
Cancers | Editor’s Choice Articles from 2022–2023 Related to Cancer Causes, Screening and Diagnosis
8 April 2024
Meet Us at the 2024 ASCO Annual Meeting, 31 May–4 June 2024, Chicago, IL, USA
2 April 2024
Join Us for the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), 10–13 June 2024, Rotterdam, the Netherlands
2 April 2024
MDPI Insights: The CEO's Letter #10 - South Korea, IWD, U2A, Japan
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Stefan Tochev (CEO, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), during media meetings at Prain Agency office in Seoul, South Korea.
Visit to Seoul, South Korea
During my recent visit to South Korea, I had the privilege of meeting various stakeholders, including representatives of government, research institutions, and academia, to understand their needs and communicate MDPI’s commitment to accessible science. Accompanied by my colleagues Dr. Giulia Stefenelli and Dr. Jisuk Kang, I engaged with the Korean scientific community, which is increasingly embracing open access (OA).
As the leading OA publisher in South Korea, MDPI is trusted by local authors and in 2023 enjoyed an approximately 30% share of the OA market. South Korea ranks sixth globally for MDPI in terms of research papers submitted and published.
MDPI and South Korea by Numbers
As at 30 March, over 76,000 MDPI articles have been authored by individuals affiliated with Korean institutions. We have over 1,800 active editorial board members (EBMs) from South Korea, with more than 880 EBMs having an H-index between 26 and 50, including 10 serving as Chief Editors.
“South Korea is the sixth-largest contributor to our total publications”
Over the past five years (2019–2023), nearly 120,000 authors affiliated with South Korean institutes have published with MDPI. Specifically in 2023, we received approximately 25,000 submissions from South Korean authors, publishing close to 13,000 articles, resulting in a rejection rate of 47.4%, which is not far below MDPI’s overall rejection rate of 56.4% in 2023.
Institutional Partnerships with South Korea
I am pleased to share that MDPI has more than 825 institutional partnerships worldwide, with 12 in South Korea, including Kyunghee University, Chung-Ang University, and Inha University, among others.
Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), and Stefan Tochev (CEO, MDPI) fielding media questions at Prain PR Agency office in Seoul, South Korea.
Over the past three years (2021–2023), we have had some of the most prestigious academic universities ranked among the top 10 Korean institutions publishing with MDPI. Seoul National University had the highest number of publications with MDPI during those three years, publishing nearly 6,000 papers. Universities such as Korea University and Yonsei University also rank among the top 10 Korean institutions publishing with MDPI.
MDPI Hosts Seminar for Academia and Media
As the world’s leading OA publisher, MDPI is actively democratizing science. This is reflected in the seminars we hosted on 21 March to address questions about our editorial processes and ethical standards. The visit garnered media coverage, reflecting our mission to providing high-quality services and fostering open dialogue in the community.
“MDPI is actively democratizing science”
MDPI in the News
Stefan Tochev (CEO, MDPI) leading a seminar on OA and MDPI at Prain PR Agency office in Seoul, South Korea.
Media coverage generated by our visit to Seoul included the following stories:
“Open access is an unstoppable trend…it will lead the development of the knowledge ecosystem.”
I greatly appreciate the contributions of everyone who took the time to meet with us, share their stories, and hold us accountable for continuing to provide high-quality publishing services while identifying areas for improvement. I am also excited to announce that we have opened an MDPI office in Seoul and will release a press release on MDPI.com, with details, by the end April 2024. The purpose of the office is to establish a local presence to connect with and support the South Korean academic community through institutional partnerships, conferences, author workshops, stakeholder communications, and more.
Impactful Research
Featured Articles on Women’s Leadership and Healthcare
In celebration of International Women’s Day (8 March 2024), MDPI curated a collection of research articles on various topics, including women’s leadership, reproductive health, preventive healthcare, and a selection of articles from our journal Women.
Women’s Leadership
- Women Entrepreneurship and Sustainable Development: Bibliometric Analysis and Emerging Research Trends
Sustainability 2022, 14, 9160. https://doi.org/10.3390/su14159160 - Refugee Women Business Mentors: New Evidence for Women’s Empowerment
Sustainability 2022, 14, 9154. https://doi.org/10.3390/su14159154 - Women and Leadership in Higher Education: A Systematic Review
Soc. Sci. 2023, 12, 555. https://doi.org/10.3390/socsci12100555 - Understanding Needs and Potentials for Gender-Balanced Empowerment and Leadership in Climate Change Adaptation and Mitigation in Africa
Sustainability 2022, 14, 9410. https://doi.org/10.3390/su14159410 - Challenges Women Experience in Leadership Careers: An Integrative Review
Merits 2023, 3, 366-389. https://doi.org/10.3390/merits3020021
Women’s Reproductive Health
- Recreational Female Athletes’ Understanding of and Perceived Impact of the Menstrual Cycle on Physical Performance, Mood, and Sleeping Behaviour
Women 2023, 3, 445-456. https://doi.org/10.3390/women3030034 - Difficulties in Adaptation of the Mother and Newborn via Cesarean Section versus Natural Birth—A Narrative Review
Life 2023, 13, 300. https://doi.org/10.3390/life13020300 - The Main Theories on the Pathogenesis of Endometriosis
Int. J. Mol. Sci. 2023, 24, 4254. https://doi.org/10.3390/ijms24054254
Women’s Preventive Healthcare
- Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Int. J. Mol. Sci. 2023, 24, 3140. https://doi.org/10.3390/ijms24043140 - Assessing Barriers Encountered by Women in Cervical Cancer Screening and Follow-Up Care in Urban Bolivia, Cochabamba
Healthcare 2022, 10, 1604. https://doi.org/10.3390/healthcare10091604 - Updates on HPV Vaccination
Diagnostics 2023, 13, 243. https://doi.org/10.3390/diagnostics13020243
Featured Articles in MDPI Journal Women
Below are a few articles from Women, our journal focused on women’s health, the social determinants of health, and the healthcare system that serves women. The aim of Women is to encourage academics to publish their experimental and theoretical results in detail, to aid reproducibility, and in an engaging style, to aid comprehensibility.
- Premenstrual Syndrome and Exercise: A Narrative Review
Women 2023, 3, 348-364. https://doi.org/10.3390/women3020026 - Increasing Awareness of the Human Papillomavirus (HPV) Vaccine for Women 18–45 Years of Age
Women 2023, 3, 365-373. https://doi.org/10.3390/women3030027 - Addressing Women’s Needs with Human Immunodeficiency Virus (HIV) and Enhancing the Visibility of Pharmacists in the Public Health Arena
Women 2022, 2, 346-352. https://doi.org/10.3390/women2040032
Inside MDPI
Championing Women’s Healthcare and Access to Healthcare Information
MDPI colleagues from our offices joined in celebrating #IWD2024. In doing so, we emphasized key missions that encompass:
- Empowering women to assume leadership and decision-making roles in both business and science.
- Helping women and girls make informed decisions about their health.
- Recruiting and developing female talent and fostering inclusive workplace environments.
“We are thrilled to recognize the accomplishments of women scientists”
I am proud to see our colleagues enthusiastically supporting the International Women’s Day call to ‘Inspire Inclusion!’ The heart-hands in the collage below symbolize our appreciation of the achievements of women researchers and the recognition of the trailblazers who have courageously made a mark on societies past and present.
We are thrilled to recognize the accomplishments of women scientists through our many MDPI awards and by highlighting success stories. As inspirational figures, female scientists are paving the way for the next generation of women aspiring to pursue careers in engineering, life sciences, computing, and various other STEM fields.
“I consider myself lucky because I work with incredibly talented women who inspire me every day.”
– Dr. Alessandra Pasut, Winner of MDPI's ‘Biology 2023 Young Investigator Award’
“It’s really important to find a supportive and enabling environment in which to do your science; it would have a big impact on you as a person and on your scientific outputs.”
– Dr. Rhea Longley, Winner of the ‘Pathogens 2023 Young Investigator Award’
Open-access publishing, in particular, allows early-career women researchers to share their work more widely, potentially attracting mentorship opportunities and collaborations. This support is crucial for career development and advancement.
Coming Together for Science
MDPI Joins United2Act in Collective Fight to Stop Paper Mills
In my February 2024 CEO Letter, I highlighted some of our recent initiatives aimed at bolstering our commitment to research integrity, including joining the STM Integrity Hub and expanding our Research Integrity and Publication Ethics team (RIPE). Continuing our efforts in coming together for science, I am pleased to share our participation in the United2Act initiative.
The text below is taken from our official announcement:
United2Act represents an international group of stakeholders in the publishing industry committed to addressing the collective challenge posed to research integrity by paper mills.
Scientists and academic publishers have increasingly noted the alarming proliferation of paper mills, recognized as fraudulent entities seeking to manipulate the publication process for financial profit. These entities engage in fraudulent practices such as falsifying or fabricating data, selling co-authorship of fake papers, manipulating peer review, and including inappropriate citations. These actions pose a significant threat to the integrity of the scholarly record, prompting widespread concern among those involved in the academic community.
MDPI has been actively contributing to combat the undermining of the scientific record. Our editors employ a set of tools to detect potential ethical breaches within a manuscript and to tackle the issue of fake papers.
United2Act’s consensus statement is the outcome of a virtual summit held in May 2023. It involved the participation of research bodies, publishers, researchers/sleuths, universities, and publishing infrastructure from 15 countries and resulted in a Consensus Statement outlining five key areas of action for all stakeholders:
- Education and awareness
- Improve post-publication corrections
- Facilitate and organise research on paper mills
- Enable the development of trust markers
- Facilitate dialogue between stakeholders
MDPI is committed to promoting transparency and integrity in scholarly publishing and is continuing to work closely with the scientific community toward this goal.
Closing Thoughts
Left to right: Ryo Hirayama (Marketing Specialist, MDPI), Takashi Sasabe (Marketing Specialist, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Stefan Tochev (CEO, MDPI), at MDPI’s office in Tokyo, Japan.
Visit to Tokyo and Kyoto, Japan
In March, I had the opportunity to visit our Tokyo office and engage with stakeholders in Tokyo and Kyoto. During the visit, I also recorded a video message to welcome Japanese scholars working with MDPI and to highlight our operations in Japan.
We held meetings with Editors-in-Chief, librarians, scholars, and external consultants to gather feedback on our efforts to enhance our reputation and explore additional steps we can take in that direction. Japan's rich cultural heritage, characterized by tradition, respect, and formality, provided valuable insights into meeting the publishing needs specific to Japan.
Japan’s Open Access statistics
Over the years, we have seen a shift from subscription-only to gold OA publishing in Japan, despite the lack of an official mandate. Here are some statistics:
- 2012: 68% of articles were subscription-only, 6% were green Open Access, and 8% were gold Open Access.
- 2016: 55% of articles were subscription-only, 6% were green Open Access, and 20% were gold Open Access.
- 2022: 43% of articles were subscription-only, 7% were green Open Access, and 39% were gold Open Access.
To learn more about the history of OA in Japan as well as about future trends, please read this blog post.
“Japan is the ninth-largest contributor to our total publications”
Left to right: Stefan Tochev (CEO, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI) visiting Kyoto University in Kyoto, Japan.
MDPI and Japan by Numbers
As at 1 April, over 50,000 MDPI articles have been authored by scholars affiliated with Japanese institutions, making the country the ninth-largest contributor to our total publications. Over the past three years (2020–2023), nearly 90,000 authors affiliated with Japanese institutes have published with MDPI, and we have collaborated with over 4,600 Guest Editors from Japan.
In 2023, we published over 8,200 papers from authors associated with Japanese institutions. MDPI collaborates with 41 institutional partnerships in Japan, including the University of Tokyo, Hokkaido University, and Nagoya University. We have over 2,100 active EBMs from Japan, more than 1,050 EBMs having an H-index between 26 and 50, including 13 serving as Editors-in-Chief.
General Feedback – a side note
A general takeaway from our discussions with stakeholders from around the world is that negative perceptions of MDPI often stem from misinformation, misconceptions, or misunderstandings about MDPI and our practices. While we acknowledge our mistakes and work diligently to address them, maintaining a strong editorial procedure and robust peer-review process, I find that educating stakeholders about our how we do what we do and our ongoing improvements tends to help shift opinions.
That said, we recognize the importance of addressing individual concerns. We take feedback seriously and are continuously working to get better while not compromising the core principles that millions of authors appreciate about MDPI.
Chief Executive Officer
MDPI AG
1 April 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Pathophysiology”
1 April 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Pathophysiology
We are delighted to share some highly viewed papers on cancer pathophysiology that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
“Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma”
by Rosa Maria Paragliola, Francesco Torino, Agnese Barnabei, Giovanni Maria Iannantuono, Andrea Corsello, Pietro Locantore and Salvatore Maria Corsello
Cancers 2023, 15(2), 529; https://doi.org/10.3390/cancers15020529
Available online: https://www.mdpi.com/2072-6694/15/2/529
“Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease—From Early Cancer Detection to Individualized Cancer Treatment”
by Paul David, Anke Mittelstädt, Dina Kouhestani, Anna Anthuber, Christoph Kahlert, Kai Sohn and Georg F. Weber
Cancers 2023, 15(7), 1924; https://doi.org/10.3390/cancers15071924
Available online: https://www.mdpi.com/2072-6694/15/7/1924
“RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma”
by Erdal Tasci, Sarisha Jagasia, Ying Zhuge, Mary Sproull, Theresa Cooley Zgela, Megan Mackey, Kevin Camphausen and Andra Valentina Krauze
Cancers 2023, 15(10), 2672; https://doi.org/10.3390/cancers15102672
Available online: https://www.mdpi.com/2072-6694/15/10/2672
“Biosynthesis and Significance of Fatty Acids, Glycerophospholipids, and Triacylglycerol in the Processes of Glioblastoma Tumorigenesis”
by Jan Korbecki, Mateusz Bosiacki, Izabela Gutowska, Dariusz Chlubek and Irena Baranowska-Bosiacka
Cancers 2023, 15(7), 2183; https://doi.org/10.3390/cancers15072183
Available online: https://www.mdpi.com/2072-6694/15/7/2183
“Classification of Pancreatic Ductal Adenocarcinoma Using MALDI Mass Spectrometry Imaging Combined with Neural Networks”
by Frederic Kanter, Jan Lellmann, Herbert Thiele, Steve Kalloger, David F. Schaeffer, Axel Wellmann, and Oliver Klein
Cancers 2023, 15(3), 686; https://doi.org/10.3390/cancers15030686
Available online: https://www.mdpi.com/2072-6694/15/3/686
“Challenges in Pharmacological Intervention in Perilipins (PLINs) to Modulate Lipid Droplet Dynamics in Obesity and Cancer”
by Victória Bombarda-Rocha, Dany Silva, Allal Badr-Eddine, Patrícia Nogueira, Jorge Gonçalves and Paula Fresco
Cancers 2023, 15(15), 4013; https://doi.org/10.3390/cancers15154013
Available online: https://www.mdpi.com/2072-6694/15/15/4013
Special Issues:
|
“Lipids and Small Metabolites in Cancer” |
“The Role of Tunneling Nanotubes in Intercellular Communication and Pathophysiology of Cancer” |
 |
 |
|
“Advances in Breast Cancer: From Pathogenesis to Therapy” |
“New Insights in Molecular Pathology of Cancers: From Biomarkers to Therapeutic Targets” |
 |
 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
29 March 2024
Meet Us at the 20th Annual International Conference of the Metabolomics Society (Metabolomics 2024), 16–20 June 2024, Osaka, Japan
27 March 2024
Cancers | Selected Papers in 2023 in the Section “Infectious Agents and Cancer”
27 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Drug Development”
20 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Epidemiology and Prevention”
19 March 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Pediatric Oncology
We are delighted to share some highly viewed papers on pediatric oncology that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
“Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience”
by Adriana Trabal, Amber Gibson, Jiasen He, David McCall, Michael Roth, Cesar Nuñez, Miriam Garcia, Meredith Buzbee, Laurie Toepfer, Aram Bidikian et al.
Cancers 2023, 15(7), 1983; https://doi.org/10.3390/cancers15071983
Available online: https://www.mdpi.com/2072-6694/15/7/1983
“Advancing Pediatric Oncology Rehabilitation: Survey Findings of Health Professionals’ Perceptions of Barriers to Care and a Framework for Action”
by Paula A. Ospina, Lesley Pritchard, David D. Eisenstat and Margaret L. McNeely
Cancers 2023, 15(3), 693; https://doi.org/10.3390/cancers15030693
Available online: https://www.mdpi.com/2072-6694/15/3/693
“Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma”
by Silvia Pomella, Sara G. Danielli, Rita Alaggio, Willemijn B. Breunis, Ebrahem Hamed, Joanna Selfe, Marco Wachtel, Zoe S. Walters, Beat W. Schäfer, Rossella Rota et al.
Cancers 2023, 15(10), 2823; https://doi.org/10.3390/cancers15102823
Available online: https://www.mdpi.com/2072-6694/15/10/2823
“Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma”
by Yujia Chen, Chao Zhao, Shenglun Li, Jun Wang and Hongwei Zhang
Cancers 2023, 15(3), 602; https://doi.org/10.3390/cancers15030602
Available online: https://www.mdpi.com/2072-6694/15/3/602
“Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature”
by Louisa Taylor, Philippa K. Wade, James E. C. Johnson, Macha Aldighieri, Sonia Morlando, Gianpiero Di Leva, Ian D. Kerr and Beth Coyle
Cancers 2023, 15(4), 1086; https://doi.org/10.3390/cancers15041086
Available online: https://www.mdpi.com/2072-6694/15/4/1086
“Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma”
by Daniela Di Carlo, Julia Chisholm, Anna Kelsey, Rita Alaggio, Gianni Bisogno, Veronique Minard-Colin, Meriel Jenney, Raquel Dávila Fajardo, Johannes H. M. Merks, Janet M. Shipley et al.
Cancers 2023, 15(6), 1644; https://doi.org/10.3390/cancers15061644
Available online: https://www.mdpi.com/2072-6694/15/6/1644
 |
 |
| “Pediatric Cancer: From Molecular Targets to Effective Therapies” Edited by: Dr. Raushan Kurmasheva Submission deadline: 29 February 2024 |
“Pediatric and AYA Sarcoma and Intermediate Tumors” Edited by: Prof. Dr. Yoshihiro Nishida Submission deadline: 25 March 2024 |
 |
 |
| “Updates on Management and Clinical Trials in Pediatric Oncology” Edited by: Dr. Atsushi Makimoto, Dr. Yasuhiro Okamoto and Dr. Yuki Yuza Submission deadline: 15 April 2024 |
“Challenges and New Strategies in the Management of Pediatric Brain Tumors” Edited by: Dr. Semi B. Harrabi and Prof. Dr. Adilia Hormigo Submission deadline: 31 May 2024 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
19 March 2024
Cancers | Selected Papers in 2023 in the Section “Pediatric Oncology”
14 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Immunology and Immunotherapy”
13 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Biomarkers”
13 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Causes, Screening and Diagnosis”
13 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Survivorship and Quality of Life”
13 March 2024
Cancers | Selected Papers in 2023 in the Section “Systematic Review or Meta-Analysis in Cancer Research”
13 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Therapy”
11 March 2024
Cancers | Selected Papers in 2023 in the Section “Molecular Cancer Biology”
11 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Metastasis”
11 March 2024
Cancers | Colorectal Cancer Awareness Month
9 March 2024
Cancers | Selected Papers in 2023 in the Section “Clinical Research of Cancer”
8 March 2024
Cancers | Myeloma Awareness Month
8 March 2024
Cancers | Selected Papers in 2023 in the Section “Methods and Technologies Development”
7 March 2024
Cancers | Selected Papers in 2023 in the Section “Cancer Informatics and Big Data”
6 March 2024
Cancers | Selected Papers in 2023 in the Section “Tumor Microenvironment”
6 March 2024
Cancers | Kidney Cancer Awareness Month
4 March 2024
MDPI Insights: The CEO's Letter #9 - Romania, Research Integrity, Viruses
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Reka Kovacs (Deputy Office Manager, MDPI), Stefan Tochev (CEO, MDPI), and Sandra Ana Spatariu (Office Manager, MDPI) at the MDPI office in Cluj, Romania.
MDPI’s Impact on Romania
In February, I visited our office in Cluj, Romania. I worked closely with our senior office managers and various teams, including the departments of training, marketing and conferences, as well as our journal relationship specialists, reviewing our service to the local scholarly community. During the visit, I also met with representatives from Babes-Bolyai University and the Technical University of Cluj-Napoca. Our multifunctional Romanian office plays an important role in supporting our collaborations with the local market as well as helping to meet MDPI’s overall business needs.
Feedback and strategy meeting with a group of MDPI’s Journal Relationship Specialists at the MDPI office in Cluj, Romania.
With 22,436 articles, Romania ranks as a top 20 contributing country to MDPI’s total number of papers published as at 28 February 2024. This highlights the importance of our collaboration with Romanian-affiliated authors and the growing opportunity to support their publishing needs. MDPI is one of the few academic publishers with a significant presence in Romania, boasting over 360 colleagues across our offices in Bucharest and Cluj. We are also proud to hire colleagues from local institutions to launch their careers within publishing.
Romania ranks as a top 20 contributing country.
The Numbers: 2019–2023
MDPI has seen a healthy increase in submissions from Romanian authors over the past three years, from 8,439 in 2021 to 11,866 by end of 2023, with most submissions going to journals such as Sustainability, Medicina, Diagnostics, IJMS, Applied Sciences, and JCM. From 2019 to 2023, MDPI published articles from 32,145 authors affiliated with Romanian institutions. Over those years, we have worked with Romanian Guest Editors on nearly 3,000 occasions to support their Special Issue and Topical collections.
With more than 300 Editorial Board Members from Romania, 34 appear on the board of Mathematics, 27 on Materials, 19 on Polymers, 18 on Coatings, and 16 on Molecules, while three serve as Section Editors-in-Chief (SEiC) on our journals Coatings (3.4 IF, 4.6 Citescore), Magnetochemistry (2.7 IF, 3.5 Citescore), and Chemosensors (4.2 IF, 3.9 Citescore).
Institutional Open Access Programs
Our commitment to working with institutions is evident in Romania, where we have established eight Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Bucharest, the University of Medicine and Pharmacy Cluj-Napoca, and most recently the National Institute for Laser, Plasma and Radiation Physics.
Our growth and presence in Romania are a true testament.
We also have IOAP agreements with Babes-Bolyai University and the Technical University of Cluj-Napoca, where I had the opportunity to meet senior stakeholders during my visit. Below are a few photos capturing our meeting with Prof. Radu Silaghi-Dumitrescu (Head of Faculty of Chemistry, Babes-Bolyai University) at the MDPI office in Cluj, Romania, along with a photo from our meeting with Vice Deans Nicoleta Cobarzan, Nicoleta Ilies, and Hoda Gavril, from the faculty of Civil Engineering at the Technical University of Cluj, Romania.
Our growth and presence in Romania are a true testament to the service we provide to the scholarly community and the relationships we foster in that region. We look forward to continuing to support Romanian scholars and institutions by providing a valuable and trusted experience with MDPI, the leader in open access publishing.
Impactful Research
MDPI Joins the STM Integrity Hub
MDPI has long been a supporter and partner of STM, with our involvement ranging from sponsoring and attending events to helping organize event programs. By joining the STM Integrity Hub, we aim to further our commitment to STM initiatives aimed at safeguarding the integrity of science.
“We are pleased to welcome MDPI as the 35th organisation participating in the Hub. This expansion is critical, as every new member enhances our capacity to prevent fraudulent submissions from entering the academic record.”
Joris van Rossum, Director of Research Integrity, STM
MDPI operates in full alignment with STM Integrity Hub's values of shared data and experiences. We strongly believe in collaboration and open exchange for the purposes of creating a holistic approach to support research integrity at MDPI itself and across the entire academic publishing industry. The Integrity Hub is an excellent example of how publishers can come together to jointly address industry-wide challenges related to research integrity, such as manuscripts that breach research integrity standards and paper-mills.
I look forward to our Research Integrity and Publication Ethics Team (RIPE) team immersing themselves in this initiative, exchanging information, best practices, and tools for the benefit of the entire scholarly ecosystem. We believe that ethical publishing standards should be implemented across the board, and we aim to be rigorous in our approach, addressing research integrity issues and improving the impact of published research.
Inside MDPI
MDPI Expands Research Integrity and Publication Ethics Team (RIPE)
In addition to external collaborations and joint initiatives aimed at further strengthening our commitment to research integrity, we are also enhancing our internal efforts. This includes improving our processes and guidelines and expanding our teams and departments to ensure quality assurance throughout our publishing process.
We are pleased to announce the expansion of our Research Integrity and Publication Ethics Team (RIPE) at MDPI. The RIPE team has recently welcomed new colleagues, each bringing unique skills and a personal commitment to prioritize ethical considerations in all our work.
The demand for research integrity and high ethical standards in academic publishing is steadily rising across our industry. Our expanded RIPE team will work to enhance and align our practices with industry best practices, ensuring excellence in research integrity and publication ethics.
Stefan Tochev (CEO, MDPI) introduces Dr. Tim Tait-Jamieson (Research Integrity Lead, MDPI) for his presentation on MDPI’s Retraction and Approval Process to a group of Journal Relationship Specialists at the MDPI office in Cluj, Romania: “The demand for research integrity and publication ethics is steadily rising across our industry.”
Introducing our Research Integrity and Publication Ethics Team
Led by Dr. Tim Tait-Jamieson (Research Integrity Lead), the RIPE team comprises Dr. Ivana Resanovic (Research Integrity Manager), Dr. Lavinia Rogojina (Research Integrity Manager), Ms. Diana Apodaritei (Research Integrity Specialist), Dr. Zoltan Mihaly (Research Integrity Specialist), Mr. Aleksandar Đukić (Research Integrity Specialist), Ms. Ana Stankovic (Research Integrity Specialist), and Ms. Anna Pena (Publication Ethics Assistant).
Please click here to access everything that you need to know about MDPI’s Research and Publication Ethics.
With this span of complementary roles, the RIPE team collaborates directly with journal editorial teams and works closely with various departments, including our Scientific Office Board and our Journal Relationship Specialists. The team’s primary objectives are to help prevent issues regarding research integrity and publication ethics during peer review, uphold MDPI’s ethics policies, adhere to industry standards, and resolve publication ethics and research integrity issues and complaints.
Quality Updates to Special Issues Oversight
At MDPI, we are committed to reviewing policies pertaining to the quality of research. In this blog post, Shaheena Patel (Communications Associate, MDPI), outlines two recent updates to MDPI journal processes. These updates pertain to Special Issue (SI) quality guidelines, in line with criteria provided by COPE and DOAJ. Alongside the SI updates, details regarding the new minor corrections policy introduced in 2024 are provided in the blog.
The two updates we implemented include greater oversight and the verification of Guest Editor credentials. These guidelines require that Editors-in-Chief (EiCs) and Editorial Board Members (EBMs) take responsibility for overseeing SIs.
PS. Thank you, James Butcher, for featuring this up in your 67th issue of the Journalogy newsletter.
Read more:
Coming Together for Science
Viruses 2024 – A World of Viruses
I am pleased to share the success of our MDPI conference Viruses 2024 – A World of Viruses, held 14-16 February, in Barcelona. With 240 registrations, this event brought together top scientists, researchers, and industry experts from 40 countries to share their findings on the latest developments in viral pathogenesis and immune responses.
Attendees gathered for the 5th edition of the Viruses’ conference, where we hosted influential keynote speeches from Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes, along with 14 invited speakers, 47 selected speakers, and nine flash poster presenters, to discuss the most significant issues in virology today.
Recap on the #Viruses2024 Conference
Take a look at the key moments from MDPI’s Viruses event and please join us in commemorating a gathering for global knowledge and cooperation. A heartfelt thank-you to all attendees; their passion and engagement played a crucial role in making this event an engaging success!
Below are calls to action from the keynote speakers encouraging collaboration and communication:
“There’s never been a better time than now to really take the power that we have both in terms of basic research and also in biotech and pharma to develop antiviral agents.” - Dr. Charles M. Rice, The Rockefeller University, New York, USA
“The collaboration between labs is absolutely essential. Improving initial detection and improving communication is a must for all of us working in science.” - Prof. Dr. Luis Enjuanes, National Center of Biotechnology (CNB-CSIC), Madrid, Spain
Our thanks go to our sponsors and partnering societies, our Viruses journal and editorial team, our Barcelona colleagues, and the social media, conference and other MDPI teams for making this event a memorable occasion. View the event gallery here.
Upcoming In-Person Event
24–26 April, 2024
4th MMCS – Harnessing the Power of New Drug Modalities
Location: Barcelona, Spain
Esteemed speakers at MMCS 2024 include Prof. Arun K. Ghosh, the mind behind the Darunavir molecule, and Prof. Paul Brennan, CSO of Alzheimer's Research UK Oxford Drug Discovery Institute.
Find more upcoming MDPI events here.
Organize Your Event with MDPI’s Sciforum
Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.
Closing Thoughts
Researcher to Reader (R2R) Conference
From 20–21 February 2024, I had the pleasure of attending the Researcher to Reader (R2R) conference in London, which MDPI has proudly sponsored over the years. The conference programme offered a variety of session formats, including workshops, panel discussions, debates, interviews, presentations, and lightning talks, with opportunities to discuss relevant topics.
We take pride in supporting the scientific community, bringing researchers across the world together to network, exchange ideas and share the latest in science and publishing. In 2023, MDPI invested close to 2 million CHF in sponsoring over 2,000 scientific and publishing-related conferences worldwide.
R2R Peer Review Innovations Workshop
I found the R2R conference to be engaging, with the workshops being particularly enjoyable. My colleague Giulia Stefenelli (Chair of Scientific Office Board) and I participated in the “Peer Review Innovations” workshop, which spanned four sessions over the two days. These sessions explored the future of peer review and how we can improve the peer review process for everyone involved. Notably, the large majority of attendees expressed their opinion that peer review, as currently practiced, requires significant improvement. Together, we collaborated on potential immediate and long-term improvements and innovative processes, aiming to create an ecosystem beneficial to all stakeholders by strengthening submission systems with the aim of reducing threats and making authors more responsible for their work. We also discussed the opportunity for academic institutions to better scrutinize the quality of the work produced and submitted to journals.
Our group comprised publishers, software providers, librarians, and more, bringing diverse perspectives to the discussions. These interactions were relevant to MDPI’s ongoing conversations, providing insights to our efforts. The session also made me appreciate that MDPI is doing well, as the group discussions included the subject of various quality checks that we have already embedded in our processes, ensuring that we keep abreast of industry standards.
The need for an optimized system to incentivize the activities of editors and reviewers was also a focus of discussion, as well as the support that reviewers need from publishers via the provision of strong reports through fixed forms, questionnaires and training.
At MDPI, we are currently auditing our reviewer program to improve reviewer recognition, guidelines, and methods for identifying suitable reviewers, while maintaining our commitment to quality and timeliness.
Congratulations to Mark Carden, Conference Director, and the R2R team for organizing a productive and successful event. PS: The break times were greatly appreciated as well!
Chief Executive Officer
MDPI AG
26 February 2024
Cancers | National Cancer Prevention Month
26 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Metastasis
We are delighted to share some highly viewed papers on cancer metastasis that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“Multidisciplinary Approach to Spinal Metastases and Metastatic Spinal Cord Compression—A New Integrative Flowchart for Patient Management”
by Miguel Esperança-Martins, Diogo Roque, Tiago Barroso, André Abrunhosa-Branquinho, Diogo Belo, Nuno Simas and Luis Costa
Cancers 2023, 15(6), 1796; https://doi.org/10.3390/cancers15061796
Available online: https://www.mdpi.com/2072-6694/15/6/1796
“Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling”
by Carlos Costas-Insua, Marta Seijo-Vila, Cristina Blázquez, Sandra Blasco-Benito, Francisco Javier Rodríguez-Baena, Giovanni Marsicano, Eduardo Pérez-Gómez, Cristina Sánchez, Berta Sánchez-Laorden and Manuel Guzmán
Cancers 2023, 15(9), 2439; https://doi.org/10.3390/cancers15092439
Available online: https://www.mdpi.com/2072-6694/15/9/2439
“Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients”
by Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Phillip Peabody, Heather B. McBride, Franklin D. Alvarez, Megumi Kai, Juhee Song, Yu Shen, Jie S. Willey et al.
Cancers 2023, 15(5), 1616; https://doi.org/10.3390/cancers15051616
Available online: https://www.mdpi.com/2072-6694/15/5/1616
“Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence”
by Ruben Touati, Vincent Bourbonne, Gurvan Dissaux, Gaëlle Goasduff, Olivier Pradier, Charles Peltier, Romuald Seizeur, Ulrike Schick and François Lucia
Cancers 2023, 15(3), 996; https://doi.org/10.3390/cancers15030996
Available online: https://www.mdpi.com/2072-6694/15/3/996
“The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo”
by Lubaid Saleh, Penelope D. Ottewell, Janet E. Brown, Steve L. Wood, Nichola J. Brown, Caroline Wilson, Catherine Park, Simak Ali and Ingunn Holen
Cancers 2023, 15(8), 2211; https://doi.org/10.3390/cancers15082211
Available online: https://www.mdpi.com/2072-6694/15/8/2211
“Biomolecules Involved in Both Metastasis and Placenta Accreta Spectrum—Does the Common Pathophysiological Pathway Exist?”
by Anna K. Rekowska, Karolina Obuchowska, Magdalena Bartosik, Żaneta Kimber-Trojnar, Magdalena Słodzińska, Magdalena Wierzchowska-Opoka and Bożena Leszczyńska-Gorzelak
Cancers 2023, 15(9), 2618; https://doi.org/10.3390/cancers15092618
Available online: https://www.mdpi.com/2072-6694/15/9/2618
Special Issues:
|
|
“Molecular Pathways in Metastasis of Lung Cancer” |
|
|
“Breast Cancer Metastasis: Novel Insights into Molecular Mechanisms and Treatments” |
|
|
“Advances in Metastatic Non-small Cell Lung Cancer–Implications on Diagnosis and Treatment as We Head towards 2024” |
|
|
“Bone and Spine Metastases” |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
23 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Drug Development
We are delighted to share some highly viewed papers on cancer drug development that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
The list of relevant papers can be seen below:
“Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition”
by Kentaro Tokumo, Takeshi Masuda, Taku Nakashima, Masashi Namba, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka et al.
Cancers 2023, 15(4), 1092; https://doi.org/10.3390/cancers15041092
Available online: https://www.mdpi.com/2072-6694/15/4/1092
“Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas”
by Luogen Peng, Yuchan Li, Sha Yao, Jochen Gaedcke, Victor M. Baart, Cornelis F. M. Sier, Albrecht Neesse, Volker Ellenrieder, Hanibal Bohnenberger, Frieder Fuchs et al.
Cancers 2023, 15(5), 1587; https://doi.org/10.3390/cancers15051587
Available online: https://www.mdpi.com/2072-6694/15/5/1587
“The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer”
by Michele Vigolo, Charlotte Urech, Sebastien Lamy, Giulia Monticone, Jovanny Zabaleta, Fokhrul Hossain, Dorota Wyczechowska, Luis Del Valle, Ruth M. O’Regan, Lucio Miele et al.
Cancers 2023, 15(15), 3957; https://doi.org/10.3390/cancers15153957
Available online: https://www.mdpi.com/2072-6694/15/15/3957
“Inhibition of Macropinocytosis Enhances the Sensitivity of Osteosarcoma Cells to Benzethonium Chloride”
by Haichao Xia, Yanran Huang, Lulu Zhang, Lijuan Luo, Xiaoxuan Wang, Qiuping Lu, Jingtao Xu, Chunmei Yang, Habu Jiwa, Shiqiong Liang et al.
Cancers 2023, 15(3), 961; https://doi.org/10.3390/cancers15030961
Available online: https://www.mdpi.com/2072-6694/15/3/961
“Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms”
by Himali Gujrati, Siyoung Ha and Bi-Dar Wang
Cancers 2023, 15(12), 3140; https://doi.org/10.3390/cancers15123140
Available online: https://www.mdpi.com/2072-6694/15/12/3140
“Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues”
by Annalisa Schirizzi, Giampiero De Leonardis, Vincenza Lorusso, Rossella Donghia, Alessandro Rizzo, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Gianluigi Giannelli et al.
Cancers 2023, 15(8), 2376; https://doi.org/10.3390/cancers15082376
Available online: https://www.mdpi.com/2072-6694/15/8/2376
Special Issues:
|
Edited by Dr. Rajeev K. Singla and Prof. Dr. Anupam Bishayee
|
“Cancer Cell Metabolism and Drug Targets” Edited by Dr. Daniel S. Sitar and Prof. Dr. Donald Miller |
|
“Molecular Mechanisms of Anti-cancer Drugs Action” Edited by Dr. Barbara Pucelik
|
“The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance, Volume II” Edited by Dr. Bi-Dar Wang and Prof. Dr. Luciane R Cavalli
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
22 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Infectious Agents and Cancer
We are delighted to share some highly viewed papers on infectious agents and cancer that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“Increased Prevalence of EBV Infection in Nasopharyngeal Carcinoma Patients: A Six-Year Cross-Sectional Study”
by Abdullah E. Al-Anazi, Bader S. Alanazi, Huda M. Alshanbari, Emad Masuadi, Maaweya E. Hamed, Iman Dandachi, Abdulrahman Alkathiri, Atif Hanif, Islam Nour, Hanadi Fatani et al.
Cancers 2023, 15(3), 643; https://doi.org/10.3390/cancers15030643
Available online: https://www.mdpi.com/2072-6694/15/3/643
“Contribution of Epstein–Barr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses”
by Mike Dorothea, Jia Xie, Stephanie Pei Tung Yiu and Alan Kwok Shing Chiang
Cancers 2023, 15(7), 2120; https://doi.org/10.3390/cancers15072120
Available online: https://www.mdpi.com/2072-6694/15/7/2120
“Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein–Barr Virus Lymphoproliferative Disorder”
by Elshafa Hassan Ahmed, Mark Lustberg, Claire Hale, Shelby Sloan, Charlene Mao, Xiaoli Zhang, Hatice Gulcin Ozer, Sarah Schlotter, Porsha L. Smith, Frankie Jeney et al.
Cancers 2023, 15(11), 3046; https://doi.org/10.3390/cancers15113046
Available online: https://www.mdpi.com/2072-6694/15/11/3046
“Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer”
by Aastha Sobti, Christina Sakellariou, Johan S. Nilsson, David Askmyr, Lennart Greiff and Malin Lindstedt
Cancers 2023, 15(7), 2165; https://doi.org/10.3390/cancers15072165
Available online: https://www.mdpi.com/2072-6694/15/7/2165
“COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study”
by Joaquín Martínez-López, Javier De la Cruz, Rodrigo Gil-Manso, Adrián Alegre, Javier Ortiz, Pilar Llamas, Yolanda Martínez, José-Ángel Hernández-Rivas, Isabel González-Gascón, Celina Benavente et al.
Cancers 2023, 15(5), 1497; https://doi.org/10.3390/cancers15051497
Available online: https://www.mdpi.com/2072-6694/15/5/1497
“Constitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria”
by Phuong-Thu Mai, Daejin Lim, EunA So, Ha Young Kim, Taner Duysak, Thanh-Quang Tran, Miryoung Song, Jae-Ho Jeong and Hyon E. Choy
Cancers 2023, 15(5), 1486; https://doi.org/10.3390/cancers15051486
Available online: https://www.mdpi.com/2072-6694/15/5/1486
Special Issues:
|
“Advances in HPV-Associated Cancers of Different Organs” Edited by Prof. Dr. Adhemar Longatto-Filho and Prof. Dr. Kari Syrjanen
|
“Epstein–Barr Virus (EBV) Associated Cancers” Edited by Dr. Mário Henrique Magalhães Barros and Dr. Paola A. Chabay |
|
Edited by Dr. Xavier Sastre-Garau
|
“Hepatitis Viruses and Cancer” Edited by Prof. Dr. John Koskinas and Dr. Urania Georgopoulou
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
22 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Epidemiology and Prevention
We are delighted to share some highly viewed papers on cancer epidemiology and prevention that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
The list of relevant papers can be seen below:
“NPM 1 Mutations in AML—The Landscape in 2023”
by Naman Sharma and Jane L. Liesveld
Cancers 2023, 15(4), 1177; https://doi.org/10.3390/cancers15041177
Available online: https://www.mdpi.com/2072-6694/15/4/1177
“Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer”
by Ilaria Capasso, Angela Santoro, Emanuela Lucci Cordisco, Emanuele Perrone, Francesca Tronconi, Ursula Catena, Gian Franco Zannoni, Giovanni Scambia, Francesco Fanfani, Domenica Lorusso et al.
Cancers 2023, 15(5), 1400; https://doi.org/10.3390/cancers15051400
Available online: https://www.mdpi.com/2072-6694/15/5/1400
“Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy”
by Florian Poullenot and David Laharie
Cancers 2023, 15(4), 1083; https://doi.org/10.3390/cancers15041083
Available online: https://www.mdpi.com/2072-6694/15/4/1083
“Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000–2018”
by Jamil S. Samaan, Yazan Abboud, Janice Oh, Yi Jiang, Rabindra Watson, Kenneth Park, Quin Liu, Katelyn Atkins, Andrew Hendifar, Jun Gong et al.
Cancers 2023, 15(3), 870; https://doi.org/10.3390/cancers15030870
Available online: https://www.mdpi.com/2072-6694/15/3/870
“In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group)”
by Luca Giannella, Giovanni Delli Carpini, Jacopo Di Giuseppe, Giorgio Bogani, Francesco Sopracordevole, Nicolò Clemente, Giorgio Giorda, Rosa Pasqualina De Vincenzo, Maria Teresa Evangelista, Barbara Gardella et al.
Cancers 2023, 15(11), 2876; https://doi.org/10.3390/cancers15112876
Available online: https://www.mdpi.com/2072-6694/15/11/2876
“Early Onset Colorectal Cancer in Arabs, Are We Dealing with a Distinct Disease?”
by Adhari Al Zaabi, Asmaa Al Shehhi, Shaymaa Sayed, Humaid Al Adawi, Faris Al Faris, Omaima Al Alyani, Maitha Al Asmi, Abdulrahman Al-Mirza, Sathiya Panchatcharam and Maha Al-Shaibi
Cancers 2023, 15(3), 889; https://doi.org/10.3390/cancers15030889
Available online: https://www.mdpi.com/2072-6694/15/3/889
Special Issues:
|
Edited by Dr. Vikas Yadav, Dr. Hardeep Singh Tuli and Prof. Dr. Mukerrem Betul Yerer Aycan
|
“Current Epidemiologic, Diagnostic, and Therapeutic Aspects of Cholangiocarcinoma (CCA)” Edited by Dr. Sven Loosen and Prof. Dr. Christoph Roderburg |
|
“Innovations in Diagnosis, Prognostic Evaluation, and Therapeutic Management of Gynecologic Tumors” Edited by Dr. Donatella Santini and Dr. Antonio De Leo
|
Edited by Dr. Natalia Issaeva and Prof. Dr. Wendell G. Yarbrough
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
21 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Molecular Cancer Biology
We are delighted to share some highly viewed papers on molecular cancer biology that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of related papers and Special Issues that we believe will interest you:
“Downregulation of Dystrophin Expression Occurs across Diverse Tumors, Correlates with the Age of Onset, Staging and Reduced Survival of Patients”
by Nancy Alnassar, Malgorzata Borczyk, Georgia Tsagkogeorga, Michal Korostynski, Namshik Han and Dariusz C. Górecki
Cancers 2023, 15(5), 1378; https://doi.org/10.3390/cancers15051378
Available online: https://www.mdpi.com/2072-6694/15/5/1378
“The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy”
by Katarzyna Starska-Kowarska
Cancers 2023, 15(6), 1642; https://doi.org/10.3390/cancers15061642
Available online: https://www.mdpi.com/2072-6694/15/6/1642
“Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges”
by Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza and Giuseppe Curigliano
Cancers 2023, 15(4), 1130; https://doi.org/10.3390/cancers15041130
Available online: https://www.mdpi.com/2072-6694/15/4/1130
“Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management”
by Leili Rejali, Romina Seifollahi Asl, Fatemeh Sanjabi, Nayeralsadat Fatemi, Hamid Asadzadeh Aghdaei, Mahsa Saeedi Niasar, Pardis Ketabi Moghadam, Ehsan Nazemalhosseini Mojarad, Enrico Mini and Stefania Nobili
Cancers 2023, 15(10), 2746; https://doi.org/10.3390/cancers15102746
Available online: https://www.mdpi.com/2072-6694/15/10/2746
“The BAFF-APRIL System in Cancer”
by Md Ashik Ullah and Fabienne Mackay
Cancers 2023, 15(6), 1791; https://doi.org/10.3390/cancers15061791
Available online: https://www.mdpi.com/2072-6694/15/6/1791
“Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance”
by Sonia Mazumder, Paul J. Higgins and Rohan Samarakoon
Cancers 2023, 15(4), 1316; https://doi.org/10.3390/cancers15041316
Available online: https://www.mdpi.com/2072-6694/15/4/1316
| “Liver Cancers Molecular Biomarkers Predicting Outcome” Edited by Dr. Nima Kokabi Submission deadline: 10 July 2024 |
“Molecular Insights into Drug Resistance in Cancer” Edited by Dr. Yang Yuqi Submission deadline: 30 June 2024 |
 |
 |
| “Exosomes in Tumor” Edited by Dr. Sandra E. Ghayad and Dr. Nader Hussein Submission deadline: 24 June 2024 |
“The Study of Cancer Susceptibility Genes (Volume II)” Edited by Prof. Dr. Youri I. Pavlov Submission deadline: 25 June 2024 |
 |
 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
21 February 2024
Cancers | Highly Viewed Papers on Systematic Review or Meta-Analysis in Cancer Research
21 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Causes, Screening and Diagnosis
We are delighted to share some highly viewed papers on cancer causes, screening and diagnosis that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
“Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review”
by Michael G. Fadel, Mosab Ahmed, Gianluca Pellino, Shahnawaz Rasheed, Paris Tekkis, David Nicol, Christos Kontovounisios and Erik Mayer
Cancers 2023, 15(2), 455; https://doi.org/10.3390/cancers15020455
Available online: https://www.mdpi.com/2072-6694/15/2/455
“Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention”
by Douglas Tjandra, Rita A. Busuttil and Alex Boussioutas
Cancers 2023, 15(15), 3913; https://doi.org/10.3390/cancers15153913
Available online: https://www.mdpi.com/2072-6694/15/15/3913
“Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review”
by Alexandra Teixeira, Luís Carreira, Sara Abalde-Cela, Belém Sampaio-Marques, Anabela C. Areias, Paula Ludovico and Lorena Diéguez
Cancers 2023, 15(5), 1362; https://doi.org/10.3390/cancers15051362
Available online: https://www.mdpi.com/2072-6694/15/5/1362
“Targeting the Molecular and Immunologic Features of Leiomyosarcoma”
by Brandon M. Cope, Raymond S. Traweek, Rossana Lazcano, Emily Z. Keung, Alexander J. Lazar, Christina L. Roland and Elise F. Nassif
Cancers 2023, 15(7), 2099; https://doi.org/10.3390/cancers15072099
Available online: https://www.mdpi.com/2072-6694/15/7/2099
“Is Pediatric Melanoma Really That Different from Adult Melanoma? A Multicenter Epidemiological, Clinical and Dermoscopic Study”
by Vincenzo De Giorgi, Elisabetta Magnaterra, Biancamaria Zuccaro, Serena Magi, Manfredi Magliulo, Matelda Medri, Laura Mazzoni, Federico Venturi, Flavia Silvestri, Gian Marco Tomassini et al.
Cancers 2023, 15(6), 1835; https://doi.org/10.3390/cancers15061835
Available online: https://www.mdpi.com/2072-6694/15/6/1835
“Is Pediatric Melanoma Really That Different from Adult Melanoma? A Multicenter Epidemiological, Clinical and Dermoscopic Study”
by Dmitri Pchejetski, Ewan Hunter, Mehrnoush Dezfouli, Matthew Salter, Ryan Powell, Jayne Green, Tarun Naithani, Christina Koutsothanasi, Heba Alshaker, Jiten Jaipuria et al.
Cancers 2023, 15(3), 821; https://doi.org/10.3390/cancers15030821
Available online: https://www.mdpi.com/2072-6694/15/3/821
Special Issues:
 |
“Innovations in Soft Tissue Sarcoma Diagnosis and Treatment” Edited by: Dr. Erlinda M. Gordon, Dr. Sant P. Chawla and Dr. Frederick L. Hall Submission deadline: 30 May 2024 |
 |
“Gynecologic Cancer: From Diagnosis to Treatment” Edited by: Dr. Vito Andrea Capozzi Submission deadline: 1 July 2024 |
 |
“Diagnosis of Hematologic Malignancies” Edited by: Dr. Leonor Arenillas and Dr. Xavier Calvo Submission deadline: 25 May 2024 |
 |
“Differential Scanning Calorimetry and Related Thermal Analysis Techniques as Complementary Approaches for Cancer Diagnosis, Prognosis, Monitoring and Assessment of Treatment Response” Edited by: Dr. Nichola C. Garbett Submission deadline: 1 May 2024 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
21 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Survivorship and Quality of Life
We are delighted to share some highly viewed papers on cancer survivorship and quality of life that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
“Deep Learning Prediction Model for Patient Survival Outcomes in Palliative Care Using Actigraphy Data and Clinical Information”
by Yaoru Huang, Nidita Roy, Eshita Dhar, Umashankar Upadhyay, Muhammad Ashad Kabir, Mohy Uddin, Ching-Li Tseng and Shabbir Syed-Abdul
Cancers 2023, 15(8), 2232; https://doi.org/10.3390/cancers15082232
Available online: https://www.mdpi.com/2072-6694/15/8/2232
“Results of DUET: A Web-Based Weight Loss Randomized Controlled Feasibility Trial among Cancer Survivors and Their Chosen Partners”
by Wendy Demark-Wahnefried, Robert A. Oster, Tracy E. Crane, Laura Q. Rogers, W. Walker Cole, Harleen Kaur, David Farrell, Kelsey B. Parrish, Hoda J. Badr, Kathleen Y. Wolin et al.
Cancers 2023, 15(5), 1577; https://doi.org/10.3390/cancers15051577
Available online: https://www.mdpi.com/2072-6694/15/5/1577
“A Scoping Review and a Taxonomy to Assess the Impact of Mobile Apps on Cancer Care Management”
by Eshita Dhar, Adama Ns Bah, Irene Alice Chicchi Giglioli, Silvia Quer, Luis Fernandez-Luque, Francisco J. Núñez-Benjumea, Shwetambara Malwade, Mohy Uddin, Umashankar Upadhyay and Shabbir Syed-Abdul
Cancers 2023, 15(6), 1775; https://doi.org/10.3390/cancers15061775
Available online: https://www.mdpi.com/2072-6694/15/6/1775
“Physician Perceptions on Cancer Screening for LGBTQ+ Patients”
by Nicolas G. Nelson, Joseph F. Lombardo, Ayako Shimada, Marissa L. Ruggiero, Alexandria P. Smith, Kevin Ko, Amy E. Leader, Edith P. Mitchell and Nicole L. Simone
Cancers 2023, 15(11), 3017; https://doi.org/10.3390/cancers15113017
Available online: https://www.mdpi.com/2072-6694/15/11/3017
“Immersive and Non-Immersive Virtual Reality for Pain and Anxiety Management in Pediatric Patients with Hematological or Solid Cancer: A Systematic Review”
by Dania Comparcini, Valentina Simonetti, Francesco Galli, Ilaria Saltarella, Concetta Altamura, Marco Tomietto, Jean-François Desaphy and Giancarlo Cicolini
Cancers 2023, 15(3), 985; https://doi.org/10.3390/cancers15030985
Available online: https://www.mdpi.com/2072-6694/15/3/985
“Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?”
by Francesco Lanfranchi, Liliana Belgioia, Michela Marcenaro, Elisa Zanardi, Giorgia Timon, Mattia Riondato, Veronica Giasotto, Jeries Paolo Zawaideh, Laura Tomasello, Guglielmo Mantica et al.
Cancers 2023, 15(1), 323; https://doi.org/10.3390/cancers15010323
Available online: https://www.mdpi.com/2072-6694/15/1/323
Special Issues:
 |
“Strategies for Cancer Pain Management” Edited by: Prof. Dr. Sebastiano Mercadante Submission deadline: 30 April 2024 |
 |
“Oncologic Emergencies: The Emergency Care of Cancer Patients” Edited by: Dr. Aiham Qdaisat and Prof. Dr. Sai-Ching Jim Yeung Submission deadline: 30 April 2024 |
 |
“Prevention and Quality of Life of Lung Cancer” Edited by: Prof. Dr. Servet Bölükbas Submission deadline: 15 May 2024 |
 |
“Anesthesia and Cancers” Edited by: Dr. Jun Lin, Prof. Dr. James P. Dilger and Dr. Ru Li Submission deadline: 31 May 2024 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
21 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Therapy
We are delighted to share some highly viewed papers on cancer therapy that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
“Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches”
by Philip Posdzich, Christopher Darr, Thomas Hilser, Milan Wahl, Ken Herrmann, Boris Hadaschik and Viktor Grünwald
Cancers 2023, 15(2), 461; https://doi.org/10.3390/cancers15020461
Available online: https://www.mdpi.com/2072-6694/15/2/461
“Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)”
by Maggie Banys-Paluchowski, Thorsten Kühn, Yazan Masannat, Isabel Rubio, Jana de Boniface, Nina Ditsch, Güldeniz Karadeniz Cakmak, Andreas Karakatsanis, Rajiv Dave, Markus Hahn et al.
Cancers 2023, 15(4), 1173; https://doi.org/10.3390/cancers15041173
Available online: https://www.mdpi.com/2072-6694/15/4/1173
“Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities”
by Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Marco Montillo and Alessandra Tedeschi
Cancers 2023, 15(5), 1504; https://doi.org/10.3390/cancers15051504
Available online: https://www.mdpi.com/2072-6694/15/5/1504
“Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer”
by Briana Kinnel, Santosh Kumar Singh, Gabriela Oprea-Ilies and Rajesh Singh
Cancers 2023, 15(4), 1320; https://doi.org/10.3390/cancers15041320
Available online: https://www.mdpi.com/2072-6694/15/4/1320
“A Recent Review on Cancer Nanomedicine”
by Paras Mani Giri, Anurag Banerjee and Buddhadev Layek
Cancers 2023, 15(8), 2256; https://doi.org/10.3390/cancers15082256
Available online: https://www.mdpi.com/2072-6694/15/8/2256
“Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment”
by Robert Kleszcz
Cancers 2023, 15(17), 4247; https://doi.org/10.3390/cancers15174247
Available online: https://www.mdpi.com/2072-6694/15/17/4247
| “Feature Review for Cancer Therapy” Edited by: Dr. Robert Kleszcz and Dr. Jarosław Paluszczak Submission deadline: 15 May 2024 |
 |
| “Correlating Patient-Reported Quality of Life before, during, and after Therapy with Objective Measures and Outcomes” Edited by: Prof. Dr. Anurag K. Singh and Dr. Evan Michael Graboyes Submission deadline: 5 July 2024 |
 |
| “Hepatocellular Carcinoma: Advances and Challenges in Research and Treatment” Edited by: Dr. Huei-Lung Liang Submission deadline: 30 April 2024 |
 |
| “Contemporary Treatment of Colorectal Cancer” Edited by: Dr. Michel Adamina Submission deadline: 10 December 2024 |
 |
| “Advances in Ovarian Cancer Research and Treatment” Edited by: Dr. Maria Barbolina Submission deadline: 24 October 2024 |
 |
| “Innovative Treatment Strategies for Lung Cancer and Radiotherapy” Edited by: Prof. Dr. Fernando Mendes and Prof. Dr. Maria Filomena Botelho Submission deadline: 15 May 2024 |
 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
20 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Transplant Oncology
We are delighted to share some highly viewed papers on transplant oncology that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology”
by Karen Abboud, Godsfavour Umoru, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, Humaid O. Al-Shamsi, Milind Javle, Ashish Saharia, Ashton A. Connor, Sudha Kodali et al.
Cancers 2023, 15(5), 1433; https://doi.org/10.3390/cancers15051433
Available online: https://www.mdpi.com/2072-6694/15/5/1433
“Prognostic Role of the Intrahepatic Lymphatic System in Liver Cancer”
by Katsunori Sakamoto, Kohei Ogawa, Kei Tamura, Masahiko Honjo, Naotake Funamizu and Yasutsugu Takada
Cancers 2023, 15(7), 2142; https://doi.org/10.3390/cancers15072142
Available online: https://www.mdpi.com/2072-6694/15/7/2142
“Influence of De Novo Malignancies on Long-Term Survival after Lung Transplantation”
by Eloisa Ruiz, Paula Moreno, Francisco Javier Gonzalez, Alba Maria Fernandez, Benito Cantador, Juan Luis Parraga, Angel Salvatierra and Antonio Alvarez
Cancers 2023, 15(15), 4011; https://doi.org/10.3390/cancers15154011
Available online: https://www.mdpi.com/2072-6694/15/15/4011
“Transplant Oncology: An Emerging Discipline of Cancer Treatment”
by Maen Abdelrahim, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, David Victor, Sudha Kodali, Yee Lee Cheah, Caroline J. Simon, Mazen Noureddin, Ashton Connor et al.
Cancers 2023, 15(22), 5337; https://doi.org/10.3390/cancers15225337
Available online: https://www.mdpi.com/2072-6694/15/22/5337
“Declined Organs for Liver Transplantation: A Right Decision or a Missed Opportunity for Patients with Hepatocellular Carcinoma?”
by Vladimir J. Lozanovski, Said Adigozalov, Elias Khajeh, Omid Ghamarnejad, Ehsan Aminizadeh, Christina Schleicher, Thilo Hackert, Beat Peter Müller-Stich, Uta Merle, Susanne Picardi et al.
Cancers 2023, 15(5), 1365; https://doi.org/10.3390/cancers15051365
Available online: https://www.mdpi.com/2072-6694/15/5/1365
“Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology”
by Saad Alghamdi and Waleed Al-Hamoudi
Cancers 2023, 15(21), 5115; https://doi.org/10.3390/cancers15215115
Available online: https://www.mdpi.com/2072-6694/15/21/5115
|
“Immunotherapy and Transplantation in the Era of Transplant Oncology” Edited by Dr. Maen Abdelrahim, Dr. Ala Abudayyeh and Dr. Abdullah Esmail
|
“Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives” Edited by Dr. Andrea Dell'Amore, Dr. Eleonora Faccioli and Dr. Alessio Campisi |
|
“Liver Transplantation for Cancer: The Future of Transplant Oncology” Edited by Prof. Dr. Tomoharu Yoshizumi
|
“Stem Cell Transplantation on Multiple Myeloma” Edited by Dr. Ho-Jin Shin
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers
Cancers Editorial Office
20 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Informatics and Big Data
We are delighted to share some highly viewed papers on cancer informatics and big data that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“Semi-Supervised Learning to Automate Tumor Bud Detection in Cytokeratin-Stained Whole-Slide Images of Colorectal Cancer”
by John-Melle Bokhorst, Iris D. Nagtegaal, Inti Zlobec, Heather Dawson, Kieran Sheahan, Femke Simmer, Richard Kirsch, Michael Vieth, Alessandro Lugli, Jeroen van der Laak et al.
Cancers 2023, 15(7), 2079; https://doi.org/10.3390/cancers15072079
Available online: https://www.mdpi.com/2072-6694/15/7/2079
“The Role of AI in Breast Cancer Lymph Node Classification: A Comprehensive Review”
by Josip Vrdoljak, Ante Krešo, Marko Kumrić, Dinko Martinović, Ivan Cvitković, Marko Grahovac, Josip Vickov, Josipa Bukić and Joško Božic
Cancers 2023, 15(8), 2400; https://doi.org/10.3390/cancers15082400
Available online: https://www.mdpi.com/2072-6694/15/8/2400
“Multimodal Data Integration to Predict Severe Acute Oral Mucositis of Nasopharyngeal Carcinoma Patients Following Radiation Therapy”
by Yanjing Dong, Jiang Zhang, Saikt Lam, Xinyu Zhang, Anran Liu, Xinzhi Teng, Xinyang Han, Jin Cao, Hongxiang Li, Francis Karho Lee et al.
Cancers 2023, 15(7), 2032; https://doi.org/10.3390/cancers15072032
Available online: https://www.mdpi.com/2072-6694/15/7/2032
“NRK-ABMIL: Subtle Metastatic Deposits Detection for Predicting Lymph Node Metastasis in Breast Cancer Whole-Slide Images”
by Usama Sajjad, Mostafa Rezapour, Ziyu Su, Gary H. Tozbikian, Metin N. Gurcan and M. Khalid Khan Niazi
Cancers 2023, 15(13), 3428; https://doi.org/10.3390/cancers15133428
Available online: https://www.mdpi.com/2072-6694/15/13/3428
“Comparative Analysis of Three Predictive Models of Performance Indicators with Results-Based Management: Cancer Data Statistics in a National Institute of Health”
by Joel Martínez-Salazar and Filiberto Toledano-Toledano
Cancers 2023, 15(18), 4649; https://doi.org/10.3390/cancers15184649
Available online: https://www.mdpi.com/2072-6694/15/18/4649
“Identification of Novel Diagnostic and Prognostic Gene Signature Biomarkers for Breast Cancer Using Artificial Intelligence and Machine Learning Assisted Transcriptomics Analysis”
by Zeenat Mirza, Md Shahid Ansari, Md Shahid Iqbal, Nesar Ahmad, Nofe Alganmi, Haneen Banjar, Mohammed H. Al-Qahtani and Sajjad Karim
Cancers 2023, 15(12), 3237; https://doi.org/10.3390/cancers15123237
Available online: https://www.mdpi.com/2072-6694/15/12/3237
|
“Artificial Intelligence in Cancer Research: Knowledge Representation and Data Perspectives” Edited by Dr. Catia Pesquita and Dr. Andreas Schlicker
|
“Advances in Cancer Data and Statistics” Edited by Prof. Dr. Vesna Zadnik |
|
“Novel Approaches to Machine Learning and Artificial Intelligence in Cancer Research and Care” Edited by Dr. Caroline Chung and Dr. Christopher Gibbons
|
“Next Generation Sequencing for Cancer Diagnostics” Edited by Dr. Gayatry Mohapatra
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers
Cancers Editorial Office
19 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Clinical Research of Cancer
We are delighted to share some highly viewed papers on clinical research of cancer that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“Current Main Topics in Multiple Myeloma”
by Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Attilio Olivieri and Massimo Offidani
Cancers 2023, 15(8), 2203; https://doi.org/10.3390/cancers15082203
Available online: https://www.mdpi.com/2072-6694/15/8/2203
“Management of Advanced Prostate Cancer in the Precision Oncology Era”
by Claire M. Gillette, Gabriel A. Yette, Scott D. Cramer and Laura S. Graham
Cancers 2023, 15(9), 2552; https://doi.org/10.3390/cancers15092552
Available online: https://www.mdpi.com/2072-6694/15/9/2552
“Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors”
by Vladimir Chernov, Anastasiya Rybina, Roman Zelchan, Anna Medvedeva, Olga Bragina, Nadejda Lushnikova, Artem Doroshenko, Evgeniy Usynin, Liubov Tashireva, Sergey Vtorushin et al.
Cancers 2023, 15(6), 1631; https://doi.org/10.3390/cancers15061631
Available online: https://www.mdpi.com/2072-6694/15/6/1631
“Development of a Patient Decision Aid for Rectal Cancer Patients with Clinical Complete Response after Neo-Adjuvant Treatment”
by Lien Smets, Annelies Debucquoy, Eva Oldenburger, Chantal Van Audenhove, Lynn Debrun, Jeroen Dekervel, Gabriele Bislenghi, André D’Hoore, Albert Wolthuis and Karin Haustermans
Cancers 2023, 15(3), 806; https://doi.org/10.3390/cancers15030806
Available online: https://www.mdpi.com/2072-6694/15/3/806
“A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma”
by Nam Bui, Hilary Dietz, Sheima Farag, Angela C. Hirbe, Michael J. Wagner, Brian A. Van Tine, Kristen Ganjoo, Robin L. Jones, Vicki L. Keedy and Elizabeth J. Davis
Cancers 2023, 15(9), 2617; https://doi.org/10.3390/cancers15092617
Available online: https://www.mdpi.com/2072-6694/15/9/2617
“Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer”
by Rieneke T. Lugtenberg, Stefanie de Groot, Danny Houtsma, Vincent O. Dezentjé, Annelie J. E. Vulink, Maarten J. Fischer, Johanneke E. A. Portielje, Jacobus J. M. van der Hoeven, Hans Gelderblom, Hanno Pijl et al.
Cancers 2023, 15(6), 1691; https://doi.org/10.3390/cancers15061691
Available online: https://www.mdpi.com/2072-6694/15/6/1691
| “Bone and Soft Tissue Tumors: Molecular Mechanisms, Clinical Practice, and Emerging Therapeutics” Edited by Prof. Dr. Toshihiro Akisue, Dr. Shintaro Iwata and Dr. Toru Akiyama Submission deadline: 31 May 2024 |
“The Evolving Treatment and Clinical Trials of Hepatocellular Carcinoma” Edited by Dr. Zachary J. Brown and Dr. John D. Allendorf Submission deadline: 31 May 2024 |
 |
 |
| “Clinical Outcomes in Urologic Cancers” Edited by Dr. Simone Morra and Prof. Dr. Pierre Karakiewicz Submission deadline: 30 June 2024 |
“Prognostic Factors in Urologic Cancers—Assessment and Integration into Clinical Care“ Edited by Prof. Dr. Maximilian Burger and Prof. Dr. Christian Thomas Submission deadline: 30 June 2024 |
 |
 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
19 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Tumor Microenvironment
We are delighted to share some highly viewed papers on tumor microenvironment that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?”
by Amol Gupta, Razelle Kurzrock and Jacob J. Adashek
Cancers 2023, 15(5), 1578; https://doi.org/10.3390/cancers15051578
Available online: https://www.mdpi.com/2072-6694/15/5/1578
“Implication of Obesity and Gut Microbiome Dysbiosis in the Etiology of Colorectal Cancer”
by Samradhi Singh, Poonam Sharma, Devojit Kumar Sarma, Manoj Kumawat, Rajnarayan Tiwari, Vinod Verma, Ravinder Nagpal and Manoj Kumar
Cancers 2023, 15(6), 1913; https://doi.org/10.3390/cancers15061913
Available online: https://www.mdpi.com/2072-6694/15/6/1913
“The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome”
by Kazutoshi Fujita, Makoto Matsushita, Marco A. De Velasco, Koji Hatano, Takafumi Minami, Norio Nonomura and Hirotsugu Uemura
Cancers 2023, 15(5), 1375; https://doi.org/10.3390/cancers15051375
Available online: https://www.mdpi.com/2072-6694/15/5/1375
“Brain Tumor Detection Based on Deep Learning Approaches and Magnetic Resonance Imaging”
by Akmalbek Bobomirzaevich Abdusalomov, Mukhriddin Mukhiddinov and Taeg Keun Whangbo
Cancers 2023, 15(16), 4172; https://doi.org/10.3390/cancers15164172
Available online: https://www.mdpi.com/2072-6694/15/16/4172
“Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response”
by Marylène Lejeune, Laia Reverté, Esther Sauras, Noèlia Gallardo, Ramon Bosch, Albert Roso, Anna Petit, Vicente Peg, Francisco Riu, Joan García-Fontgivell et al.
Cancers 2023, 15(3), 597; https://doi.org/10.3390/cancers15030597
Available online: https://www.mdpi.com/2072-6694/15/3/597
“The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer”
by Pariyada Tanjak, Amphun Chaiboonchoe, Tharathorn Suwatthanarak, Onchira Acharayothin, Kullanist Thanormjit, Jantappapa Chanthercrob, Thanawat Suwatthanarak, Bundit Wannasuphaphol, Kemmapon Chumchuen, Bhoom Suktitipat et al.
Cancers 2023, 15(4), 1098; https://doi.org/10.3390/cancers15041098
Available online: https://www.mdpi.com/2072-6694/15/4/1098
 |
“Targeting Signal Transduction Pathways in Cancer” Edited by Dr. Mohd W. Nasser, Prof. Dr. Shahab Uddin, Prof. Dr. Klaus Podar and Dr. Martin Sattler Submission deadline: 31 March 2024 |
 |
“Tumor Microenvironment in Primary Liver Cancer” Edited by Dr. Stefania Mantovani and Dr. Barbara Oliviero Submission deadline: 28 June 2024 |
 |
“Unique Perspectives in Cancer Signaling” Edited by Dr. Peiwen Fei Submission deadline: 15 September 2024 |
 |
“Tumor-Associated Microenvironments and Inflammation” Edited by Prof. Dr. Ren Xu and Prof. Dr. Bing Li Submission deadline: 15 April 2024 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
19 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Methods and Technologies Development
We are delighted to share some highly viewed papers on methods and technologies development that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of relevant papers and Special Issues that we believe will interest you:
“18F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?”
by Domenico Albano, Giorgio Treglia, Francesco Dondi, Anna Calabrò, Alessio Rizzo, Salvatore Annunziata, Luca Guerra, Silvia Morbelli, Alessandra Tucci and Francesco Bertagna
Cancers 2023, 15(9), 2494; https://doi.org/10.3390/cancers15092494
Available online: https://www.mdpi.com/2072-6694/15/9/2494
“Role of PET/CT in Oropharyngeal Cancers”
by Emily W. Avery, Kavita Joshi, Saral Mehra and Amit Mahajan
Cancers 2023, 15(9), 2651; https://doi.org/10.3390/cancers15092651
Available online: https://www.mdpi.com/2072-6694/15/9/2651
“Artificial Intelligence in CT and MR Imaging for Oncological Applications”
by Ramesh Paudyal, Akash D. Shah, Oguz Akin, Richard K. G. Do, Amaresha Shridhar Konar, Vaios Hatzoglou, Usman Mahmood, Nancy Lee, Richard J. Wong, Suchandrima Banerjee et al.
Cancers 2023, 15(9), 2573; https://doi.org/10.3390/cancers15092573
Available online: https://www.mdpi.com/2072-6694/15/9/2573
“See Lung Cancer with an AI”
by Joanna Bidzińska and Edyta Szurowska
Cancers 2023, 15(4), 1321; https://doi.org/10.3390/cancers15041321
Available online: https://www.mdpi.com/2072-6694/15/4/1321
“Multimodal Deep Learning-Based Prognostication in Glioma Patients: A Systematic Review”
by Kaitlyn Alleman, Erik Knecht, Jonathan Huang, Lu Zhang, Sandi Lam and Michael DeCuypere
Cancers 2023, 15(2), 545; https://doi.org/10.3390/cancers15020545
Available online: https://www.mdpi.com/2072-6694/15/2/545
“Long Axial Field-of-View PET/CT Could Answer Unmet Needs in Gynecological Cancers”
by Elizabeth Katherine Anna Triumbari, Vittoria Rufini, Clemens Mingels, Axel Rominger, Abass Alavi, Francesco Fanfani, Ramsey D. Badawi and Lorenzo Nardo
Cancers 2023, 15(9), 2407; https://doi.org/10.3390/cancers15092407
Available online: https://www.mdpi.com/2072-6694/15/9/2407
 |
|
| “The Role of PET Imaging in Oncology: New Advancements in Clinical and Research Setting” Edited by Dr. Pierpaolo Alongi and Dr. Desiree Deandreis Submission deadline: 31 March 2024 |
“Artificial Intelligence and Machine Learning in Precision Oncology” Edited by Dr. Carmen Belli and Dr. Santosh Anand Submission deadline: 30 April 2024 |
 |
 |
| “Recent Trends in PET/CT Tracer Development and Multimodal Imaging” Edited by Prof. Dr. Olaf Prante and Prof. Dr. Tobias Bäuerle Submission deadline: 30 June 2024 |
“Radionuclide Therapy and Hybrid Imaging in Oncology” Edited by Dr. Amir Sabet and Prof. Dr. Frank Grünwald Submission deadline: 29 February 2024 |
 |
 |
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
7 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Biomarkers in 2023
We are delighted to share some highly viewed papers on cancer biomarkers that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
The list of relevant papers can be seen below:
“Effect of Selenium and Lycopene on Radiation Sensitivity in Prostate Cancer Patients Relative to Controls”
by Varinderpal S. Dhillon, Permal Deo and Michael Fenech
Cancers 2023, 15(3), 979; https://doi.org/10.3390/cancers15030979
Available online: https://www.mdpi.com/2072-6694/15/3/979
“Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors”
by Yasuyuki Matsumoto and Tongzhong Ju
Cancers 2023, 15(14), 3536; https://doi.org/10.3390/cancers15143536
Available online: https://www.mdpi.com/2072-6694/15/14/3536
“Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1”
by Jessica M. Logan, Ashley M. Hopkins, Carmela Martini, Alexandra Sorvina, Prerna Tewari, Sarita Prabhakaran, Chelsea Huzzell, Ian R. D. Johnson, Shane M. Hickey, Ben S.-Y. Ung et al.
Cancers 2023, 15(12), 3215; https://doi.org/10.3390/cancers15123215
Available online: https://www.mdpi.com/2072-6694/15/12/3215
“Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Biological Data”
by Katrin S. Kurz, Sabrina Kalmbach, Michaela Ott, Annette M. Staiger, German Ott and Heike Horn
Cancers 2023, 15(3), 785; https://doi.org/10.3390/cancers15030785
Available online: https://www.mdpi.com/2072-6694/15/3/785
“Mucins as Potential Biomarkers for Early Detection of Cancer”
by Shailendra K. Gautam, Parvez Khan, Gopalakrishnan Natarajan, Pranita Atri, Abhijit Aithal, Apar K. Ganti, Surinder K. Batra, Mohd W. Nasser and Maneesh Jain
Cancers 2023, 15(6), 1640; https://doi.org/10.3390/cancers15061640
Available online: https://www.mdpi.com/2072-6694/15/6/1640
“LC-MS/MS Based Volatile Organic Compound Biomarkers Analysis for Early Detection of Lung Cancer”
by Shuaibu Nazifi Sani, Wei Zhou, Balarabe B. Ismail, Yongkui Zhang, Zhijun Chen, Binjie Zhang, Changqian Bao, Houde Zhang and Xiaozhi Wang
Cancers 2023, 15(4), 1186; https://doi.org/10.3390/cancers15041186
Available online: https://www.mdpi.com/2072-6694/15/4/1186
 |
|
| “Head and Neck Cancers—Novel Approaches and Future Outlook” Edited by Dr. Claudia Maletzki Submission deadline: 31 October 2024 |
“Feature Papers in Section "Cancer Biomarkers" in 2023–2024” Edited by Prof. Dr. Maxim V. Berezovski Submission deadline: 31 May 2024 |
|
|
|
| “Advances in Soft Tissue and Bone Sarcoma” Edited by Dr. Catrin Sian Rutland Submission deadline: 30 April 2024 |
“Liquid Biopsy for Lung Cancer Treatment” Edited by Dr. Maria Palmieri and Dr. Frullanti Elisa Submission deadline: 30 July 2024 |
|
|
|
| “PTEN: Regulation, Signalling and Targeting in Cancer” Edited by Dr. Mark G.H. Scott, Dr. Larissa Kotelevets and Dr. Éric Chastre Submission deadline: 31 December 2024 |
“Genome Sequencing of Cancer: Identifying Targets and Biomarkers for Therapy” Edited by Dr. Haruhiko Takeda Submission deadline: 25 October 2024 |
|
|
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
6 February 2024
Cancers | Highly Viewed Papers and Hot Topic Special Issues on Cancer Immunology and Immunotherapy
We are delighted to share some highly viewed papers on cancer immunology and immunotherapy that were published in Cancers (ISSN: 2072-6694) in 2023. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.
“Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment”
by Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis, Georgios Xynos and Helen Gogas
Cancers 2023, 15(10), 2718; https://doi.org/10.3390/cancers15102718
Available online: https://www.mdpi.com/2072-6694/15/10/2718
“Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events”
by Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan et al.
Cancers 2023, 15(5), 1629; https://doi.org/10.3390/cancers15051629
Available online: https://www.mdpi.com/2072-6694/15/5/1629
“Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes”
by Mefotse Saha Cyrelle Ornella, Narayanasamy Badrinath, Kyeong-Ae Kim, Jung Hee Kim, Euna Cho, Tae-Ho Hwang and Jae-Joon Kim
Cancers 2023, 15(8), 2383; https://doi.org/10.3390/cancers15082383
Available online: https://www.mdpi.com/2072-6694/15/8/2383
“Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma”
by Tatsuya Deguchi, Naoya Maekawa, Satoru Konnai, Ryo Owaki, Kenji Hosoya, Keitaro Morishita, Motoji Nakamura, Tomohiro Okagawa, Hiroto Takeuchi, Sangho Kim et al.
Cancers 2023, 15(11), 3013; https://doi.org/10.3390/cancers15113013
Available online: https://www.mdpi.com/2072-6694/15/11/3013
“Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis”
by Melissa M. De Meza, Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers et al.
Cancers 2023, 15(2), 409; https://doi.org/10.3390/cancers15020409
Available online: https://www.mdpi.com/2072-6694/15/2/409
“Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma”
by Gitanjali Sharma, Marta C. Braga, Chiara Da Pieve, Wojciech Szopa, Tatjana Starzetz, Karl H. Plate, Wojciech Kaspera and Gabriela Kramer-Marek
Cancers 2023, 15(12), 3131; https://doi.org/10.3390/cancers15123131
Available online: https://www.mdpi.com/2072-6694/15/12/3131
| “Anticancer Immunity with Physical Treatment Modalities” Edited by Dr. Sander Bekeschus Submission deadline: 1 June 2024 Available online: https://www.mdpi.com/journal/cancers/special_issues/GWHKI53P66 |
“Cancer and Immunomediated Inflammatory Diseases (IMIDs)” Edited by Prof. Dr. Sandro Ardizzone Submission deadline: 10 June 2024 Available online: https://www.mdpi.com/journal/cancers/special_issues/D63VX78S95 |
|
|
|
| “The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II)” Edited by Prof. Dr. Razelle Kurzrock, Dr. Anwaar Saeed, Dr. Linlin Guo and Dr. Ludimila Cavalcante Submission deadline: 20 June 2024 Available online: https://www.mdpi.com/journal/cancers/special_issues/4BPEBEU010 |
“Immune Checkpoint Inhibitors for Urologic Cancers” Edited by Dr. Panagiotis Vlachostergios Submission deadline: 30 June 2024 Available online: https://www.mdpi.com/journal/cancers/special_issues/9LF513VT85 |
|
|
|
You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
2 February 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Drug Development”
1 February 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Immunology and Immunotherapy”
31 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Pathophysiology”
31 January 2024
MDPI Insights: The CEO's Letter #8 - Altmetric and Flat Fee Agreement
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI and Digital Science Meeting
At MDPI, we are committed to providing our authors with the essential tools to publish, promote, and track their research. In line with this commitment, we have established a longstanding collaboration with Digital Science, a company specializing in research data and analytical insights for the research community. Our collaboration integrates their Altmetric tool, offering us and our authors the ability to track a variety of sources that monitor and report attention surrounding publications.
As part of our collaboration, we recently hosted Cathy Holland, Director of Global Publisher Business Development, and Helen Cooke, Managing Director of Publisher Sales, from Digital Science, at our MDPI headquarters in Basel, Switzerland.
Left to right: Facundo Santomé (Senior Marketing Manager, MDPI), Constanze Shelhorn (Indexing Manager, MDPI), Cathy Holland (Director of Global Publisher Business Development, Digital Science), Helen Cooke (Managing Director of Publisher Sales, Digital Science), and Stefan Tochev (CEO, MDPI) in front of MDPI headquarters in Basel, Switzerland.
During our meeting, we discussed MDPI’s publishing philosophy and explored further avenues for collaboration. We look forward to continuing our partnership with Digital Science, aiming to improve our services yet further and meet the needs of our authors more closely than ever.
What is Altmetric?
You will notice that MDPI articles feature an Altmetric score, a colourful doughnut capturing the score in the upper right corner of the article page. This score represents ‘alternative metrics,’ as distinct from traditional metrics such as Impact Factor, CiteScore, and Scimago Journal Rank.
Altmetrics complement traditional citation-based metrics by capturing online discussions related to a specific research topic. By analyzing both sets of data, we can obtain a comprehensive understanding of the attention a particular research output receives and the sources in which it is mentioned.
“Almetric provides visual insights into where research is being discussed”
Sources Tracked by Altmetric
Altmetric badge showing the Altmetric score and colour-coded mention sources.
Altmetric monitors various sources, categorizing them into segments such as policy documents, peer reviews, Wikipedia, news and blogs, and social media, among other sources. Each category is identifiable by a specific colour.
The Altmetric badge provides visual insights into where the research is being discussed. A more colourful badge indicates broader mentions across multiple platforms. Such tracking enables us to gauge the extent of an article’s online dissemination, noting that increased visibility may correlate with higher citation rates.
Read more:
Impactful Research
Ten High-Altmetric Articles Published by MDPI
As at 30 January 2024, Altmetric has tracked 670,500 MDPI research outputs from MDPI, resulting in over 4.3 million mentions. This includes over 71,894 mentions in policy and patents and 294,714 mentions in news and blogs, with some achieving an Altmetric score as high as 28,754.
So, what is a good Altmetric score? There are various ways to put this score into context. You can find out more about the score in context and how to evaluate your work by this means.
Here are ten MDPI papers ranking in the top 5% of all research outputs scored by Altmetric.
|
|
“Accuracy in Wrist-Worn, Sensor-Based Measurements of Heart Rate and Energy Expenditure in a Diverse Cohort” J. Pers. Med. 2017, 7(2), 3; https://doi.org/10.3390/jpm7020003 Altmetric page: https://mdpi.altmetric.com/details/20477344 Altmetric shows that this article appeared in 253 news stories from 209 outlets including Forbes, BBC, and Fox News. |
|
|
“Daylight Saving Time and Acute Myocardial Infarction: A Meta-Analysis” J. Clin. Med. 2019, 8(3), 404; https://doi.org/10.3390/jcm8030404 Altmetric page: https://mdpi.altmetric.com/details/57654628 Altmetric shows that this article appeared in 295 news stories from 207 outlets including Forbes, The Atlantic, and New York Times. |
|
|
“The Preliminary Analysis of Cave Lion Cubs Panthera spelaea (Goldfuss, 1810) from the Permafrost of Siberia” Quaternary 2021, 4(3), 24; https://doi.org/10.3390/quat4030024 Altmetric page: https://mdpi.altmetric.com/details/111086701 Altmetric shows that this article appeared in 182 news stories from 134 outlets including CBC News, CNN, and National Geographic. |
|
|
“Not the Cat’s Meow? The Impact of Posing with Cats on Female Perceptions of Male Dateability” Animals 2020, 10(6), 1007; https://doi.org/10.3390/ani10061007 Altmetric page: https://mdpi.altmetric.com/details/83796184 Altmetric shows that this article appeared in 124 news stories from 98 outlets including VICE, CNN and The Guardian. |
|
|
“Behaviour and Welfare Impacts of Releasing Elephants from Overnight Tethers: A Zimbabwean Case Study” Animals 2022, 12(15), 1933; https://doi.org/10.3390/ani12151933 Altmetric page: https://mdpi.altmetric.com/details/133463915 Altmetric shows that this article appeared in 192 news stories from 186 outlets. |
How do I use altmetrics?
Altmetric Explorer provides a detailed step-by-step guide and instruction video for first-time users of the tool. The guide includes useful diagrams that make it easy to get started.
Sharing Research Online
For research to be tracked across different sources, Altmetric needs a research output with a persistent identifier: a DOI, ISBN, PubMed ID, handle ID, etc. When sharing research, it is important to include a link to the original research output.
|
|
“An Update on Eukaryotic Viruses Revived from Ancient Permafrost” Viruses 2023, 15(2), 564; https://doi.org/10.3390/v15020564 Altmetric page: https://mdpi.altmetric.com/details/142929875 Altmetric shows that this article appeared in 250 news stories from 180 outlets including CTV, Fox News, and CNN. |
|
|
“The Global Problem of Insufficient Sleep and Its Serious Public Health Implications” Healthcare 2019, 7(1), 1; https://doi.org/10.3390/healthcare7010001 Altmetric page: https://mdpi.altmetric.com/details/53406248 Altmetric shows that this article appeared in 252 news stories from 168 outlets including BBC, Harvard Business Review, and Forbes. |
|
|
“A Detailed Review Study on Potential Effects of Microplastics and Additives of Concern on Human Health” Int. J. Environ. Res. Public Health 2020, 17(4), 1212; https://doi.org/10.3390/ijerph17041212 Altmetric page: https://mdpi.altmetric.com/details/86529137 Altmetric shows that this article appeared in 197 news stories from 150 outlets including BBC, The Tribune, and World Economic Forum. |
|
|
“An Empirical Study of Chronic Diseases in the United States: A Visual Analytics Approach to Public Health” Int. J. Environ. Res. Public Health 2018, 15(3), 431; https://doi.org/10.3390/ijerph15030431 Altmetric page: https://mdpi.altmetric.com/details/34714141 Altmetric shows that this article appeared in 232 news stories from 149 outlets including Forbes, New York Times, and Harvard Business Review. |
|
|
“Garden Scraps: Agonistic Interactions between Hedgehogs and Sympatric Mammals in Urban Gardens” Animals 2023, 13(4), 590; https://doi.org/10.3390/ani13040590 Altmetric page: https://mdpi.altmetric.com/details/142934305 Altmetric shows that this article appeared in 172 news stories from 168 outlets including BBC. |
Inside MDPI
MDPI Annual Meeting Celebrations in China
On Thursday 25 January, over 1,300 MDPI colleagues from our two offices in Beijing gathered to kick off MDPI’s traditional ‘Annual Meetings.’ These celebrations take place in MDPI’s offices across China, including Dalian, Tianjin, Wuhan, and Nanjing.
The evenings include performances, informative talks and presentations, awards, and entertainment, providing an ideal platform to recognize our colleagues, celebrate their achievements, and set our sights on the future.
“It is essential that we stay connected and share best practices”
I sent a video congratulating everyone on their work and sharing our vision of building MDPI into the most trusted OA publisher, highlighting the roles each of us has to play in achieving that goal.
Unfortunately I could not join in person, but you may recall my recent trip, when I visited our offices in Beijing and Wuhan, which I look forward to visiting again this year.
Although our headquarters are in Basel, Switzerland, and we are expanding throughout Europe and North America, the majority of MDPI’s workforce is in China and throughout the Asia-Pacific region, including offices in Singapore, Thailand, Japan, and newly opened office in South Korea. It is essential that as a global organization, we stay connected and share best practices in order to grow collectively and continue providing the exceptional service to our authors.
The Annual Meeting is a moment to reflect and enjoy the year’s hard work and dedication.
I extend our best wishes to all for the Chinese New Year (Xīnnián kuàilè)!
Coming Together for Science
MDPI and TU Delft Adopt Flat Fee Model in Extended Partnership
We are excited to announce a renewed three-year partnership with Delft University of Technology (TU Delft) in the Netherlands. This collaboration introduces a fixed lump-sum fee, covering publishing costs from 2024 to 2026.
“This initiative reflects our dedication to transparent and inclusive publishing”
TU Delft-affiliated authors will enjoy cost-free publishing in any MDPI journal during this period, aligning with our commitment to removing barriers for open access publishing. The agreement supports Plan S compliance and facilitates a seamless publishing process for TU Delft corresponding authors. This initiative reflects our dedication to transparent and inclusive publishing, providing stability and predictability both for authors and for institutions.
For further details on our Institutional Open Access Program (IOAP), please contact us.
Benefits to MDPI’s IOAP
At MDPI we have a long tradition of partnerships, including our Institutional Open Access Program (IOAP). IOAP supports institutions through simplification, access, transparency, APC discounts, and institutional repository deposits. The program simplifies administrative processes, offers central payment, and allows easy opting in and out. Participants gain free access to Susy, MDPI’s online submission system, with extensive article metadata and exportable data. APC discounts and Book Processing Charge discounts are available for affiliated authors. Automated deposits to institutional repositories and streamlined matching of papers to IOAP participants enhance the overall experience.
For further information, see our IOAP FAQ.
Closing Thoughts
Reflections on the 2024 APE Conference
MDPI was proud to co-sponsor the Academic Publishing in Europe (APE) 2024 Conference that took place in Berlin, Germany, from 9–10 January 2024.
The conference theme, ‘Keep the Conversation Going!’, explored the evolving landscape of scholarly communication. APE is one of the key conferences I make a point to attend each year. January offers a valuable opportunity to engage with new contacts, reconnect with familiar faces, and participate in impactful discussions and presentations among professionals, scholars, and practitioners in the field.
“It's fascinating to see how other publishers are leveraging AI”
Highlights
Some of the standout panels for me include: the role of the UN Sustainable Development Goals (SDGs) within the publishing industry. It was encouraging to hear the current status quo, though I was eager also to learn about the exciting projects planned for 2024 and beyond. These will allow us to track progress in subsequent years. At MDPI, we remain committed to promoting Open–Access (OA) content on SDGs through scientific articles and books. Furthermore, we extend our commitment to sustainability by financially supporting researchers through initiatives such as the World Sustainability Award and the Emerging Sustainability Leader Award, as well as waiving the APC for feature papers on each SDG.
In recent years, discussions on AI have become increasingly prominent at such conferences. It’s fascinating to see how other publishers are leveraging AI to meet the evolving needs of their audiences while at the same time using it to safeguard the scientific process. Other engaging panels that I enjoyed included updates on transformation beyond transformative agreements, the principles of lean change, incentive structures related to research integrity, and the panel on reviewer incentives.
“We can share best practices and lessons learned”
Incorporating MDPI’s Insights into Conferences
I must confess that I sometimes feel overlooked when MDPI is not invited to participate in crucial industry discussions. As the leading open access publisher and the third-largest publisher overall, we possess extensive experience in many of these areas and can offer valuable contributions to these discussions. We can share best practices, lessons learned, and our thinking about future trajectories. For instance, in panels discussing reviewer incentives, at MDPI we offer a discount voucher to reviewers for future submissions, reflecting our commitment to fostering a robust peer review process. In 2022 alone, MDPI collected over 1.4 million peer review reports, informing the decision-making processes of our editors. Given our expertise in these areas, it would be natural to include MDPI in such discussions. I therefore extend an invitation to future conference organizers to consider MDPI for speaking engagements and collaborative opportunities.
Chief Executive Officer
MDPI AG
30 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Pediatric Oncology”
26 January 2024
Acknowledgment of the Reviewers of Cancers in 2023
25 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Therapy”
25 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Epidemiology and Prevention”
25 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Metastasis”
24 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Molecular Cancer Biology”
24 January 2024
Cancers | Cervical Cancer Awareness Month
24 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Infectious Agents and Cancer”
23 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Survivorship and Quality of Life”
22 January 2024
Cancers | Highly Cited Papers in 2023 in the Section “Clinical Research of Cancer”
22 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Systematic Review or Meta-Analysis in Cancer Research”
22 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Cancer Causes, Screening and Diagnosis”
19 January 2024
Cancers | Top 10 Cited Papers in 2023 in the Section “Methods and Technologies Development”
18 January 2024
Cancers | Highly Cited Papers in 2023 in the Section “Cancer Informatics and Big Data”
17 January 2024
Cancers | Highly Cited Papers in 2023 in the Section “Tumor Microenvironment”
17 January 2024
Cancers | Highly Cited Papers in 2023 in the Section “Cancer Biomarkers”
9 January 2024
Meet Us at the 7th Symposium on Primary Breast Cancer in Older Women, 1 March 2024, Nottingham, UK
2 January 2024
MDPI Insights: The CEO’s Letter #7 - Nobel Laureates Entrust MDPI with Their Research
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Nobel Prize Laureates Entrust MDPI with Their Research
The Nobel Prize stands as a hallmark of distinction, honouring ground-breaking research across disciplines. Annually, the Nobel Prizes are awarded in six categories: Physics, Chemistry, Medicine or Physiology, Literature, Peace, and Economic Sciences.
Through the years, renowned scholars have entrusted MDPI with their work. As at December 2023, 26 Nobel laureates have contributed to more than 75 articles across 25 MDPI journals, including: Antibiotics, Applied Sciences, Biology, Biomedicines, Cancers, Catalysts, Cells, Crystals, Entropy, Games, IJMS, Life, Materials, Micromachines, Molecules, Pharmaceuticals, Pharmaceutics, Photonics, Quantum Beam Science, Remote Sensing, Sensors, Solids, Universe, Vaccines, and Viruses.
The best of the best trust us with their work.
Nobel Prize Laureates Who Have Published with MDPI
We are proud to list the names of Pierre Agostini, Hiroshi Amano, Werner Arber, Aaron Ciechanover, Robert H. Grubbs, Oliver Hart, Gerard ‘t Hooft, Michael Houghton, Harald zur Hausen, Katalin Karikó, Jean-Marie Lehn, Gérard Mourou, Ferid Murad, Shuji Nakamura, William Nordhaus, Kostya S. Novoselov, Giorgio Parisi, Charles M. Rice, Alvin E. Roth, Donna Strickland, K. Barry Sharpless, George F. Smoot, Anne L’Huillier, Drew Weissman, Kurt Wüthrich, Ada Yonath.
The privilege of hosting such contributors resonates deeply with our editorial teams. For instance, in this interview, the Editor-in-Chief (EiC) of Universe speaks on the significance of publishing a paper by Nobel laureate Gerard ’t Hooft within the journal.
2023 Nobel Prize Winners Published by MDPI
Nobel Prize Winners, 2023: Katalin Karikó, Drew Weissman, Anne L’Huillier (Ill. Niklas Elmehed © Nobel Prize Outreach)
Three laureates from the 2023 Nobel Prize cohort have trusted MDPI as their publishing platform. Notably, in a 2022 Pharmaceutics paper, molecular biologist Katalin Karikó and her team presented a methodology for evaluating mRNA capping efficiency, pivotal for therapeutic applications. Pharmaceutics had previously dedicated a Special Issue to “mRNA Therapeutics: A Themed Issue in Honor of Professor Katalin Karikó”, spotlighting ten articles from August 2021 to February 2022.
In the journal Vaccines, Professor Drew Weissman, collaborating with scholars from Pennsylvania University and George Mason University, contributed an influential review titled “Nanomaterial Delivery Systems for mRNA Vaccines”. His collaborative efforts spanned five papers across MDPI journals between 2021 and 2023.
Furthermore, Anne L'Huillier of Lund University, only the fifth female recipient of the Physics Prize, co-authored an article in Applied Sciences focusing on "Advanced EUV and X-Ray Optics". Similarly, Pierre Agostini, an Emeritus Professor from Ohio State University, co-authored an article featured in the special issue "Attosecond Science and Technology: Principles and Applications".
We extend heartfelt congratulations to all Nobel Prize laureates and express sincere gratitude for their confidence in MDPI as a platform for their scholarly contributions.
Read more:
Impactful Research
MDPI Journals Newly Indexed in 2023
The aim of indexing is to enhance the quality and credibility of published research, ensuring that researchers access the most credible resources available. While the principle behind citation indexing is straightforward, it remains one of the most dependable methods for tracking an idea's evolution across various scientific disciplines.
Throughout the year, MDPI works to expand the reach of our publications across premier multidisciplinary databases like Web of Science, Scopus, EBSCO, and ProQuest. This initiative is spearheaded by MDPI's Indexing team, under the leadership of Dr. Constanze Schelhorn.
In 2023, MDPI achieved 54 new acceptances in Scopus, 29 in Web of Science, 52 in EBSCO, and 83 in DOAJ: Directory of Open Access Journals.
The team prioritizes ensuring that our journals feature in numerous specialized databases, including PMC, PubMed, MEDLINE, Inspec, CAS, and FSTA, among others. Currently, MDPI collaborates with over 65 renowned international databases, consistently enhancing our database affiliations annually.
MDPI’s journals are indexed in all major global databases.
Furthermore, we collaborate with universities and government organizations to list our journals in country-specific ranking lists and relevant institutional repositories. This ensures compliance with requirements often set by funders or institutions for authors to publish in specific journals.
Web of Science Adds 24 MDPI Journals to Emerging Sources Citation Index (ESCI)
Clarivate recently analysed MDPI’s new journals, resulting in 24 journals, mainly established in 2020, being added to the ESCI in November and December 2023. Additionally, five journals passed this assessment earlier in the year. For a complete list of our journals in Web of Science, refer here. Journals in the ESCI meet 24 quality criteria, ensuring editorial rigor. They may be considered for inclusion in broader indices like the Science Citation Index Expanded (SCIE), the Social Sciences Citation Index (SSCI), or the Arts and Humanities Citation Index (AHCI), based on four impact criteria.
Read more:
Inside MDPI
MDPI Appoints New Chief Operating Officer (COO)
Alistair Freeland returned to MDPI and assumed the role of Chief Operating Officer in November 2023, a position he previously held from 2013 to 2019. He succeeds Dr. Yu Lin, who will remain a member of MDPI’s Board of Directors, overseeing significant financial decisions for the company. I would like to express my sincere thanks to Dr. Yu Lin for his service as COO.
Alistair brings extensive experience not only in scholarly publishing but also in technology and business management. Prior to rejoining MDPI, he was associated with SIX Group, the entity responsible for Switzerland's financial market infrastructure. There, he played a pivotal role in developing the blockchain-based platform SDX (SIX Digital Exchange), which has gained traction among major Swiss banks and the Swiss National Bank.
As COO, Alistair will collaborate with the MDPI management team to improve the practices and services we offer to scholarly communities. I am pleased to welcome Alistair back to MDPI and look forward to his contributions going forward.
Coming Together for Science
MDPI’s 2024 In-Person Academic Events Schedule
MDPI's Conference Team is dedicated to organizing and hosting in-person academic events across Europe, Asia-Pacific, and North America. We recognize conferences as invaluable platforms for scientific collaboration, scholarly exchange, discussions on contemporary topics, networking, and forging collaborations.
Here's a glimpse of the notable events we currently have scheduled for 2024:
|
|
14–16 February, 2024 |
|
|
24–26 April, 2024 |
|
|
28–31 May, 2024 |
|
|
1–4 August, 2024 |
Upcoming events with details to be announced:
- September 2024, Materials 2024 – Basel, Switzerland
- 19–21 September 2024, International Conference on Nanomaterials Sciences 2024 – Beijing, China
- October 2024, ncRNA 2024 – Basel, Switzerland
- November 2024, Pharmaceuticals 2024 – Barcelona, Spain
- 22–26 November 2024, International Conference on Science of Electronics – Wuhan, China
- Stay tuned for more details on the Sustainable Publishing Forum 2024.
Click here for all upcoming MDPI events.
Organize Your Event with MDPI’s Sciforum
Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.
Closing Thoughts
Reflecting on 2023 and Looking Ahead to 2024
As we approach 2024, I reflect on the incredible journey we’ve had together at MDPI this year. The past 12 months have been marked by ambitious projects and initiatives to improve our internal processes, and a commitment to continue delivering top-notch services to our stakeholders. I’d like to thank each and every one of our staff members for contributing to the positive experiences our stakeholders have reported in our surveys. Your dedication to speed, efficiency, and effective communication with our stakeholders is very much recognized and appreciated.
Becoming a stronger organisation
While we have encountered challenges in 2023, it’s important to understand that these are a part of our growth process. Difficulties provide us with opportunities to reflect, address problems at their roots, and ultimately evolve into a stronger organization. Our stakeholders expect us to overcome tough times, and it’s an expectation that we have for ourselves.
I extend my sincere appreciation to every MDPI employee, from our editorial office and IT department to marketing, indexing, IOAP, societies, Scientific Office board, products, production, conferences, finance, operations, admin, and beyond. To our newest team members, a warm welcome; to our longstanding colleagues, your dedication is invaluable.
“I am committed to taking MDPI to a new level of excellence.”
Interacting with many of you during my visits to our offices and representing MDPI at external events has been a personal highlight. I am deeply grateful to Dr. Lin for entrusting me with the role of CEO of MDPI. Looking forward, I am committed to working closely with our management team to lead MDPI and take it to a new level of excellence, aiming to establish it as the most trusted publisher in open access worldwide. This is a collective endeavour, with each of us shaping MDPI’s reputation. I therefore encourage us to take pride in our work, as it represents not only our craft but also MDPI as a whole.
Accountability and communication
As we look forward to 2024, there’s a lot to be excited about. Together, we’ll navigate challenges, seize growth opportunities, and refine our practices. To solidify MDPI’s position as the premier open access publisher globally, we must bolster accountability, improve stakeholder communication, share MDPI’s best practices, champion the open access philosophy, and educate stakeholders about our mission, methodologies, and motivations.
Thank you for engaging with the CEO Letter over the past six months of 2023. I will continue to release this newsletter as a method of sharing the great work being done at MDPI. Please feel free to connect directly with any insights or questions.
Here’s to a joyous and prosperous 2024!
Chief Executive Officer
MDPI AG
5 December 2023
Cancers 2023 Young Investigator Award—Winner Announced
30 November 2023
MDPI Insights: The CEO’s Letter #6 - MDPI Spain Summit and ResearchGate
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Spain Summit
Stefan Tochev (CEO, MDPI) gives the opening speech at the MDPI Spain Summit.
On Friday 10 November 2023 I was in Barcelona, Spain, to deliver the opening presentation and participate in a panel at MDPI’s Spain Summit, a two-day event, inspired by our salon events in China.
With 16 Editors-in-Chief (EiCs) and 20 Editorial Board Members (EBMs) in attendance, the event, organized by our conference team and Barcelona office, featured presentations on open access (OA), MDPI, and publishing market trends in Spain.
The event provided a great opportunity to engage with stakeholders from various MDPI journals, including Nutrients, Vaccines, Buildings, IJMS, and others. We were able to gather feedback and have open conversations around manuscript quality, the peer-review process, and journal development, as well as accreditation agencies.
Connecting with Editorial Board Members
Stefan Tochev in conversation with Summit participants: "Our EBMs are passionate about the journals they serve."
Interacting with our EBMs in person provides a valuable opportunity to show how important it is to us to connect with them, hear their perspectives on their journals and learn more about their own experience collaborating with MDPI.
From my conversations, it was clear that our EBMs are passionate about the journals they serve. I know the advice they provide may sometimes involve just small tweaks, but these can lead to important improvements. As the saying goes, small hinges swing open big doors.
As at November 2023, MDPI has over 6,300 EBMs affiliated with Spanish institutions, with more than 30 of them serving as EiCs or section EiCs. Furthermore, over 68,000 Spanish scholars have contributed as reviewers in MDPI journals.
Open Access in Spain
In 2023, Spain implemented legislation mandating immediate OA for all publicly funded research, aligning with the EU’s Plan S initiative to expedite the transition to OA. The Spanish government also approved a four-year, €23.8 million annual budget for the first national OA strategy, aiming to make publicly funded research freely accessible upon publication. This strategy aims to strengthen the quality and transparency of research in Spain, and to help promote movement towards a digital, low-carbon economy.
For further details of Spain's OA policy and the history of government mandates, click here.
Spain has already seen a notable decline in subscription-only articles, decreasing by 62% over a 10-year period, while gold OA increased by 42%. Green OA slightly decreased, suggesting a shift towards publishing in gold OA journals rather than traditional subscription-based ones. Here are some statistics from Scopus.
A big thank-you to the various MDPI teams, including our conference team and the Barcelona office, for organizing this very successful event!
MDPI colleagues from various offices gathered to host and support the first MDPI Spain Summit, in Barcelona, Spain.
I think this type of gathering has the potential to become an annual event in various locations. For example, Manchester could be an option, as we have over 30 EiCs and over 3,000 EBMs in the UK, a top market for MDPI that publishes high-quality research.
Impactful Research
769 Editorial Board Members of MDPI Journals Recognized as Highly Cited Researchers in 2023
Congratulations to our 769 Editorial Board Members from 40 countries/territories who have been awarded Highly Cited Researcher status for 2023 by Clarivate. This recognition is based on their outstanding scientific research contributions and significant influence in various fields, as evidenced by Web of Science data.
Click here to view the full list of 769 Editorial Board Members.
Clarivate's Highly Cited ResearchersTM list identifies individuals with exceptional impact in scientific and social science domains over the past decade. Their papers rank in the top 1% of citations in 21 fields analysed in ‘Essential Science Indicators,’ showcasing their substantial influence.
This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.
These researchers demonstrate exceptional influence, representing a small fraction of contributors pushing the boundaries of knowledge, contributing to global well-being, sustainability, and security.
Congratulations to these scholars for their remarkable achievement: we are honoured to have them on board with our journals!
Inside MDPI
Corporate Marketing and Communications Strategy Session
Members of MDPI’s Corporate Marketing & Communications team.
For the past few years, I have led the Corporate Marketing & Communications department in our annual strategy session.
This typically involves 2–3 days of focused sessions covering key topics including budgeting, hiring targets, campaign reviews, and planning for the upcoming year, department strategy, and structure.
We are constantly exploring ways to optimize the Corporate Marketing & Communications department to support MDPI’s primary objectives and better convey the MDPI story while serving the scholarly community.
The strategy session also serves as a team-building activity, during which the team voted on bowling!
Strategy Session
In this strategy session, we looked at how to align our teams in order to better streamline our content with our campaigns, build a dedicated marketing team to strategically support our core MDPI products, expand our communications teams and functionalities to focus on company-critical campaigns and press releases, align our new brand design system with our marketing initiatives, set up a community and engagement team to support various teams with their outreach and communication efforts, and increase our use of data in the evaluation of campaign performance.
To grow in these areas, we will be hiring for various positions, including those of Public Relations Manager, Communications Manager, Internal Communications Manager, Campaign Manager, Marketing Associate, and Editorial Engagement Manager.
I am grateful for the way our Corporate Marketing & Communications department has grown and gelled over the years, and I look forward to supporting the department teams and their ideas for the future.
Coming Together for Science
ResearchGate and MDPI Partner to Boost the Visibility of Open Access Content through Journal Home
Stefan Tochev (CEO, MDPI) and Sören Hofmayer (Co-Founder and Chief Strategy Officer, ResearchGate) meet in Berlin, Germany to take their ongoing discussion further.
When I assumed the role of CEO at MDPI, my primary focus was to initiate the building of essential partnerships and collaborations within our industry. After all, I am a firm believer in achieving our goals by helping others achieve theirs and focusing on co-opetition wherever there is an opportunity. I first touched on the notion of co-opetition in MDPI Insights: The CEO's Letter #3, particularly when discussing collaborations with Elsevier.
In light of this, Sören Hofmayer (Co-Founder and Chief Strategy Officer at ResearchGate) and I connected recently to continue a discussion that had been ongoing for months. I was quickly brought up to speed and felt there was an opportunity for MDPI journals to pilot the Journal Home service that ResearchGate had launched. This would provide a new way for MDPI to engage with authors and readers and amplify the visibility of our journals.
While I receive many offers and opportunities for discussions with vendors, I am a firm believer that timing is everything, and in this case, the time for us is now. Sören and I met in person during my recent visit to Berlin and decided to proceed with piloting ten MDPI journals with the Journal Home service.
The press release below provides further details.
Press Release: Berlin (Germany) and Basel (Switzerland), 15 November 2023
ResearchGate, the professional network for researchers, and MDPI, the largest open access publisher in the world and a pioneer in open access publishing, today announced a partnership that will see ten of MDPI’s open access journals benefit from an enhanced presence on ResearchGate through its innovative Journal Home offering.
This new partnership will expand the reach and visibility of MDPI’s participating flagship journals with ResearchGate’s highly relevant community of more than 25 million researchers globally.
Around 210,000 version-of-record articles from these 10 titles will be readily available on ResearchGate, including the full archive material and all new articles as they are published. These journals also benefit from enhanced brand visibility, with dedicated journal profiles, prominent representation on all associated article pages and all relevant touchpoints across the ResearchGate network – keeping the journals top-of-mind with their reader and author audiences. All articles covered by the new partnership will automatically be added to the authors’ publication records in ResearchGate. This not only reduces MDPI authors’ needs for direct management but also offers them valuable insights into the impact of their work, including data about readership and citations.
Closing Thoughts
November is Men’s Health Awareness Month
Stefan Tochev (CEO, MDPI) listening to music as he writes at a coffee shop in Basel, Switzerland.
November is dedicated to raising awareness of various men’s health issues. I have been fortunate to have positive male role models in my life, and I strive to share my experiences with others.
I used to take part in Movember, growing my moustache throughout November to raise awareness and funds and to help “change the face of men’s health.” With male family and friends impacted by physical and mental health issues, I have recently become more interested in men’s overall well-being.
Men often face stigma involving the perceived need always to be strong and have things figured out. Recently, I’ve had meaningful conversations with male friends and colleagues about issues we rarely discuss, and it was a positive experience.
Various factors impact men’s health and well-being, all too easily leading to risky health behaviours including a lack of health awareness, poor health education, and negative, culturally induced, behaviour patterns in our work and personal lives. I hope we can break down these barriers in our work environment.
Healthy men help build healthy families and a healthy society
Men are less likely than women to seek help with their physical and mental health struggles. This is a reminder to prioritize your overall well-being. I hope that as men, we will continue to open up to one another, becoming vulnerable in order to share what we are going through. By sharing and by supporting each other, we can learn and grow together. You are not alone, and when you fall, you can still get up and stand tall.
From one broski to another, you are loved and appreciated. I hope this mindset carries into December and beyond.
Mindfulness
Our content team recently released a handful of articles on mindfulness, a practice that I believe provides a good opportunity for stress release and self-reflection:
Chief Executive Officer
MDPI AG
29 November 2023
Cancers | Highly Cited Special Issues on Pediatric Oncology in 2022
We are pleased to invite you to read the highly cited Special Issues on pediatric oncology in 2022. The Special Issues list is as follows:
|
|
Edited by: Dr. Saurabh Agarwal and Dr. Jianhua Yang |
|
|
“Targeted Therapies for Pediatric Solid Tumors” Edited by: Dr. Michele Bernasconi |
|
|
“Recent Advances in Pediatric, Adolescent and Young Adult (AYA) Psycho-Oncology” Edited by: Dr. Ursula Sansom-Daly, Dr. Jordana McLoone, Dr. Christina Signorelli and Dr. Lauren Winkler |
|
|
“Childhood and Adolescent Cancer” Edited by: Dr. Henrike Karim-Kos and Dr. Rob Pieters |
|
|
Edited by: Dr. Irit Ben Aharon and Dr. Savio George Barreto |
|
|
“Frailty in Pediatric and Young Adult Cancer Survivors: From Bench to Bedside” Edited by: Prof. Francesca Rossi |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers.
Cancers Editorial Office
28 November 2023
Editorial Board Members from Cancers Featured in the 2023 Highly Cited Researchers List Published by Clarivate
23 November 2023
Cancers | Highly Cited Special Issues on Cancer Pathophysiology in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on Cancer Pathophysiology. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“Signaling Pathway in Gastrointestinal Cancer” |
“Advances in Oral Cancer: From Pathology to Treatment” |
|
|
|
|
“Update in Lung Cancer Molecular Pathology: Technological Advances and Clinical Practice” |
“Image Analysis and Computational Pathology in Cancer Diagnosis” |
|
|
|
|
“Pathophysiology and Treatment of Gallbladder Cancer” |
“Predictive and Prognostic Markers in Brain Tumors: From Physiopathology to Clinical Applications” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office at cancers@mdpi.com.
Cancers Editorial Office
22 November 2023
Cancers | Lung Cancer Awareness Month
November is designated as “Lung Cancer Awareness Month”, with various global activities that highlight and increase awareness of lung cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of lung cancers, which published in Cancers (ISSN: 2072-6694). We hope this announcement will provide the useful information for this field.
“Upregulation of CD36, a Fatty Acid Translocase, Promotes Colorectal Cancer Metastasis by Increasing MMP28 and Decreasing E-Cadherin Expression”
by James Drury, Piotr G. Rychahou, Courtney O. Kelson, Mariah E. Geisen, Yuanyuan Wu, Daheng He, Chi Wang, Eun Y. Lee, B. Mark Evers and Yekaterina Y. Zaytseva
Cancers 2022, 14(1), 252; https://doi.org/10.3390/cancers14010252
Available online: https://www.mdpi.com/2072-6694/14/1/252
“Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers”
by Guillaume Anthony Odri, Joëlle Tchicaya-Bouanga, Diane Ji Yun Yoon and Dominique Modrowski
Cancers 2022, 14(2), 360; https://doi.org/10.3390/cancers14020360
Available online: https://www.mdpi.com/2072-6694/14/2/360
“Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges”
by Bocheng Wu, Quaovi H. Sodji and Adegboyega K. Oyelere
Cancers 2022, 14(3), 552; https://doi.org/10.3390/cancers14030552
Available online: https://www.mdpi.com/2072-6694/14/3/552
“Exosomal Proteins and Lipids as Potential Biomarkers for Lung Cancer Diagnosis, Prognosis, and Treatment”
by Ming-Tsung Hsu, Yu-Ke Wang and Yufeng Jane Tseng
Cancers 2022, 14(3), 732; https://doi.org/10.3390/cancers14030732
Available online: https://www.mdpi.com/2072-6694/14/3/732
“Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done”
by Austin J. Bartl, Mary Mahoney, Mark W. Hennon, Sai Yendamuri, Gregory M. M. Videtic, Kevin L. Stephans, Shankar Siva, Mark K. Farrugia, Sung Jun Ma and Anurag K. Singh
Cancers 2022, 14(3), 790; https://doi.org/10.3390/cancers14030790
Available online: https://www.mdpi.com/2072-6694/14/3/790
“Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2”
by Swati Misri, Kirti Kaul, Sanjay Mishra, Manish Charan, Ajeet Kumar Verma, Martin P. Barr, Dinesh K. Ahirwar and Ramesh K. Ganju
Cancers 2022, 14(5), 1181; https://doi.org/10.3390/cancers14051181
Available online: https://www.mdpi.com/2072-6694/14/5/1181
“Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance”
by Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux and Michèle Beau-Faller
Cancers 2022, 14(5), 1321; https://doi.org/10.3390/cancers14051321
Available online: https://www.mdpi.com/2072-6694/14/5/1321
“Application of Artificial Intelligence in Lung Cancer”
by Hwa-Yen Chiu, Heng-Sheng Chao and Yuh-Min Chen
Cancers 2022, 14(6), 1370; https://doi.org/10.3390/cancers14061370
Available online: https://www.mdpi.com/2072-6694/14/6/1370
“Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis”
by Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso and Gennaro Palmiotti
Cancers 2022, 14(6), 1404; https://doi.org/10.3390/cancers14061404
Available online: https://www.mdpi.com/2072-6694/14/6/1404
“Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine”
by Laetitia Seguin, Manon Durandy and Chloe C. Feral
Cancers 2022, 14(7), 1759; https://doi.org/10.3390/cancers14071759
Available online: https://www.mdpi.com/2072-6694/14/7/1759
|
“Prevention and Quality of Life of Lung Cancer” Edited by: Prof. Dr. Servet Bölükbas
|
“Mechanisms of Therapy Resistance in Lung Cancer” Edited by: Dr. Andrea De Giglio |
|
“Novel Biomarkers in Non-small Cell Lung Cancer (NSCLC)” Edited by: Dr. Alfredo Tartarone
|
“Genetic, Epigenetic, and Epitranscriptomic Changes in Lung Cancer” Edited by: Dr. Giovanni Nigita, Dr. Mario Acunzo and Dr. Patrick Nana-Sinkam
|
You are welcome to submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
21 November 2023
769 Editorial Board Members of MDPI Journals Achieve Highly Cited Researcher Recognition in 2023
21 November 2023
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Drug Development”
17 November 2023
Cancers | Highly Cited Special Issues on Cancer Epidemiology and Prevention in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on cancer epidemiology and prevention. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. You can contact the Editorial Office at cancers@mdpi.com.
Cancers Editorial Office
16 November 2023
Cancers | Highly Cited Special Issues on Tumor Microenvironment in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on tumor microenvironment. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
 “Molecular Aspects of Tumor Microenvironment of Colorectal Cancers”Edited by Prof. Dr. Maria Cristina Curia Viewed by 17900+ | Cited by 70+ |
 “Engineering the Tumor Immune Microenvironment”Edited by Dr. Scott S. Verbridge Viewed by 35900+ | Cited by 60+ |
 “Primary Bone Tumors: Microenvironment, Signaling and Therapeutic Targeting”Edited by Dr. Françoise Rédini and Dr. Franck Verrecchia Viewed by 14900+ | Cited by 30+ |
 “Inflammation and the Immunosuppressive Pancreatic Cancer Microenvironment“Edited by Dr. Brian A. Boone and Dr. Tim D. Eubank Viewed by 19500+ | Cited by 90+ |
 “Multicellular Effects of STAT3 in the Tumour Microenvironment”Edited by Dr. Ashwini L. Chand Viewed by 19200+ | Cited by 70+ |
 “Cancer Microenvironment–Hypoxia“Edited by Dr. María Dolores Chiara Romero Viewed by 15900+ | Cited by 40+ |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
16 November 2023
Cancers | Highly Cited Special Issues on Infectious Agents and Cancer in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on the topic of infectious agents and cancer.
The Special Issues list is as follows:
 “Molecular Pathogenesis of Epstein-Barr Virus-Associated Malignancy”Edited by Prof. Dr. Hironori Yoshiyama, Prof. Dr. Asuka Nanbo and Prof. Dr. Tomoharu Yasuda Views: 12600+ | Cited by 11+ |
|
|
|
|
“
“
“You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
16 November 2023
Cancers | Highly Cited Special Issues on Cancer Therapy in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on cancer therapy. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“Advances in Lung Cancer Therapy” |
“Application of Proton Beam Therapy in Cancer Treatment” |
|
|
|
|
“Drug Repurposing for Cancer Therapy” |
“Novel Targets and Approaches in Cancer Therapy” |
|
|
|
|
“New Strategies in Diagnosis and Treatments for Brain Tumors” |
“Radiation Therapy in Thoracic Tumors: Recent Trends and Current Issues” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
16 November 2023
Cancers | Highly Cited Special Issues on Cancer Metastasis in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on cancer metastasis. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“From Progression to Metastasis of Solid Cancer” |
“Brain Metastasis in Breast Cancer” |
|
|
|
|
“Understanding Molecular Regulation of Cancer Progression and Metastasis” |
“Colorectal Cancer Heterogeneity and the Impact on Metastasis Formation and Therapy Efficacy” |
|
|
|
|
“Metastasis and Tumor Cell Migration of Solid Tumors” |
“Genomic Landscape of Breast Cancer: From Primary to Metastasis” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office at cancers@mdpi.com.
Cancers Editorial Office
15 November 2023
Cancers | Highly Cited Special Issues on Methods and Technologies Development in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on the topic of methods and technologies development.
The Special Issues list is as follows:
|
|
|
|
“Novel Techniques and Technology for Treatment of Brain Tumors” |
“Biophotonics and Imaging for Cancer Screening, Diagnosis and Treatment Monitoring” |
|
|
|
|
“Recent Advances in Nanotechnologies for Cancer Detection and Treatment” |
“Non-Invasive Imaging and Spectroscopic Methods in Cancer” |
|
|
|
|
“Application of Emerging Technologies in Zebrafish and Mammalian Cancer Models for Disease Characterization and Therapeutic Target Discovery” |
“Current Advances in Chimeric Antigen Receptor Technology” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
15 November 2023
Cancers | Highly Cited Special Issues on Molecular Cancer Biology in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on molecular cancer biology. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“Updates on Molecular Targeted Therapies for CNS Tumors” |
“Molecular Genetics and Treatment of Chronic Myeloid Leukemia” |
|
|
|
|
“Molecular Mechanisms Underlying Tumor Onset and Progression in Liver Cancers” |
“Molecular Pathogenesis and Management of Anaplastic Large Cell Lymphoma” |
|
|
|
|
“Molecular Mechanisms of Lung Cancer and Mesothelioma” |
“Molecular Pathogenesis of Cervical Cancer” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers.
Cancers Editorial Office
15 November 2023
Cancers | Highly Cited Special Issues on Cancer Immunology and Immunotherapy in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on cancer immunology and immunotherapy. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“Tumor Immunology and Immunotherapy Resistance” |
“Perspectives of Immunotherapy in Tumors of the Gastrointestinal Tract” |
|
|
|
|
“Immunotherapy of Triple-Negative Breast Cancer” |
“Cancer Immunotherapy and Immune-Related Adverse Events” |
|
|
|
|
“Oncolytic Viruses as Cancer Immunotherapy Agents” |
“Immunotherapy for Solid Tumors” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
14 November 2023
Cancers | Highly Cited Special Issues on Clinical Research of Cancer in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on clinical research of cancer. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“Clinical Perspective and Translational Oncology of Liquid Biopsy” |
“Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?” |
|
|
|
|
“Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again” |
“Clinical, Pathological, and Molecular Characteristics in Colorectal Cancer” |
|
|
|
|
“Latest Basic, Translational and Clinical Advancements in HER2-Positive Breast Cancer” |
“Ewing Sarcoma: Basic Biology, Clinical Challenges and Future Perspectives” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
13 November 2023
Cancers | Highly Cited Special Issues on Cancer Drug Development in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on cancer drug development. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
 |
 |
| “New Diagnostic and Therapeutic Tools Against Multidrug Resistant Tumors” Edited by Prof. Dr. Chiara Riganti, Dr. M. Helena Vasconcelos and Prof. Dr. Catherine Passirani Viewed by 38700+ | Cited by 160+ |
“Tumor Models and Drug Targeting In Vitro” Edited by Dr. Sascha Kopp and Dr. Marcus Krüger Viewed by 18700+ | Cited by 30+ |
 |
 |
| “The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance” Edited by Dr. Bi-Dar Wang and Prof. Dr. Luciane R Cavalli Viewed by 20900+ | Cited by 80+ |
“Cancer Stem Cells (CSCs) in Drug Resistance and Their Therapeutic Implications in Cancer Treatment” Edited by Dr. Peter Van Veldhuizen Viewed by 18000+ | Cited by 50+ |
 |
 |
| “Recent Advances in Drug Therapy for Glioblastoma” Edited by Dr. Juan Manuel Sepúlveda-Sánchez Viewed by 17000+ | Cited by 30+ |
“microRNA and Oxidative Drugs in Cancer Therapy and Prevention” Edited by Prof. Dr. Alberto Izzotti and Prof. Dr. Ming You Viewed by 17300+ | Cited by 30+ |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
10 November 2023
Cancers | Highly Cited Special Issues on Cancer Survivorship and Quality of Life in 2022
We are pleased to invite you to read the Highly Cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on Cancer Survivorship and Quality of Life. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
|
“The Role of Lifestyle-Related Factors in Cancer Survivorship” |
“Lymphoma Survivorship” |
|
|
|
|
“New Sights in Cancer Survival Analysis: Non-clinical Determinants of Survival for Patients with Cancer” |
“Lifestyle Modifications and Survival of Cancer Patients” |
|
|
|
|
“Palliative and Supportive Care in Oncology: An Update” |
“Physical Activity and Cancer Care” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers.
https://www.mdpi.com/journal/cancers/special_issues.
Cancers Editorial Office
10 November 2023
Cancers | Highly Cited Special Issues on Cancer Causes, Screening and Diagnosis in 2022
We are pleased to invite you to read the Highly Cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on Cancer Causes, Screening and Diagnosis. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
| “Cervical Cancer Screening and Treatment in the 21st Century” by Dr. Alina E. Sturdza Views: 13600 + | Citations: 25+ |
“Artificial Intelligence and Advanced Medical Imaging in Cancer Diagnosis and Precision Care” |
|
|
|
| “Uveal Melanoma: From Diagnosis to Therapy” by Dr. Emine Kilic Views: 30400 + | Citations: 65+ |
“Bio-Pathological Markers for the Diagnosis and Therapy of Cancers, Volume II” by Dr. Lucia Salvatorelli and Dr. Giuseppe Broggi Views: 13700 + | Citations: 35+ |
|
|
|
|
“Cancer Genomics: Interpreting the Changing Landscape in Cancer Diagnosis and Treatment” |
“Recent Developments of Nuclear Medicine in Cancer Diagnosis and Theranostics” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers.
https://www.mdpi.com/journal/cancers/special_issues.
Cancers Editorial Office
10 November 2023
Cancers | Highly Cited Special Issues on Cancer Informatics and Big Data in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on cancer informatics and big data. We hope this announcement will provide useful information for this field.
The Special Issues list is as follows:
|
|
|
| “Bioinformatics, Big Data and Cancer” Edited by Prof. Dr. Alan Hutson and Prof. Dr. Song Liu Viewed by 65000+ | Cited by 180+ |
“Inside Cancer Genomics: From Structure to Therapy” |
|
|
|
| “Genomics of Rare Hematologic Cancers” Edited by Dr. Francesc Solé Viewed by 35000+ | Cited by 50+ |
“The Application of Biostatistics in Cancers” Edited by Dr. Luciano Cascione, Dr. Francesco Denti and Dr. Antonietta Mira Viewed by 11000+ | Cited by 20+ |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, please contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
8 November 2023
Cancers | Highly Cited Special Issues on Cancer Biomarkers in 2022
We are pleased to invite you to read the highly cited Special Issues in 2022 in Cancers (ISSN: 2072-6694) on the topic of cancer biomarkers. The Special Issues list is as follows:
|
|
|
| “Circulating Biomarkers in Cancer” Edited by Dr. Atocha Romero Viewed by 19938 | Cited by 27 |
“Biomarkers in Melanoma Patients” Edited by Prof. Dr. Piotr L. Rutkowski and Prof. Dr. Mario Mandalà Viewed by 18525 | Cited by 20 |
|
|
|
|
“Diagnostic, Prognostic, Predictive Biomarkers and New Targets for Treatment in Head and Neck Cancers” |
“Novel Biomarkers: Validity, Evaluation and Biological Roles for Breast Cancer” |
|
|
|
|
“Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients. A Selection of Papers from the Third Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)” |
“Models, Mechanisms, and Biomarkers of Prostate Cancer Progression” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
1 November 2023
MDPI Insights: The CEO’s Letter #5 - OA Week, UK, and Strategy
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access Week 2023 – the Global Drive to Open Continues
As the world's largest open-access (OA) publisher, we believe that unrestricted access to research findings is the cornerstone of transparency, efficiency, and quality control across scientific disciplines. At MDPI, we provide free, immediate access to scientific papers, empowering scientists to examine, validate, replicate, and build upon existing results. This minimizes redundancy, optimizes resources, and fosters innovative approaches.
International OA Week, held from 23 to 29 October 2023, provided a unique opportunity to link the global movement toward open sharing and open science with the progress of policy changes at the local level. Our mission, during OA Week and all the year round, is to offer educational resources highlighting the benefits of open-access publishing. The MDPI Blog is a valuable resource for information on open access and open science.
Core principles of OA publishing
Accessibility, transparency, and collaboration are core principles of OA publishing. OA aims to break down barriers that have traditionally restricted research access, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Our commitment to diverse pathways for OA publishing worldwide includes discounts for researchers. You can learn more about how MDPI supports scientific communities here.
One of the key strengths of OA publishing is its ability to facilitate interdisciplinary research. By removing paywalls and promoting knowledge-sharing across disciplines, OA encourages collaboration and innovation. Researchers from various fields can access and build upon each others’ work, fostering a holistic approach to addressing complex global challenges.
OA holds the potential to democratize knowledge, advance science, and drive positive societal change.
Policy driving change
Governments, institutions, and funding agencies have recognized the transformative potential of OA and have implemented policies to promote it. These policies often require publicly funded research to be made openly accessible, accelerating the growth of OA repositories and journals. Check out our spotlights on OA policies in the US, EU and China.
OA publishing is continuously evolving, with community-driven models and technologies shaping its future. Initiatives such as “Plan S” and “cOAlition S” promote OA publishing from the perspective of national funders, requiring grantees to publish their research openly. A new policy announced by the US administration last year mandates that, with effect from January 2026, all US federally funded research should be freely and immediately available after publication.
Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.
For more than two decades, OA publishing has been revolutionizing academic publishing by promoting accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As OA continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.
MDPI is proud to lead the transition to open access.
Read more:
Impactful Research
Spotlight on Smart Cities
Smart cities will serve as a cornerstone for future human development. Their implementation will help us tackle many of the significant challenges we are facing – climate change, ageing populations, waste management, public safety, travel, and so on. Recognising the importance of this multifaceted field, MDPI launched the inaugural issue of Smart Cities in 2018 to provide an advanced forum for research into smart technology and society. Here we take a look at how this journal has developed, and its impact in this exciting field.
As at 30 October, 2023, Smart Cities has published 421 papers and has an Impact Factor of 6.4. It also has a CiteScore of 8.5, and more than one quarter of its published papers – 124 – have been cited 10 times or more.
Highly cited papers in Smart Cities
Below are several highly cited papers recently published in Smart Cities. Citation metrics are current as at 31 October 2023.
1. “Introducing the “15-Minute City”: Sustainability, Resilience and Place Identity in Future Post-Pandemic Cities”
Authors: Carlos Moreno, Zaheer Allam, Didier Chabaud, Catherine Gall and Florent Pratlong
Smart Cities 2021, 4(1), 93-111; https://doi.org/10.3390/smartcities4010006
Citations: Crossref (338), Scopus (366), Web of Science (270), Google Scholar (710)
The paper discusses the socio-economic impacts of the COVID-19 on cities, including increasing inequalities and rising unemployment. It introduces the concept of the "15-Minute City," a form of "chrono-urbanism," as a response to the challenges posed by the pandemic.
2. “A Review on Electric Vehicles: Technologies and Challenges”
Authors: Julio A. Sanguesa, Vicente Torres-Sanz, Piedad Garrido, Francisco J. Martinez and Johann M. Marquez-Barja
Smart Cities 2021, 4(1), 372-404; https://doi.org/10.3390/smartcities4010022
Citations: Crossref (359), Scopus (363), Web of Science (268), Google Scholar (558)
This paper provides an overview of the progress in Electric Vehicles (EVs), focusing on battery technology, charging methods, and emerging research challenges. It also analyzes the global EV market and its future outlook.
3. “IoT in Smart Cities: A Survey of Technologies, Practices and Challenges”
Authors: Abbas Shah Syed, Daniel Sierra-Sosa, Anup Kumar and Adel Elmaghraby
Smart Cities 2021, 4(2), 429-475; https://doi.org/10.3390/smartcities4020024
Citations: Crossref (121), Scopus (151), Web of Science (91), Google Scholar (215)
This paper gives an overview of the Internet of Things (IoT) in the context of Smart Cities, discussing the fundamental components, technologies, architectures, networking technologies, and artificial algorithms that underpin IoT-based Smart City systems.
4. “Artificial Intelligence Techniques in Smart Grid: A Survey”
Authors: Olufemi A. Omitaomu and Haoran Niu
Smart Cities 2021, 4(2), 548-568; https://doi.org/10.3390/smartcities4020029
Citations: Crossref (76), Scopus (94), Web of Science (57), Google Scholar (120)
This survey paper reviews the utilization of artificial intelligence (AI) techniques in the context of the smart grid. It covers various applications of AI in load forecasting, power grid stability assessment, fault detection, and security issues in the smart grid and power systems.
5. “The Metaverse as a Virtual Form of Smart Cities: Opportunities and Challenges for Environmental, Economic, and Social Sustainability in Urban Futures”
Authors: Zaheer Allam, Ayyoob Sharifi, Simon Elias Bibri, David Sydney Jones and John Krogstie
Smart Cities 2022, 5(3), 771-801; https://doi.org/10.3390/smartcities5030040
Citations: Crossref (72), Scopus (75), Web of Science (43), Google Scholar (176)
This paper discusses the concept of the Metaverse, a virtual world introduced by Meta (formerly Facebook), and its potential impact on urban life. It explores how emerging technologies such as AI, Big Data, IoT, and Digital Twins could reshape urban design and services in the context of the Metaverse.
Testimonial
“It was indeed a great and pleasant experience with MDPI regarding our recent publication. The submission process was very straightforward and less time-consuming than the norm. The review process was very fast compared to many other open access journals, which is praiseworthy. The support from the Editorial Office during the revision process was highly useful as well. We look forward to publishing with MDPI in the future, and I will most definitely recommend MDPI to my colleagues and collaborators.” – Dr. Luís Rosa, University of Minho
Article in Smart Cities: Mobile Networks and Internet of Things Infrastructures to Characterize Smart Human Mobility
Inside MDPI
MDPI Manchester office, UK Visit
Allie Shi (Editorial Director, MDPI), Stefan Tochev (CEO, MDPI), Jamie Anderson (Manchester Office Manager, MDPI), Michael O’Sullivan (Senior Scientific Officer, MDPI), Hushneara Akhtar, and Becky Castellon (IOAP Team Lead, MDPI), dining out in Manchester, UK.
In October, I visited MDPI’s new office in Manchester. During the visit, I connected with our English Editing (EE) managers, Scientific Officer, members of the Editorial team, the Marketing team, and IOAP Team Lead.
Our Manchester office focuses primarily on EE services and provides local support for the UK market. Additionally, we regularly visit Editorial Board members and participate in local conferences.
I would like to thank Jamie Anderson, Manchester Office Manager, and her team, for their deep commitment to our Manchester staff and to MDPI’s impact on the UK market.
The UK by numbers
The UK is a hub for the world’s top universities, making it a key market for MDPI and the publishing world in general. It is home to two of the top-five-ranked universities globally, 11 in the top 100, and 15 in the top 200.
As a result, the UK plays a key role in MDPI’s global market. As at October 2023, it ranks as the seventh-largest contributor to the total number of papers published by MDPI. We have 3,500 Editorial Board members affiliated with UK institutions, including 34 serving as Editors-in-Chief (EiCs). Our commitment to collaboration with institutions is evident in the UK, where we have successfully established some 60 Institutional Open Access Program (IOAP) agreements with esteemed institutions, such as the University of Oxford, the University of Cambridge, Imperial College London, the University of Edinburgh, and more.
According to InCites Dataset + ESCI for the period 2018–2022, as at October 2023, nearly 65% of UK papers are now published as OA. Just over 10% of total OA publications are by UK authors. UK papers are known for their high quality, with an average of 11 citations per paper. Furthermore, 2.16% of UK papers are in the top 1% of cited papers, and 14.61% are in the top 10% of cited papers, showcasing their impact.
We are currently hiring EEs in various locations worldwide.
English Editing at MDPI
Our English Editing (EE) department consists of two main branches, Quality Control and Learning and Development, reflecting our priorities. We are continuously enhancing the quality of our English Editing services and have raised the relevant standards, which now extend to company-wide communications. English editors participate in international interviews, conduct English assessments, and provide colleagues with presentations on ways to improve their use of written and spoken English.
While expanding, the EE department has proactively refocused its efforts on the quality of our work and how the English Editing department can benefit the company more broadly. We currently have approximately 140 full-time English Editors based across five offices worldwide, supplemented by over 700 freelance English editors.
Our Manchester office serves as the hub for the EE Department, with EE Managers situated there, except for Kurtis Jackson, who serves as the Head of EE and is located in our Basel office. Manchester EEs play a critical role in establishing and developing EE teams in our other offices, overseeing management and recruitment. The EE department plays a vital role in MDPI’s operations, as it is the department that touches every published paper. If this work interests you, I encourage you to explore our available EE positions, whether you are seeking full-time or freelance opportunities.
Testimonials
“MDPI provides an excellent service compared to any other previously used services. It delivers fast and high-quality results but at an affordable price.” – Ardha Apriyanto, University of Potsdam
“In my role as a professor, I consider that MDPI Author Services offer an excellent quality in the editing of Western academic writing while maintaining the required standards of clarity, precision and rigor. Additionally, delivery times are fast compared to other available services.” – Jesus Insuasti, University of Nariño
Read more:
Coming Together for Science
STM and Frankfurt Book Fair
Attending STM
MDPI has been a proud sponsor of the STM Conference for several years. The STM Conference is a dynamic event featuring interactive sessions, expert panellists, idea-sharing, and ample networking opportunities. On 16 October, the event kicked off with arrival drinks, sponsored by MDPI, followed by a welcoming dinner, providing a great chance to connect and network with industry professionals. The following day was filled with speakers, sessions, and further opportunities to connect. STM exemplifies the collaborative spirit of the scientific community, with session topics including achieving open, visible, and impactful research at scale; maintaining research integrity in a rapidly changing world; and exploring the impact of ever-evolving technology in the scholarly community.
Meeting with Web of Science
On a personal note, one of the highlights of STM was a candid and productive conversation with Nandita Quaderi, Editor-in-Chief and SVP at Web of Science. During our discussion, we talked about MDPI, Web of Science, the IJERPH delisting, and ways of moving forward. This open conversation aimed at fostering better collaboration for the future.
“We discussed ways to improve our communication and collaboration.”
I appreciated our frank discussion and felt that Nandita wholeheartedly supports open access. She also expressed her appreciation for the monthly CEO Letter, which she sees as a way to add personality to the MDPI brand and provide insight into the great work we do at MDPI. While we highlighted the positives, we also discussed ways to improve our communication and collaboration moving forward. This meeting alone made the trip worthwhile, and I hope Nandita doesn’t mind my sharing that she found our chat to be “the most honest and constructive discussion” she’s had with someone from MDPI in recent years.
75th Frankfurt Book Fair
Jelena Milojevic (Book Editor, MDPI), Jovana Dubajic (Book Editor, MDPI), Evan Escamilla (Project Manager, MDPI), Laura Wagner (Head of Books, MDPI), and Jenny Knowles (Commissioning Editor, MDPI), at the Frankfurt Book Fair in Frankfurt am Main, Germany.
For the 75th time, the Frankfurter Buchmesse opened its doors in October to celebrate exciting stories and their authors. If you haven’t yet had the chance to visit the Frankfurt Book Fair, I highly recommend it. It’s the largest book fair in the world, attracting thousands of visitors from around the globe. This is the place to gain valuable industry insights from top-class publishing professionals, connect with publishers directly, and learn about the latest trends in publishing.
MDPI Books
Our Books team was also present at the Frankfurt Book Fair, networking and learning from various panels. Did you know that our MDPI Books department publishes OA Books?
The book publishing program includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.
If you have a book proposal you would like to discuss, please feel free to contact our Books team to understand the benefits and methods of publishing your next book with the OA model.
Closing Thoughts
MDPI Strategy Meeting
As the newly appointed CEO, this is my first year leading the MDPI Senior Management Strategy session. I saw it as an opportunity to explore what MDPI has the potential to become in the next five years. Guided by the vision of its founder and President, Dr. Shu-kun Lin, the company has accomplished remarkable feats over the past 27 years and currently holds the position as the world’s third-largest academic publisher, following Springer Nature and Elsevier.
Our primary objective is to build upon the milestones of the past decades and consolidate MDPI’s position as well-established publishing brand. The two-day meeting emphasized the importance of communicating MDPI’s values more actively via its brand and adopting a straightforward yet impactful approach to managing MDPI as a mature academic publisher.
“Our primary objective is to consolidate MDPI’s position as well-established publishing brand”
As the world’s number one open-access publisher, MDPI has long been a game-changer in the scholarly community, serving millions of authors. The challenge in being a trailblazer is the need to continuously improve and at the same time explore the next blue-ocean strategy, while also maintaining the smooth operation of the business. Our collection model, featuring guest-curated thematic topics in the form of Special Issues, has disrupted the industry. Other publishers closely study us and attempt to replicate our models. The future of this collection model is something we are actively addressing – while, of course, looking ahead to what comes next!
Chief Executive Officer
MDPI AG
31 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Pathophysiology”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Pathophysiology”. The Special Issues list is as follows:
|
|
|
|
“Metabolic Alterations in Cancer” |
“Wnt Pathway Targets in Cancer” |
|
|
|
|
“Interplay between Signaling Pathways and Metabolism in Brain Tumors” |
“Molecular Pathogenesis of Cervical Cancer (Second Edition)” |
|
|
|
|
“Actionable Vulnerabilities in Hematological Malignancies” |
“New Developments in the Treatment of Early-Stage and Advanced Melanoma” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com. You can contact the Editorial Office (cancers@mdpi.com) for any questions you may have.
Cancers Editorial Offices
31 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Pathophysiology”
26 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Tumor Microenvironment”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Tumor Microenvironment”. The Special Issues list is as follows:
|
|
|
|
|
“The Signal-Processing in Tumor” |
|
|
|
|
|
|
|
“Oxidative Stress and Cancer: Possible Beneficial and Antioxidant Strategies” |
“Endothelial Cells in Inflammation, Tissue Repair, Ageing and Cancer” |
|
|
|
|
|
|
“The Development of Effective Therapy Targeting the Microenvironment of Cancer” |
“The Role of Cancer-Associated Fibroblasts in Cancer” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
26 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Infectious Agents and Cancer”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Infectious Agents and Cancer”. The Special Issues list is as follows:
|
|
|
|
“Chronic Viral Infections and Cancer, Openings for Therapies and Vaccines” |
“COVID-19 Infection and Hematological Malignancies” |
|
|
|
|
“Host-Microbiome Interaction and Cancer” |
“Epstein-Barr Virus-Associated Cancers: From Pathogenesis to Treatment” |
|
|
|
|
“Molecular Pathogenesis of Epstein-Barr Virus-Associated Malignancy” |
“Epidemiology of HPV-Associated Oropharyngeal Squamous Cell Carcinoma” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
26 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Pediatric Oncology”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Pediatric Oncology”. The Special Issues list is as follows:
|
|
|
|
“Pediatric/Adolescent Cancer and Exercise” |
“Rare Tumors in Children: Trends in Diagnosis, Treatment and Prevention” |
|
|
|
|
“Updates on Management and Clinical Trials in Pediatric Oncology” |
“Pediatric Cancer Biology: Basic and Translational Implications” |
|
|
|
|
“New Perspectives on Acute Myeloid Leukemia in Children” |
“Advances in Pediatric Acute Myeloid Leukemia” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
25 October 2023
Cancers | Most Viewed Special Issues in the Section “Transplant Oncology”
We are pleased to invite you to read the most viewed Special Issues in Cancers (ISSN: 2072-6694) in the Section “Transplant Oncology”. The Special Issues list is as follows:
|
|
|
|
“Immunotherapy and Transplantation in the Era of Transplant Oncology” |
“Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives” |
|
|
|
|
“Advances in Surgery and Transplantation for Liver Cancer” |
“Liver Transplantation for Cancer: The Future of Transplant Oncology” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
25 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Therapy”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Therapy”. The Special Issues list is as follows:
|
|
|
|
Edited by Prof. Dr. Cristina Müller |
“Radiotherapy for Thoracic Malignancies: New Advances and Challenges” Edited by Dr. Eric C. Ko |
|
|
|
|
“An Update on Surgical Treatment for Hepato-Pancreato-Biliary Cancers” Edited by Dr. Nikolaos Machairas, Dr. Nikolaos Machairas and Dr. Nikolaos Machairas |
Edited by Dr. Navid Sobhani and Dr. Gabriella Nesi |
|
|
|
|
“Recent Advances in Myelodysplastic Syndromes: Diagnosis, Prognosis and Clinical Therapy” Edited by Dr. Thomas Schroeder |
“Contemporary Treatment of Colorectal Cancer” Edited by Dr. Michel Adamina |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
25 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Tumor Microenvironment”
25 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Therapy”
25 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Infectious Agents and Cancer”
25 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Pediatric Oncology”
24 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Drug Development”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Drug Development”. The Special Issues list is as follows:
|
“Advances in Anticancer Drugs and Pharmacotherapy of Cancer” |
“Measurable Residual Disease in Cancer” |
|
|
|
|
“Drug Resistance in Gastrointestinal Cancer” |
“Molecular Mechanisms of Anti-cancer Drugs Action” |
|
|
|
|
“Advanced Cancer Nanotheranostics” |
“Cancer Cell Metabolism and Drug Targets” |
|
|
|
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
24 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Informatics and Big Data”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Informatics and Big Data”. The Special Issues list is as follows:
|
|
|
|
“Application of Multi-Omics Analysis in Cancer Diagnosis, Treatment and Prognosis” |
“Computational Studies of Mutagenic Processes in Cancer” |
|
|
|
|
“Bioinformatics in Cancer Diagnostics and Screening” |
“Global Management of Sarcoma Data: Is Real-Time Predictive Analytics on the Horizon?” |
|
|
|
|
“Genome Maintenance Systems in Cancer” |
“Unlocking the Potential of AI and Big Data in Cancer Research: Advances and Applications” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
24 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Metastasis”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Metastasis”. The Special Issues list is as follows:
|
|
|
|
|
“Breast Cancer Survivors and Supportive Therapies” |
|
|
|
|
|
|
|
“Treatment Advancement in Localized and Metastatic Renal Cell Carcinoma” |
“Novel Insights into Glioblastoma and Brain Metastases” |
|
|
|
|
|
|
“Metastatic Cutaneous Neoplasms and Not Only: Current Knowledge and Perspectives” |
“The Role of Neutrophils in Tumor Progression and Metastasis” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
23 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Molecular Cancer Biology”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Molecular Cancer Biology”. The Special Issues list is as follows:
|
|
|
|
“The Landscape of Transcriptomic Diversity in Oncology” |
“Colorectal Cancers: From Present Problems to Future Solutions Volume II” |
|
|
|
|
“Mucins and Cancers” |
“BRCA-Associated Breast Cancer” |
|
|
|
|
“Advances in Precision Medicine: Targeting Known and Emerging Oncogenic Targets in Lung Cancer” |
“Oxidative Phosphorylation System Dysfunction Role and Mechanisms in Cancer and Its Therapies” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
23 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Clinical Research of Cancer”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Clinical Research of Cancer”. The Special Issues list is as follows:
|
“New Insights into Clinical and Translational Research in Nasopharyngeal Carcinoma” |
“Advances in Bone Tumor and Sarcoma” |
|
|
|
|
“Prognostic Factors in Urologic Cancers—Assessment and Integration into Clinical Care” |
“Steps towards the Clinics in Spatially Fractionated Radiation Therapy” |
|
|
|
|
“Precision Medicine Approaches to Tackle RAS/RAF-Mutant Cancer” |
“PARP Inhibitors in Cancers” |
|
|
|
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
20 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Immunology and Immunotherapy”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Immunology and Immunotherapy”. The Special Issues list is as follows:
|
|
|
|
“Targeted Treatment and Immunotherapy for Hepato-Biliary Tumors” |
“PD-1/PD-L1 Immune Checkpoint Therapy: From Predictive Biomarkers to Noninvasive Imaging” |
|
|
|
|
“Mechanisms of Immunosuppression in Cancer” |
“Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma” |
|
|
|
|
“B Cells and Antibodies in Immune Surveillance and Therapy for Cancer” |
“Anti-tumor Immune Responses: Mechanisms and Escape Mechanisms” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. If you have any questions, you can contact the Editorial Office via cancers@mdpi.com.
Cancers Editorial Office
20 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Molecular Cancer Biology”
20 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Biomarkers”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Biomarkers”. The Special Issues list is as follows:
|
|
|
|
“Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers” Edited by Dr. Edoardo Francini, Dr. Pier Vitale Nuzzo and Dr. Giuseppe Fanelli |
“Glycosylation in Cancer—Biomarkers and Targeted Therapies” Edited by Dr. Jennifer Munkley |
|
|
|
|
Edited by Dr. Ayse U. Akarca |
“Views and Perspectives of Cutaneous Squamous Cell Carcinoma” Edited by Dr. Thomas Meyer and Dr. Alexandra Geusau |
|
|
|
|
“Liquid Biopsy for Lung Cancer Treatment” Edited by Dr. Maria Palmieri and Dr. Frullanti Elisa |
“Genome Sequencing of Cancer: Identifying Targets and Biomarkers for Therapy” Edited by Dr. Haruhiko Takeda |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
20 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Biomarkers”
20 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Immunology and Immunotherapy”
20 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Methods and Technologies Development”
20 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Methods and Technologies Development”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Methods and Technologies Development”. The Special Issues list is as follows:
|
|
|
|
“Recent Trends in PET/CT Tracer Development and Multimodal Imaging” Edited by: Prof. Dr. Olaf Prante and Prof. Dr. Tobias Bäuerle |
“Artificial Intelligence and Machine Learning in Precision Oncology” Edited by: Dr. Carmen Belli and Dr. Santosh Anand |
|
|
|
|
“Decision-Support Systems for Cancer Diagnosis and Prognosis” Edited by: Dr. Margarida Julia-Sape |
“Urologic Cancer: Endoscopic, Laparoscopic, and Robot-Assisted Surgery Managment” Edited by: Dr. Kouji Izumi |
|
|
|
|
“Recent Advances in Oncology Imaging” Edited by: Dr. Li Liu and Prof. Dr. Yicheng Ni |
“PET/CT in Head and Neck Cancer” Edited by: Dr. Sam Payabvash |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. You can contact the Editorial Office (cancers@mdpi.com) for any questions you may have.
Cancers Editorial Office
19 October 2023
Open Access Week 2023 – the Global Drive to Open Continues
19 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Causes, Screening and Diagnosis”
19 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Survivorship and Quality of Life”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Survivorship and Quality of Life”. The Special Issues list is as follows:
|
|
|
|
“The Survival of Colon and Rectal Cancer” Edited by Prof. Dr. Susanne Merkel |
“Palliative Care in Cancer: Recent Advances and Upcoming Trends” Edited by Prof. Dr. Philipp Lenz and Dr. Mitra Tewes |
|
|
|
|
“Management of Side Effects of Cancer Treatments: New Approaches” Edited by Prof. Dr. Martine Berliere and Dr. Francois P. Duhoux |
“Approaches to Improve the Prognosis of Head-and-Neck Cancer” Edited by Dr. Hajime Suzuki and Prof. Dr. Norifumi Nakamura |
|
|
|
|
“Palliative Care for Patients with Cancer” Edited by Prof. Dr. Andrew Davies |
“Medical Complications and Supportive Care in Patients with Cancer” Edited by Dr. Javier Marco-Hernández |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
19 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Systematic Review or Meta-Analysis in Cancer Research”
19 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Causes, Screening and Diagnosis”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Causes, Screening and Diagnosis”. The Special Issues list is as follows:
|
|
|
|
“Perihilar Cholangiocarcinoma” |
“New Insights in Neuroendocrine Neoplasms (NENs) and Thyroid Cancer: Focus on Basic, Translational, and Clinical Research” |
|
|
|
|
“Innovations in Soft Tissue Sarcoma Diagnosis and Treatment” |
“Advanced Research in Pancreatic Ductal Adenocarcinoma” |
|
|
|
|
“Gynecologic Cancer: From Diagnosis to Treatment” |
“Brain and Spinal Cord Tumors: Symptoms, Diagnosis, and Treatment” |
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers via cancers@mdpi.com.
Cancers Editorial Office
19 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Drug Development”
19 October 2023
Cancers | Most Viewed Papers in 2023 on Transplant Oncology
19 October 2023
Cancers | Promotional Video
19 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Clinical Research of Cancer”
19 October 2023
Cancers | Most Viewed Special Issues in 2023 in the Section “Cancer Epidemiology and Prevention”
We are pleased to invite you to read the most viewed Special Issues in 2023 in Cancers (ISSN: 2072-6694) in the Section “Cancer Epidemiology and Prevention”. The Special Issues list is as follows:
|
“Feature Paper in Section “Cancer Epidemiology and Prevention” Edited by Prof. Dr. Roger Anderson and Dr. Paweł Koczkodaj
|
Edited by Dr. Vikas Yadav, Dr. Hardeep Singh Tuli and Prof. Dr. Mukerrem Betul Yerer Aycan |
|
“Advancing Health Equity to Reduce Cancer Health Disparities” Edited by Prof. Dr. Shailesh Singh and Dr. Rajesh Singh
|
“Lifestyles and Hepatocellular Carcinoma” Edited by Prof. Dr. Jean-François Dufour
|
|
“Inherited Breast Cancer Risk: BRCA Mutations and Beyond” Edited by Prof. Dr. George Fountzilas, Dr. Helena Linardou and Dr. Alexia Eliades
|
Edited by Dr. Sanjay Premi and Dr. Jyoti Srivastava
|
You are welcome to view all the Special Issues and submit relevant papers to the journal Cancers. You can contact the Editorial Office (cancers@mdpi.com) for any questions you may have.
Cancers Editorial Office
19 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Epidemiology and Prevention”
17 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Metastasis”
16 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Informatics and Big Data”
12 October 2023
Cancers | Most Viewed Papers in 2023 in the Section “Cancer Survivorship and Quality of Life”
8 October 2023
Meet Us at APHA’s 2023 Annual Meeting and Expo, 12–15 November 2023, Atlanta, USA
2 October 2023
MDPI Insights: The CEO’s Letter #4 - MDPI Presence in China
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access in China
It is Saturday, 23 September, and I have just returned from an unforgettable 12-day trip to China, visiting our main offices in Beijing and Wuhan. In the wake of a packed and very enjoyable agenda of internal and external meetings, I would like to use this edition of the CEO Letter to showcase how MDPI supports the scholarly community in China.
Coincidentally, Jack McKenna, Communications Associate from MDPI’s corporate content team, has just released a blog article discussing China’s open access (OA) policy. It is a timely read, providing a concise overview of the development of the OA movement in China and reflecting on its future. I shall draw some content from Jack’s piece and use this edition of the CEO Letter to highlight the various ways in which MDPI is involved in this market. And it would be remiss of me not to include some pictures and highlights from my travels!
Open Access Policy in China
As per Jack’s post, in 2020, China became the world’s leading producer of research articles. Today, China is experiencing a “substantial growth rate in OA [Open Access] publication”. This growth is supported by the State’s commitment to research & development and its policy “requiring the promotion of open science”.
Over the past two decades, there have been gradual developments in China’s OA framework, with repositories and platforms being developed in a consistent manner. Currently, key institutions across China – including the National Science Library, the National Science and Technology Library, and the Natural Science Foundation of China – support OA. The State aims to establish consistent policies across government agencies – a framework for a more encompassing embrace of OA across institutions.
In China, the number of subscription-only articles decreased by nearly 30% over the 10-year period of 2011–2021, while gold OA increased by 22%. Between 2017 and 2020 alone, China published 800,921 academic papers in an OA format.
In 2023, as the leading publisher of academic research, China is pursuing “self-reliance”. Therefore, the State will be establishing consistent policies across government agencies, including those related to OA. Additionally, it will want to ensure that Chinese people can access the research that is supported by Chinese funding and produced by Chinese academics. For this reason, “Open Access is a matter of priority in China”.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI’s founder is very much rooted in China. Dr. Shu-kun Lin, Founder and President of MDPI, graduated with a BSc from Wuhan University in 1982. He also studied physical chemistry at the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (1982–1986; MSc in 1985), and at the University of Louisville, USA (1987–1989). Dr. Lin completed his doctorate in organic chemistry at the Swiss Federal Institute of Technology (ETH-Zürich) in 1992.
Stefan Tochev (CEO, MDPI) at MDPI’s Wuhan office.
In 2002, MDPI’s Basel headquarters moved to Matthäusstrasse 11, 4052 Basel, and Dr. Lin opened an editorial office in Qingdao, China, which launched the journal Marine Drugs in the following year. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
Our Strength is in Our People
With over 6,000 MDPI staff, across 20 offices in 11 countries, MDPI is able to offer authors responsive and efficient round-the-clock support, enabling a rapid publication process.
In my experience, stakeholders are genuinely surprised when they realize the extent of our global operations. My response is to reiterate that our people are our strength. This is why we have fast and efficient processes and top-notch responsiveness. Our global presence ensures that your manuscript is constantly attended to, rather than sitting on someone’s desk. We prioritize our authors’ needs and act quickly to move things through the various stages of publication. MDPI is built on speed, convenience, and competence, which I believe are core pillars for success in any industry. We continually strive to improve our systems and processes on the basis of these core strengths. We literally have over 6,000 staff worldwide dedicated to serving your needs. It’s not magic: it’s people; it’s real.
Impactful Research
MDPI Awards
To support the academic community, and especially young researchers, and also to enhance communication among scientists, MDPI journals offer various awards in specific fields. We serve the scientific community by funding research to facilitate the development of sustainable global solutions through our annual World Sustainability Award and Emerging Sustainability Leader Award.
In 2022, MDPI made awards totalling over US$1 million in recognition and support of researchers worldwide.
Across our journal catalogue, we have granted over 2,000 awards to recognize and support researchers from all disciplines. Since 2016, these awards have served as a source of recognition, acknowledging the impact of research by heightening the influence of talented individuals. The award types mainly include the Young Investigator Award, the Best PhD Thesis Award, the Best Paper Award, and the Outstanding Reviewer Award.
To learn more about MDPI Awards and to find out which are currently available, please click here.
MDPI Awards to Scholars from China
Since 2021, there have been 23 Best Paper Awards granted to authors affiliated with Chinese institutions, identifying their papers as having high-quality scientific impact. A total of 45 Chinese scholars have received awards such as the Young Investigator Award, the Best PhD Thesis Award, the Outstanding Reviewer Award, and the Tu Youyou Award, among others. Prizes for these awards include MDPI grants for paid publications, totalling over CHF 70,000 for scholars affiliated with Chinese institutions.
MDPI’s Tu Youyou Award
Prof. Tu Youyou (left), Dr. Shu-Kun Lin (President, MDPI).
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” In order to commemorate Professor Tu’s contributions to human health and to promote the passion and spirit conveyed by her experiences, MDPI in 2016 established the ‘Tu Youyou Award’, which runs biennially to recognize outstanding scholars dedicated to the research of natural products and medicinal chemistry.
The 2022 Tu Youyou Award was granted to Prof. Dr. Xiaoguang Lei of Peking University. Click here to access the interview with the winner.
2015 Nobel Prize for Medicine Awarded to Professor Youyou Tu
Professor Tu’s work was celebrated in a Special Issue from Molecules on the occasion of her 80th birthday. The Special Issue: 'Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of her 80th Anniversary” was created five years before she won the Nobel Prize, highlighting the visibility MDPI provides researchers and their work.
Highly Cited Articles by Chinese Scholars Published in MDPI
Click here to access the most cited MDPI papers published by scholars affiliated with Chinese institutions. This list presents the most influential research from the more than 287,000 MDPI papers published by Chinese scholars. With over 9 million total citations, I encourage you to maximize your visibility and impact by publishing with MDPI, the number one most cited open access publisher.
Read more:
- Tu Youyou Award
- World Sustainability Awards
- Available Awards
Inside MDPI
Stefan Tochev (CEO, MDPI) with the Beijing Marketing team.
Marketing Department in China
During my visit to our offices in Beijing and Wuhan, I had the opportunity to meet with, and to present to, our local marketing teams. These teams are responsible for various journal-related and corporate promotional activities, including newsletters, conferences, seminars, author training, journal awards, content creation, digital marketing, and social media.
I was pleased by the ambition and curiosity of our marketing colleagues. They showed a strong desire to collaborate and acquire knowledge and tactics to effectively market and promote MDPI-journal-related activities. I presented some of the principles and objectives that we apply in the Corporate Marketing and Communications department, and used the opportunity to strengthen our collaborative communications across offices.
Stefan Tochev (CEO, MDPI) with the Wuhan Marketing team.
Coming Together for Science
Collaborations, Scholarships and Meetings
MDPI maintains partnerships with nearly 190 learned societies and over 800 institutions and consortia, helping to facilitate the transition to OA publishing. Our commitment to working with institutions is evident in China, where we have successfully established over 35 Institutional Open Access Programs (IOAP) with esteemed institutions such as the Tsinghua University, Huazhong University of Science and Technology, and Shanghai Jiao Tong University.
Our institutional partnerships, waiver programs, and article processing cost discounts create diverse pathways to OA publishing for researchers worldwide.
Scholarships in China
Since 2021, several MDPI journals (Sensors, Photonics, Coatings, Materials, Energies, and Journal of Fungi) have funded full scholarships for four Master’s and five Ph.D. projects in China. These scholarships align with Tianjin University, Wuhan University of Technology, Central South University, the Chinese Academy of Sciences, and the China University of Petroleum (Beijing).
Meeting with the Society of Chinese University Journals (CUJS)
Prof. Tieming Zhang (President of CUJS, centre) and MDPI colleagues at CUJS office.
I am pleased to have participated in some highly productive meetings during my visit to China, including one with the Society of Chinese University Journals (CUJS). The meeting involved Prof. Tieming Zhang (President of CUJS), Assoc. Prof. Xin Zhang (Vice President and Secretary General), and Dr. Fei Gao (Executive Member of CUJS). Alongside my colleagues Dr. Guoshi Liu, Dr. Giulia Stefenelli, and Anita Sun, I represented MDPI and held an open discussion to address any questions regarding OA and MDPI.
We discussed several methods for collaboration, including a workshop on the future of peer review, MDPI sponsoring a funding grant for early-career researchers, and transitioning journals from diamond to gold OA. I am thankful for the opportunity to have met our colleagues at CUJS in person and feel very confident about our future collaborations in support of OA publishing in China.
MDPI hosts free academic seminars, author training sessions, and academic conferences as part of its commitment to enrich and support the scholarly community. CUJS often stages academic events (e.g., conferences, editor training, and editor competitions), and I believe there are great opportunities for CUJS and MDPI to collaborate accordingly.
Meeting with National Science Library, Chinese Academy of Sciences (NSLC)
Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Officers, MDPI), Anita Sun (PR Manager, MDPI) and Dr. Guoshi Liu (Managing Director, MDPI) at the National Science Library, Chinese Academy of Sciences.
We also visited the NSLC Director, Xiwen Liu, and colleagues Ying Jin, Zhesi Shen, and Sichao Tong. Following our introductions, we gave a presentation on the history and editorial process at MDPI, discussing specific details related to MDPI’s business and data. We highlighted the status of our IOAP collaborations in China and the makeup of our author base, specifically in China, and drew attention to the fact that MDPI has published research by authors from every country in the world. We then discussed the design indicators, calculation methods and implementation purposes of the ‘Early Warning Journal List’ and how we can have open communication to provide any data regarding MDPI journals. I am pleased to report that we reached a consensus on future communications, and am grateful to NSLC for hosting us in their offices.
In-person meetings with stakeholders provide an invaluable opportunity to communicate what MDPI is about and the various ways in which we serve the scholarly community. While digital marketing and online communication are essential, they are no replacement for the understanding and trust that come about through in-person interactions.
The Numbers
As at September 2023, China holds the largest position in MDPI’s global market, ranking as the largest contributor to the total number of papers published by MDPI.
At this point in time, there were more than 847,000 China mainland scholars who have published with MDPI, 51 of whom are Section-Editors-in-Chief (SEiC) of MDPI journals, with seven serving as Editors-in-Chief (EiCs) for journals such as Air, Big Data and Cognitive Computing, Blockchains, Future, Nanoenergy Advances, and Targets.
Our growth and presence in China are a true testament to the service we provide to the scholarly community, and to the relationships we foster through collaborative activities. We look forward to continuing to support the growth of the scholarly community in China, providing a valuable and trusted experience with MDPI.
Closing Thoughts
Final Reflections on our MDPI Offices in Beijing and Wuhan
Stefan Tochev (CEO, MDPI), Dr. Constanze Schelhorn (Indexing Manager, MDPI), Jiale Shang (Admin, Tongzhou, MDPI) at Beijing Capital International Airport, Beijing.
I spent approximately two weeks visiting some of our offices in China, and the first word that comes to mind when describing my experience is ‘hospitality.’ My colleagues and I were met with enthusiasm and delight at the airport by the Tongzhou Admin team (thank you, Jiale Shang, and thank you, Eric Wang, for keeping us organized on this trip!) and were taken care of with great attention. From hotels to transportation, dinners, and meetings, our stay was catered for perfectly.
Perhaps this is where MDPI’s focus on customers and service originates. At our core, we are a service company that provides a publishing platform for its authors. It’s therefore no surprise that authors consistently rate their experience with MDPI very highly.
95% of submitting authors rate their overall experience with the MDPI publication process as Excellent or Good (Springer Nature report 90%).
91% of submitting authors rate their overall experience with the MDPI peer review process as Excellent or Good.
Speed/Efficiency and Editorial Relationship are two key reasons underlying this high satisfaction score. ‘Editorial Relationship’ can be further explored, but in the past month, the most commonly noted aspects were the professionalism, kindness, availability, communicativeness, and personalized assistance provided by our editorial staff throughout the process. These attributes are at the core of our work across all our offices and continents.
Hospitality and Service
Just as our Chinese colleagues strove to keep us engaged by showing us the city sights (thank you, Thea Pan, and Jason Wu from the Wuhan Marketing team!) and sharing a variety of wonderful meals, our editorial staff are committed to serving our authors throughout their publishing journey. Our aim is to place the author at the centre of everything we do, eager to welcome our ‘guests’ and provide them with a pleasant publishing experience.
I asked my colleague Francis Wu (Senior Publisher, Wuhan office) where this hospitality originates. He responded that it is part of Chinese culture. I reflected long and deep on this answer. China is a vast country, and when visitors arrive, hosts want to ensure they feel welcomed and taken care of in order to maximize their time and visit. I can’t think of a better analogy for how I would want our authors to feel when they visit MDPI for their publishing needs. A company culture that prioritizes service, something that goes beyond products and productivity, and focuses on the overall experience. Over 6,000 people, across all MDPI offices, are ready, willing and able to go the extra mile for their colleagues and their customers. This is something I am truly proud of.
Chief Executive Officer
MDPI AG
27 September 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Tumor Microenvironment
We are delighted to share some highly cited papers on tumor microenvironment that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment”
by Maximilian Haist, Henner Stege, Stephan Grabbe and Matthias Bros
Cancers 2021, 13(2), 210; https://doi.org/10.3390/cancers13020210
Available online: https://www.mdpi.com/2072-6694/13/2/210
“The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression”
by Almudena García-Ortiz, Yaiza Rodríguez-García, Jessica Encinas, Elena Maroto-Martín, Eva Castellano, Joaquín Teixidó and Joaquín Martínez-López
Cancers 2021, 13(2), 217; https://doi.org/10.3390/cancers13020217
Available online: https://www.mdpi.com/2072-6694/13/2/217
“Energy Sources for Exosome Communication in a Cancer Microenvironment”
by Abhimanyu Thakur, Amanda Johnson, Emily Jacobs, Kui Zhang, Jonathan Chen, Zhubo Wei, Qizhou Lian and Huanhuan Joyce Chen
Cancers 2022, 14(7), 1698; https://doi.org/10.3390/cancers14071698
Available online: https://www.mdpi.com/2072-6694/14/7/1698
“Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets”
by Ralf-Peter Czekay, Dong-Joo Cheon, Rohan Samarakoon, Stacie M. Kutz and Paul J. Higgins
Cancers 2022, 14(5), 1231; https://doi.org/10.3390/cancers14051231
Available online: https://www.mdpi.com/2072-6694/14/5/1231
“Cyclic Hypoxia: An Update on Its Characteristics, Methods to Measure It and Biological Implications in Cancer”
by Samuel B. Bader, Mark W. Dewhirst and Ester M. Hammond
Cancers 2021, 13(1), 23; https://doi.org/10.3390/cancers13010023
Available online: https://www.mdpi.com/2072-6694/13/1/23
|
“Tumor Microenvironment Targeted and Immunotherapies for Brain Cancer” Edited by: Dr. Lisa Sevenich
|
“Unique Perspectives in Cancer Signaling” Edited by: Dr. Peiwen Fei |
|
“The Role of Immunity in the Tumor Microenvironment” Edited by: Dr. Nand K Roy
|
“Microenvironment of Leukemia” Edited by: Dr. Francesco Bertolini
|
We hope this announcement will provide useful information for the field of tumor microenvironment.
22 September 2023
Cancers | Thyroid Cancer Awareness Month
20 September 2023
Meet Us at the 109th Radiological Society of North America Scientific Assembly and Annual Meeting (RSNA 2023), 26–29 November 2023, Chicago, USA
20 September 2023
Cancers | Prostate Cancer Awareness Month
19 September 2023
Meet Us at the 13th Member Congress of the Chinese Society of Biochemistry and Molecular Biology and 2023 National Academic Congress, 19–22 October 2023, Hefei, China
14 September 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Hepatocellular Carcinoma Research
We are delighted to share some highly cited papers on hepatocellular carcinoma research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma”
by Hyuk Moon and Simon Weonsang Ro
Cancers 2021, 13(12), 3026; https://doi.org/10.3390/cancers13123026
Available online: https://www.mdpi.com/2072-6694/13/12/3026
“Emerging Therapies for Hepatocellular Carcinoma (HCC)”
by Eesha Chakraborty and Devanand Sarkar
Cancers 2022, 14(11), 2798; https://doi.org/10.3390/cancers14112798
Available online: https://www.mdpi.com/2072-6694/14/11/2798
“Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy”
by Konstantinos Arvanitakis, Triantafyllia Koletsa, Ioannis Mitroulis and Georgios Germanidis
Cancers 2022, 14(1), 226; https://doi.org/10.3390/cancers14010226
Available online: https://www.mdpi.com/2072-6694/14/1/226
“The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma”
by Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Anwaar Saeed, Hannah Hildebrand et al.
Cancers 2022, 14(1), 186; https://doi.org/10.3390/cancers14010186
Available online: https://www.mdpi.com/2072-6694/14/1/186
“Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience”
by Maen Abdelrahim, David Victor, Abdullah Esmail, Sudha Kodali, Edward A. Graviss, Duc T. Nguyen, Linda W. Moore, Ashish Saharia, Robert McMillan, Joy N. Fong et al.
Cancers 2022, 14(3), 650; https://doi.org/10.3390/cancers14030650
Available online: https://www.mdpi.com/2072-6694/14/3/650
“Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances”
by Blanca Cucarull, Anna Tutusaus, Patricia Rider, Tania Hernáez-Alsina, Carlos Cuño, Pablo García de Frutos, Anna Colell, Montserrat Marí and Albert Morales
Cancers 2022, 14(3), 621; https://doi.org/10.3390/cancers14030621
Available online: https://www.mdpi.com/2072-6694/14/3/621
|
“Recent Advances in Hepatobiliary Cancers: From Diagnosis to Treatment” Edited by: Dr. Ilyas Sahin
|
“Efficacy and Complications of Liver Resection for Liver Cancer” Edited by: Prof. Dr. Massimo Rossi, Prof. Dr. Quirino Lai and Prof. Dr. Silvia Quaresima |
|
“An Update on Surgical Treatment for Hepato-Pancreato-Biliary Cancers” Edited by: Dr. Nikolaos Machairas, Dr. Stylianos Kykalos and Dr. Dimitrios Schizas
|
“Radiology for Diagnosis and Treatment of Liver Cancer” Edited by: Prof. Dr. Takahito Nakajima and Dr. Wenchao Gu
|
We hope this announcement will provide useful information for this field.
13 September 2023
Cancers | Blood Cancer Awareness Month
8 September 2023
Cancers | Gynaecological Cancer Awareness Month
8 September 2023
Cancers | Childhood Cancer Awareness Month
6 September 2023
Recap of Awards Granted to Scholars in 2022
31 August 2023
Cancers | Top 10 Cited Papers in 2020 in the Section “Cancer Drug Development”
30 August 2023
MDPI Insights: The CEO’s Letter #3 - Sustainability and Co-opetition
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Our Commitment to Sustainability
As a pioneer in academic open access publishing since 1996, MDPI has always been dedicated to facilitating scientific exchange across all disciplines. Our approach to open science is guided by principles such as Open Access (OA), Timeliness and Efficiency, Simplicity, High-Quality Service, Flexibility, and a commitment to Sustainability. This commitment involves preserving published papers for the long term and supporting the future of science through partnerships, sponsorships, and awards.
In this edition of the CEO Letter, I will delve into MDPI’s various sustainability initiatives. As a leader in OA publishing, we are able to provide the public with a significant amount of environment-related content at no cost.
MDPI and the Sustainable Development Goals (SDGs)
In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs. We also support authors from underrepresented communities by waiving publication charges for selected SDG-related papers. Detailed sustainability practices and supported publications are available in the report under each Goal page.
“More than 80% of MDPI articles and reviews published in 2022 relate to the Sustainable Development Goals.” [source: InCites, Accessed on 21.08.2023]
As at August 2023, MDPI boasts 14 journals dedicated to sustainability-related topics. Our first journal in this area, Sustainability, has published over 29,000 articles on the SDGs, accumulating over 240,000 citations (source: InCites, as at 1 January 2023). These journals serve as vital platforms for researchers to share insights and address environmental challenges. In addition:
MDPI journals specializing in sustainability-related topics:
- 2009: Sustainability
- 2012: Resources
- 2013: Climate
- 2014: Environments
- 2016: Recycling
- 2019: Clean Technologies
- 2020: Sustainable Chemistry
- 2021: Wind, Biomass, Conservation, Pollutants, Solar
- 2022: Waste, Microplastics
Read more:
Impactful Research
Highly Cited Articles in Sustainability
In 2022, content published in Sustainability and indexed in Journal Citation Reports (JCR) received nearly 190,000 citations. This highlights the fact that Sustainability publishes highly cited research articles related to environmental sciences and SDG-related topics such as climate action.
We are pleased to share that Sustainability received a 2022 CiteScore of 5.8, marking a 16% increase from the 2021 metric. Specifically, the CiteScore positions Sustainability as follows: Q1 (27 out of 163) in the “Environmental Science (miscellaneous)” category, and Q1 (101 out of 779) in the “Geography Planning and Development” category. For additional journal statistics, please visit here.
“Sustainability received a 2022 CiteScore of 5.8”
While MDPI journals such as Climate and Atmosphere have a distinct focus on atmosphere pollution and its impact on climate processes, journals like Sustainability, Environments, Water, Remote Sensing, and IJERPH publish content related to climate change. These journals have published over 32,300 articles related to SDG 13: Climate Action.
Highly Cited Papers in Sustainability
Below are several highly cited papers published in Sustainability over the past three years. Citation metrics are current as at 15 August 2023.
1. “A Global Assessment: Can Renewable Energy Replace Fossil Fuels by 2050?”Authors: Jerry L. Holechek, Hatim M. E. Geli, Mohammed N. Sawalhah, and Raul Valdez
Sustainability 2022, 14(8), 4792; https://doi.org/10.3390/su14084792
Citations: Crossref (97), Scopus (91), Web of Science (82), Google Scholar (125)
This paper addresses one of the most significant challenges of climate change – achieving Net Zero Carbon by 2050. The meta-analysis suggests that while difficult, this transition is possible through the concerted application of pathways, lifestyle changes, and global cooperation.
2. “Anxiety and the Ecological Crisis: An Analysis of Eco-Anxiety and Climate Anxiety”Author: Panu Pihkala
Sustainability 2020, 12(19), 7836; https://doi.org/10.3390/su12197836
Citations: Crossref (144), Scopus (121), Web of Science (159), Google Scholar (382)
This paper has received substantial media attention, including coverage by The Guardian, BBC, Vice, and CNBC. An interview with Dr. Panu Pihkala, a leading interdisciplinary researcher on the topic, can be found on MDPI’s podcast: Insight Faster, Episode 1.
3. “Impact of Climate Change on Agriculture and Its Mitigation Strategies: A Review”Authors: Gurdeep Singh Malhi, Manpreet Kaur, and Prashant Kaushik
Sustainability 2021, 13(3), 1318; https://doi.org/10.3390/su13031318
Citations: Crossref (207), Scopus (221), Web of Science (186), Google Scholar (355)
This paper reviews literature on climate change, addressing its causes, future projections, impact on agriculture, including plant physiology, growth, productivity, pest infestation, and the economic implications of mitigation strategies.
4. “Impacts of Plastic Pollution on Ecosystem Services, Sustainable Development Goals, and Need to Focus on Circular Economy and Policy Interventions”Authors: Rakesh Kumar, Anurag Verma, Arkajyoti Shome, Rama Sinha, Srishti Sinha, Prakash Kumar Jha, Ritesh Kumar, Pawan Kumar, Shubham, Shreyas Das, Prabhakar Sharma, and P. V. Vara Prasad
Sustainability 2021, 13(17), 9963; https://doi.org/10.3390/su13179963
Citations: Crossref (134), Scopus (136), Web of Science (113), Google Scholar (184)
This review aims to assess the adverse effects of plastic pollution on ecosystems, link the management of plastic with the SDGs, and propose policy measures using transdisciplinary approaches. Empowering communities to reduce plastic use is crucial. Addressing global plastic pollution is a priority.
Sustainability is an international, cross-disciplinary, open access journal that explores environmental, cultural, economic, and social sustainability of human beings. It provides a forward-looking platform for research on sustainability and sustainable development, and is published semi-monthly online by MDPI. Sustainability is affiliated with The Canadian Urban Transit Research & Innovation Consortium (CUTRIC) and The International Council for Research and Innovation in Building and Construction (CIB).
Read more:
- Testimonials: See what our editors and authors say about Sustainability.
Inside MDPI
President of Ireland Authors Editorial in MDPI Journal Sustainability
It’s a very special occasion when the president of a country takes the initiative to write an editorial for a journal. Michael D. Higgins, President of the Republic of Ireland, has contributed his insights to a forthcoming Special Issue in Sustainability:
This Special Issue, focusing on “making sustainable development happen” at grassroots levels, allows for perspectives from, and on, the major world faiths, exploring how challenges have been conceptualised and addressed, in addition to case studies of faith-based sustainability initiatives in practice.
The experience of faith institutions and communities in translating theological and moral commitments to sustainable development into action is now a topic we must examine with urgency; one on which I am so glad this Special Issue focuses.
As President of Ireland, I very much support this Special Issue of Sustainability. It is my great hope that the contents of the papers contained herein will assist in making sustainable development happen at grassroots levels across the world so that we can cooperate together, people of faith and of none, to ensure a just, inclusive and sustainable future for all on our fragile planet.
Read the completed editorial here:
Special Issue “Faith and Sustainable Development: Exploring Practice, Progress and Challenges among Faith Communities and Institutions”: Foreword by the President of Ireland
Author: Michael D. Higgins
Sustainability 2023, 15(12), 9683; https://doi.org/10.3390/su15129683
Coming Together for Science
The World Sustainability Forum 2023
The World Sustainability Forum (WSF) is a biennial MDPI event focused on sustainability. WSF 2023 marks the tenth anniversary of the conference series, taking place on 14 September. For the first time, the event will be hosted as a 24-hour conference across three locations – Singapore, Basel in Switzerland, and Toronto in Canada – alongside virtual streaming.
This unique format allows us to span three time zones, providing live coverage of critical sustainability-related topics throughout the day:
- The Singapore Hub, chaired by Professor Horn Mun Cheah and Associate Professor Renee Tan, will explore “Sustainability for Social and Community Impact”.
- The Basel Hub, chaired by Prof. Dr. Anet Režek Jambrak and Dr. Lela Mélon, will delve into “Sustainability in the industry, and at university and corporate settings”.
- The Toronto Hub, led by Dr. Umberto Berardi, will discuss “The Sustainable Built Environment”.
MDPI Sustainability Foundation: Recognizing Excellence in Sustainability Research
The MDPI Sustainability Foundation supports researchers through two sustainability-focused awards:
- The World Sustainability Award, amounting to USD 100,000, is given to senior researchers.
- The Emerging Sustainability Leader Award, valued at USD 20,000, sponsored by the journal Sustainability, is presented to early-career researchers.
The winners of the Sustainability Foundation will be formally awarded during the WSF2023 on 14 September. Interviews with the award winners and finalists are available below.
2023 World Sustainability Award Winners
Interviews with 2023 Emerging Sustainability Leader Award Finalists
- Dr. Bahareh Kamranzad
- Dr. Youjin Kim
- Dr. Julia Lohmann
As a hybrid event, WSF23 provides scholars with the option to attend in person at one of the conference sites or, for a more sustainable approach, virtually. All sessions will be recorded and archived for future access. Registration is open until 3 September 2023, with in-person and virtual tickets available here.
Read more:
Closing Thoughts
“Co-opetition”: Collaboration Plus Healthy Competition – A Visit to Elsevier
I firmly believe in fostering collaboration and at the same time promoting healthy competition within the academic publishing industry. The market offers ample room for publishers and related companies to provide valuable services and products that enrich the academic community. While MDPI is recognized for its efficient and streamlined processes –thanks to our over 6,000 colleagues, in-house tools, and initiatives that support the author journey – our ethos has always involved learning from and collaborating with other organizations.
MDPI’s Interaction with Elsevier
In January 2023, I had a brief conversation with Judy Verses, President of Global Academic and Government Markets at Elsevier, following her participation in a panel discussion at the Academic Publishers Europe event in Berlin. One of the highlights for me was Judy’s insight into the impact of research, particularly her emphasis on the role of collaboration, including policy and showing the impact of research to influence on funding decisions.
“Such collaborations drive forward-looking strategies to elevate our support for the scholarly community”
Judy and I resumed our discussion in August, when I visited Elsevier's office to review current projects, such as our recent agreement with Science Direct and the continued indexing of MDPI journals in Scopus (indexing database owned by Elsevier). We also explored possible opportunities for the future, including a potential collaboration to expand MDPI’s Scilit data infrastructure. This endeavour aims to aggregate and provide access to scholarly metadata encompassing journal articles, conference papers, books, preprints, and more. While these discussions are ongoing, the underlying principle remains that such collaborations drive forward-looking strategies to elevate our services and support for the scholarly community.
It was great that Judy and I acknowledged the merits of 'co-opetition,' a concept based of the belief that fostering cooperation alongside healthy competition can lead to shared advancements for both individual companies and the industry at large.
‘Fully OA’ Organizations Dedicated to Open Access
MDPI proudly aligns with the ‘Fully OA’ group, a collaborative initiative comprising nine organizations dedicated to Open Access. Our monthly meetings, including an OASPA representative, serve as platforms to share non-confidential information, resources, and projects. These gatherings also facilitate discussions on topics relevant to fully OA organizations. Occasionally, joint actions spring from these interactions, such as collaborative blog posts on pertinent subjects and joint statements, such as a recent response to the House Appropriations Committee.
This display of cooperation among competing entities forms a strategic alliance focused on nurturing the best interests of the OA publishing model.
As I wrap up this third edition of the CEO Letter, I encourage you to seize opportunities for collaboration and contribute to advancing our shared academic culture. As the African proverb has it, “If you want to go fast, go alone; if you want to go far, go together.”
Chief Executive Officer
MDPI AG
28 August 2023
Cancers | National Immunization Awareness Month
24 August 2023
Meet Us at the ASHG Annual Meeting 2023, 1–5 November 2023, Washington D.C., USA
22 August 2023
Cancers | Selected Papers in 2021–2022 in the Section “Cancer Immunology and Immunotherapy”
18 August 2023
MDPI’s 2022 Young Investigator Awards in Medicine and Pharmacology—Winners Announced
18 August 2023
MDPI’s 2022 Travel Awards in Medicine and Pharmacology—Winners Announced
18 August 2023
MDPI’s 2022 Outstanding Reviewer Awards in Medicine and Pharmacology—Winners Announced
18 August 2023
MDPI’s 2022 Best PhD Thesis Awards in Medicine and Pharmacology—Winners Announced
18 August 2023
MDPI’s Best Paper Awards in Medicine and Pharmacology—Winners Announced in 2022
17 August 2023
Cancers | Selected Papers in 2021–2022 in the Section “Cancer Epidemiology and Prevention”
15 August 2023
Meet Us at the 29th Annual Meeting of Japan Society of Gene and Cell Therapy, 11–13 September 2023, Osaka, Japan
10 August 2023
Cancers | Selected Papers in 2021–2022 in the Section “Methods and Technologies Development”
10 August 2023
Cancers | Selected Papers in 2021–2022 on Cancer Biomarkers
9 August 2023
Cancers | Selected Papers in 2021–2022 on Molecular Cancer Biology
9 August 2023
Cancers | Selected Papers in 2021–2022 on Cancer Metastasis
9 August 2023
Cancers | Selected Papers in 2021–2022 on Clinical Trials of Cancer
9 August 2023
MDPI World Hepatitis Day Webinar 2023, Held on 28 July 2023
To commemorate the World Hepatitis Day 2023, MDPI organized a webinar on 28 July 2023 to encourage researchers to come together, take action, and highlight how the exchange of findings facilitates efforts to raise awareness of hepatitis. The low coverage of testing and treatment is the most important gap to be addressed to achieve the global elimination goals of hepatitis B virus (HBV) by 2030.
Session 1:
| Speaker/Presentation |
| Introduction |
| Prof. Dr. Chia-Yen Dai Achieving Elimination of Hepatitis C in Taiwan |
| Dr. Tan Yee Joo Understanding the Functions of Hepatitis B Viral Proteins and Targeting Them in Antiviral Drug Development |
| Dr. Sheikh Mohammad Fazle Akbar Standing at the Half-Way: An Analysis of “Elimination of Hepatitis by 2030” in Developed and Developing Countries |
| Q&A Session |
You can watch the recorded webinar below:
Session 2:
| Speaker/Presentation |
| Introduction |
| Prof. Dr. John Tavis The International Coalition to Eliminate HBV (ICE-HBV): Promoting Global Scientific Collaboration in HBV Cure Research |
| Prof. Dr. Mark A. Feitelson Microbial Metabolites that Attenuate the Pathogenesis of Cancer and Autoimmunity |
| Prof. Dr. Natalia Osna Hepatitis in HIV Infection |
| Q&A Session |
You can watch the recorded webinar below:
Relevant Special Issues:
Pathogens
“Research on Hepatitis B Virus: Past, Present, and Future”
Edited by: Hyung Joon Yim
Submission deadline: 31 August 2023
JPM
“Novel Challenges and Therapeutic Options for Liver Diseases”
Edited by: Guido Gerken
Submission deadline: 30 September 2023
Medicina
“Viral Hepatitis Research: Updates and Challenges”
Edited by: Endrit Shahini, Antonio Giovanni Solimando and Antonella Argentiero
Submission deadline: 15 October 2023
Cells
“Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States”
Edited by: Jérôme Eeckhoute
Submission deadline: 15 February 2024
Diagnostics
“Diagnosis and Management of Liver Diseases—2nd Edition”
Edited by: Jeong-Ju Yoo
Submission deadline: 30 September 2023
Vaccines
“Vaccination and Treatments against Viral Hepatitis: Achievements, Challenges and Perspectives”
Edited by: Bárbara Vieira Do Lago and Vinicius M. Mello
Submission deadline: 15 October 2023
8 August 2023
Cancers | Selected Papers in 2021–2022 in the Section “Cancer Therapy”
8 August 2023
Cancers | Selected Papers in 2021–2022 in the Section “Cancer Informatics and Big Data”
8 August 2023
Cancers | Selected Papers in 2021–2022 on Cancer Pathophysiology
8 August 2023
Cancers | Selected Papers in 2021–2022 on Cancer Causes, Screening and Diagnosis
7 August 2023
Cancers | Selected Papers in 2021–2022 on Pediatric Oncology
4 August 2023
Cancers | Selected Papers in 2021–2022 on Infectious Agents and Cancer
1 August 2023
Cancers | Selected Papers in 2021–2022 on Transplant Oncology and Cancer Nursing Care
27 July 2023
MDPI Insights: The CEO’s Letter #2 - Open Peer-Review and IJERPH
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Peer Review Reports
Continuing the topic of openness from my inaugural monthly CEO letter, in these Opening Thoughts, I highlight the growth and importance of open peer-review reports at MDPI. Open peer reports align with the principles of open science, making the publishing process more transparent and facilitating rigorous peer review.
MDPI journals operate an open peer-review option by default, allowing authors to publish review reports and author responses (often referred to as open reports) together with the published paper. Publishing the reviewer reports and author responses together with the article provides greater transparency and trust for readers, as this allows them to track the editorial decision-making process. Open peer-review also encourages reviewers and editors to provide high-quality comments, as these will be made public if the article is accepted for publication.
Start and Growth of Open Peer Review at MDPI
The MDPI journal Life was a pioneer in offering this opportunity to its authors in 2014. The first MDPI article with peer-review reports openly published was a review by the Nobel Laureate Werner Arber, in which the review reports were published as supplementary material. By 2018, open peer-review was available across all MDPI journals. As such, MDPI authors have embraced the open peer-review model, providing a steady increase in the number of MDPI articles. As of 2023, approximately one-third (34.0%) of MDPI articles were published with open review reports.
As at July 2023, the percentage of MDPI articles published with open peer review has increased to 36.2% of the total papers published in 2023 so far, indicating ongoing growth in adoption.
Open peer review continues to play a critical role in the assessment of the peer-review process in Life. For further insights, please see the recent editorial by Dr. Pabulo Henrique Rampelotto, the former Editor-in-Chief of Life, who spearheaded the implementation of the open peer-review process.
Benefits of Open Peer Review
The benefits of open peer review include increased transparency, trust and constructive feedback. To promote open communication further and increase the robustness of the peer-review process, we encourage reviewers to sign their reports so that their name appears on the review report (this process is referred to as open identity). The default option is for reviewers to remain anonymous; however, by signing the reports, reviewers receive direct credit for their contribution to the peer-review process and show their commitment towards open science.
As the leading open access publisher, MDPI remains committed to promoting open peer-review and encourages authors to choose this approach. Our goal is to provide a rigorous and transparent peer-review process that benefits the scientific community, and we believe that open peer-review is a vital step in fostering openness and collaboration in scientific communication.
Impactful Research
MDPI Papers Cited in the News – IJERPH edition
Every month, our corporate marketing team compiles data from Altmetrics to create a list of MDPI papers that have been cited in the news. This list continues to grow as renowned news outlets regularly reference research published by MDPI in their articles.
During 2022, a total of 111,965 MDPI research papers were mentioned in prominent news outlets such as National Geographic, The Washington Post, Forbes, The Guardian, the BBC, CNN, Time, and Harvard Business Review.
Highly Cited Journal Publications
IJERPH, known for publishing impactful research, received the most news mentions among all MDPI journals in 2022, based on Altmetrics data:
- International Journal of Environmental Research and Public Health: 3509 mentions
- Nutrients: 2698 mentions
- International Journal of Molecular Sciences: 1701 mentions
- Journal of Clinical Medicine: 1131 mentions
- Viruses: 1111 mentions
These numbers show the recognition and impact of the articles published in IJERPH. For a more detailed view of the journal’s most cited and viewed papers, you can visit here. In total, IJERPH has garnered over 28,000 mentions in prominent news outlets, and as at July 2023, an impressive count of over 17,000 papers cited 10 times or more. These figures highlight the impactful contribution of IJERPH publications to the scientific community.
Example of Recent Mentions
During May and June 2023, a noteworthy selection of articles from IJERPH was cited in news articles, including:
The Washington Post: “Bringing nature inside can improve your health. Here’s how to do it.”
IJERPH paper: “Physiological Benefits of Viewing Nature: A Systematic Review of Indoor Experiments”
Harvard Business Review: “How to Take Better Breaks at Work, According to Research”
IJERPH paper: “Canine-Assisted Therapy Improves Well-Being in Nurses”
National Geographic: “Lyme disease is spreading fast—but a vaccine may be on the way”
IJERPH paper: “Range Expansion of Tick Disease Vectors in North America: Implications for Spread of Tick-Borne Disease”
Inside MDPI
MDPI Develops an Artificial Intelligence Tool to Enhance the Peer-Review Process
At MDPI, we believe that rigorous peer-review is the corner-stone of high-quality academic publishing. We are grateful to the scholars who generously dedicate their time to peer-review articles submitted to MDPI journals. Their contributions are invaluable to the advancement of science.
Peer-review is a critical part of the publication process, ensuring that MDPI upholds the highest quality standards for the papers we publish. Every manuscript submitted to our journals undergoes a comprehensive peer-review process conducted by subject-matter experts.
To further enhance our peer-review process, our Data Analytics team has developed an Artificial Intelligence (AI) tool designed to support the selection of reviewers. This proprietary tool utilizes Natural Language Processing (NLP), a specially designed AI language model, to extract information from the title and abstract of submitted papers. It then searches our database for similar manuscripts and suggests potential reviewers based on this analysis. Integrated with MDPI's submission system (SuSy), the AI tool cross-references the suggested candidates with our reviewer database to verify their invitation status and availability.
The goal of this tool is to provide better targeted peer-review invitations, reducing the number of emails sent for each paper and increasing the efficiency of our editorial staff.
In the near future, our Data Analytics team plans to deploy similar AI projects to improve other critical aspects of our services, offering an enhanced experience to our authors and readers.
Click here to learn about MDPI’s review process, including procedures, responsibilities, and benefits.
Read more:
Coming Together for Science
The Future of IJERPH
On 5 July 2023, Prof. Dr. Paul B. Tchounwou, the founding Editor-in-Chief of IJERPH, along with five Section Editors in Chief (Prof. Dr. Germán Vicente-Rodríguez, Prof. Dr. Karl Goodkin, Prof. Dr. William A. Toscano, Prof. Dr. Jimmy T. Efird, and Prof. Dr. William Douglas Evans), gathered in Basel to discuss the future of the journal. The meeting provided an opportunity to address the recent decision by The Web of Science to delist IJERPH due to the journal failing the Content Relevance criterion, and propose best strategies that will ensure high scientific rigor as well as a clear scope and aim of IJERPH, going forward.
While the delisting is disappointing for IJERPH, as well as for our authors, academic editors, and the entire scientific community supporting our journal, we see it as an opportunity to reflect and prepare for the future direction of the journal.
Since its launch in 2004, IJERPH’s vision and mission have evolved to be more complete and comprehensive in engaging scientific communities. In light of this, we will refresh the journal’s aims and scope, ensuring they align with the organic expansion of IJERPH. Additionally, we will restructure the journal sections into broader categories, encouraging collaborative research and transdisciplinary approaches for authors. This is designed to foster collaboration and knowledge exchange among diverse fields, contributing to a holistic understanding of health promotion and disease prevention. We are confident that these next steps will enhance the scientific strength and societal impact of our journal.
Journal Achievements
In addition to the productive discussions, we took the time to celebrate some of the remarkable achievements of IJERPH, which I highlight below:
- Founded by Prof. Dr. Paul B. Tchounwou in 2004
- Indexed in PubMed in 2008
- Received its first Impact Factor in 2012
- Published its 5000th paper in 2017
- Over 60,000 papers published as at June 30, 2023
- 131,628,173 paper views in 2018–2022
- Over 28,000 mentions in prominent news outlets
- 17,000 papers cited 10 times or more as at June 30, 2023
- No.1 journal in the 2022 Google Scholar Metrics in the category of Public Health
- Awarded several editions of Young Investigator Awards, Travel Awards, and Outstanding Reviewer Awards since 2018.
These achievements showcase the journal’s significant contributions to the field and its impact on global health. We are proud of the exceptional work accomplished by the IJERPH team and look forward to building upon this success in the years to come.
Closing Thoughts
MDPI’s Impact in Spain
During the past month, I had the opportunity to visit our new office building in Barcelona, where I met with our local colleagues to discuss the ways we serve the scholarly community, particularly in Spain. The multi-functional office plays a vital role in supporting various business needs, including editorial, design, conference management, data analytics, journal relationship management, publishing partnerships, and collaborations with societies.
Spain holds a significant position in MDPI’s global market, ranking as the fourth-largest contributor to the total number of papers published by MDPI as at July 2023, ranking next to Italy, the USA, and China, with Germany completing the top five.
The Numbers
Out of the 1,680,000 total MDPI articles published as at 25 July, almost 80,000 articles are contributed by Spanish authors, representing nearly 40,000 unique authors affiliated with Spanish institutions. Remarkably, over 6,300 of these authors hold editorial board member (EBM) positions within MDPI journals, with 30 of them serving as Editors-in-Chief (EiCs).
Our commitment to working with institutions is very evident in Spain, where we have successfully established over 40 Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Barcelona, the Autonomous University of Barcelona, Pompeu Fabra University, the University of Navarre, and Complutense University of Madrid.
Over the past five years, we have successfully organized eight in-person conferences in Barcelona, attracting over 1,150 registrations, with two forthcoming events scheduled for 2024. Barcelona's excellent connectivity to international airports makes it easily accessible to participants from around the world. Its welcoming atmosphere provides us with the perfect environment for knowledge-sharing, networking, and contributing to the local economy.
Our growth and presence in Spain are a true testament to the incredible service we provide to the scholarly community and the relationships we foster through responsive and collaborative communication. We look forward to continuing to support Spanish scholars, providing them a valuable and trusted experience with MDPI, the leader in open access publishing.
Testimonials
I close this letter as I did in the first edition, by sharing testimonials from our stakeholders. Here are a few IJERPH testimonials from a Spanish guest editor and an author:
Guest Editor
“I want to thank the kindness, attention and professionalism of the MDPI team throughout the editorial process of the Special Issue. I believe that it is a very professional and quality editorial process.”
- Professor Víctor Arufe-Giráldez, University of A Coruña
Special Issue in International Journal of Environmental Research and Public Health: Physical Activity in Childhood and Adolescence
Special Issue in International Journal of Environmental Research and Public Health: Physical Education: Present and Future
__
Author
“I want to thank the rigor of the revisions made to the manuscripts to improve their quality, the support to the authors for the editor assignment system they have and the follow-up they carry out, for the speed in answering and in carrying out the entire process of the revision, and for doing all this at an affordable price.”
- Dr. María Paz García-Caro, University of Granada
Article in International Journal of Environmental Research and Public Health: Factors Associated with Suicide Attempts and Suicides in the General Population of Andalusia (Spain)
Chief Executive Officer
MDPI AG
26 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Anti-cancer Research
We are delighted to share some highly cited papers on anti-cancer research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives”
by Robert Jenke, Nina Reßing, Finn K. Hansen, Achim Aigner and Thomas Büch
Cancers 2021, 13(4), 634; https://doi.org/10.3390/cancers13040634
Available online: https://www.mdpi.com/2072-6694/13/4/634
“3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs”
by Mélanie A. G. Barbosa, Cristina P. R. Xavier, Rúben F. Pereira, Vilma Petrikaitė and M. Helena Vasconcelos
Cancers 2022, 14(1), 190; https://doi.org/10.3390/cancers14010190
Available online: https://www.mdpi.com/2072-6694/14/1/190
“Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin”
by Esra Küpeli Akkol, Iffet Irem Tatlı, Gökçe Şeker Karatoprak, Osman Tuncay Ağar, Çiğdem Yücel, Eduardo Sobarzo-Sánchez and Raffaele Capasso
Cancers 2021, 13(11), 2733; https://doi.org/10.3390/cancers13112733
Available online: https://www.mdpi.com/2072-6694/13/11/2733
“Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update”
by Jen-Fu Hsu, Shih-Ming Chu, Chen-Chu Liao, Chao-Jan Wang, Yi-Shan Wang, Mei-Yin Lai, Hsiao-Chin Wang, Hsuan-Rong Huang and Ming-Horng Tsai
Cancers 2021, 13(2), 195; https://doi.org/10.3390/cancers13020195
Available online: https://www.mdpi.com/2072-6694/13/2/195
“Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review”
by Sareh Kamran, Ajantha Sinniah, Mahfoudh A. M. Abdulghani and Mohammed Abdullah Alshawsh
Cancers 2022, 14(5), 1100; https://doi.org/10.3390/cancers14051100
Available online: https://www.mdpi.com/2072-6694/14/5/1100
“The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions”
by Tadeusz Robak, Magda Witkowska and Piotr Smolewski
Cancers 2022, 14(3), 771; https://doi.org/10.3390/cancers14030771
Available online: https://www.mdpi.com/2072-6694/14/3/771
“The Renaissance of Cyclin Dependent Kinase Inhibitors”
by Tobias Ettl, Daniela Schulz and Richard Josef Bauer
Cancers 2022, 14(2), 293; https://doi.org/10.3390/cancers14020293
Available online: https://www.mdpi.com/2072-6694/14/2/293
|
“Cancer Cell Metabolism and Drug Targets” Edited by: Dr. Daniel S. Sitar and Prof. Dr. Donald Miller
|
“Drug Resistance in Gastrointestinal Cancer” Edited by: Dr. Rosalba D’Alessandro and Dr. Carmelo Ferrai |
|
“Anticancer Drugs: Recent Advances and Challenges” Edited by: Dr. Moutih Rafei and Dr. Sebastien Talbot
|
“Drug Development for Acute Lymphoblastic Leukemia” Edited by: Dr. Rajesh Ramakrishnan Nair
|
We hope this announcement will provide useful information for this field.
18 July 2023
Meet Us at the MDPI World Hepatitis Day Webinar 2023, 28 July 2023
The low coverage of testing and treatment is the most important gap to be addressed to achieve the global elimination goals of hepatitis B virus (HBV) by 2030.
To commemorate the World Hepatitis Day 2023, MDPI is launching a special webinar to encourage researchers to come together, take action, and highlight how the exchange of findings facilitates efforts to raise awareness of hepatitis.
We are looking forward to seeing you at the MDPI World Hepatitis Day Webinar 2023.
Conference secretariat: Ms. Shun Li
Date and time: 28 July 2023, 7:00 a.m. and 3:00 p.m., CEST
This is a free webinar. After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.
Unable to attend? Register anyway and we will let you know when the recording is available to watch.
Session 1:
| Speaker/Presentation | Time in CEST |
| Introduction | 7:00 a.m.–7:10 a.m. |
| Prof. Dr. Chia-Yen Dai Achieving Elimination of Hepatitis C in Taiwan |
7:10 a.m.–7:40 a.m. |
| Dr. Tan Yee Joo Understanding the Functions of Hepatitis B Viral Proteins and Targeting Them in Antiviral Drug Development |
7:40 a.m.–8:10 a.m. |
| Dr. Sheikh Mohammad Fazle Akbar Standing at the Half-Way: An Analysis of “Elimination of Hepatitis by 2030” in Developed and Developing Countries |
8:10 a.m.–8:40 a.m. |
| Q&A Session | 8:40 a.m.–9:00 a.m. |
Register for Session 1 for free!
Session 2:
| Speaker/Presentation | Time in CEST |
| Introduction | 3:00 p.m.–3:10 p.m. |
| Prof. Dr. John Tavis The International Coalition to Eliminate HBV (ICE-HBV): Promoting Global Scientific Collaboration in HBV Cure Research |
3.10 p.m.–3:40 p.m. |
| Prof. Dr. Mark A. Feitelson Microbial Metabolites that Attenuate the Pathogenesis of Cancer and Autoimmunity |
3:40 p.m.–4:10 p.m. |
| Prof. Dr. Natalia Osna Hepatitis in HIV Infection |
4:10 p.m.–4:40 p.m. |
| Q&A Session | 4:40 p.m.–5:00 p.m. |
Register for Session 2 for free!
Relevant Special Issues:
Pathogens
"Research on Hepatitis B Virus: Past, Present, and Future"
Edited by: Hyung Joon Yim
Submission deadline: 31 August 2023
JPM
"Novel Challenges and Therapeutic Options for Liver Diseases"
Edited by: Guido Gerken
Submission deadline: 30 September 2023
Medicina
"Viral Hepatitis Research: Updates and Challenges"
Edited by: Endrit Shahini, Antonio Giovanni Solimando and Antonella Argentiero
Submission deadline: 15 October 2023
Cells
"Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States"
Edited by: Jérôme Eeckhoute
Submission deadline: 15 February 2024
Diagnostics
"Diagnosis and Management of Liver Diseases—2nd Edition"
Edited by: Jeong-Ju Yoo
Submission deadline: 30 September 2023
Vaccines
"Vaccination and Treatments against Viral Hepatitis: Achievements, Challenges and Perspectives"
Edited by: Bárbara Vieira Do Lago and Vinicius M. Mello
Submission deadline: 15 October 2023
14 July 2023
Meet Us at 2023 BMES Annual Meeting, 11–14 October 2023, Seattle, USA
11 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Methods and Technologies Development
We are delighted to share some highly cited papers on methods and technologies development that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“Artificial Intelligence for Thyroid Nodule Characterization: Where Are We Standing?”
by Salvatore Sorrenti, Vincenzo Dolcetti, Maija Radzina, Maria Irene Bellini, Fabrizio Frezza, Khushboo Munir, Giorgio Grani, Cosimo Durante, Vito D’Andrea, Emanuele David et al.
Cancers 2022, 14(14), 3357; https://doi.org/10.3390/cancers14143357
Available online: https://www.mdpi.com/2072-6694/14/14/3357
“A Review of Circulating Tumour Cell Enrichment Technologies”
by Amelia J. Rushton, Georgios Nteliopoulos, Jacqueline A. Shaw and R. Charles Coombes
Cancers 2021, 13(5), 970; https://doi.org/10.3390/cancers13050970
Available online: https://www.mdpi.com/2072-6694/13/5/970
“Novel Transfer Learning Approach for Medical Imaging with Limited Labeled Data”
by Laith Alzubaidi, Muthana Al-Amidie, Ahmed Al-Asadi, Amjad J. Humaidi, Omran Al-Shamma, Mohammed A. Fadhel, Jinglan Zhang, J. Santamaría and Ye Duan
Cancers 2021, 13(7), 1590; https://doi.org/10.3390/cancers13071590
Available online: https://www.mdpi.com/2072-6694/13/7/1590
“Organoid and Spheroid Tumor Models: Techniques and Applications”
by Sreenivasulu Gunti, Austin T. K. Hoke, Kenny P. Vu and Nyall R. London, Jr.
Cancers 2021, 13(4), 874; https://doi.org/10.3390/cancers13040874
Available online: https://www.mdpi.com/2072-6694/13/4/874
“Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field”
by Fernanda Andrade, Maria Mercé Roca-Melendres, Esteban F. Durán-Lara, Diana Rafael and Simó Schwartz, Jr.
Cancers 2021, 13(5), 1164; https://doi.org/10.3390/cancers13051164
Available online: https://www.mdpi.com/2072-6694/13/5/1164
“Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment”
by Sumaira Anjum, Mariam Hashim, Sara Asad Malik, Maha Khan, José M. Lorenzo, Bilal Haider Abbasi and Christophe Hano
Cancers 2021, 13(18), 4570; https://doi.org/10.3390/cancers13184570
Available online: https://www.mdpi.com/2072-6694/13/18/4570
|
“Recent Trends in PET/CT Tracer Development and Multimodal Imaging” Edited by: Prof. Dr. Olaf Prante and Prof. Dr. Tobias Bäuerle
|
“New Technologies in Brain Tumor Diagnosis and Therapies: Basic, Clinical, and Translational Research” Edited by: Dr. Mingli Liu |
|
“Application of Advanced Biomedical Imaging in Cancer Treatment” Edited by: Prof. Dr. Edyta Szurowska and Dr. Maciej Bobowicz
|
“Artificial Intelligence and Machine Learning in Precision Oncology” Edited by: Dr. Carmen Belli and Dr. Santosh Anand
|
We hope this announcement will provide useful information for this field.
11 July 2023
MDPI’s Newly Launched Journals in June 2023
With the first issue released in June 2023, five new MDPI journals disseminating multi-disciplinary science are due to launch, which will cover the subjects of medicine & pharmacology, biology and physical sciences.
The newly launched journals will be overseen by professional Editorial Board Members and Editors to ensure an accurate and rapid publication, rigorous peer review and broad visibility.
Please feel free to browse and discover more about the new journals below.
| Journal | Founding Editor-in-Chief | Journal topics (selected) |
 |
Prof. Dr. Jun Ma, Peking University, China| Editorial | view inaugural issue | growth and development; diet and nutrients; school health promotion policies and practices; child health and care; adolescent health and wellbeing | view journal scope | submit an article |
 |
Prof. Dr. Bernd Rehm, Griffith University, Australia | Editorial | view inaugural issue | DNA and gene synthesis; synthetic transcription factors; protein engineering; viral engineering; metabolic engineering | view journal scope | submit an article |
 |
Prof. Dr. Varsha Gandhi, University of Texas MD Anderson Cancer Center, USA | Editorial | view inaugural issue | lymphatics; cancers associated with lymphocytes and lymphoblasts; lymphatic tissues; lymphoma; lymphoid leukemia | view journal scope | submit an article |
 |
Dr. Bradley Turner, University of Melbourne, Australia | Editorial | view inaugural issue | multiple sclerosis; amyotrophic lateral sclerosis; primary lateral sclerosis; atherosclerosis; systemic sclerosis | view journal scope | submit an article |
 |
Prof. Dr. Clemens Burda, Case Western Reserve University, USA | Editorial | view inaugural issue | Gamma ray, X-ray, and UV–Vis spectroscopies; NIR/mid-infrared/Raman spectroscopy; microwave and THz spectroscopy; high-resolution gas-phase atomic, molecular, and cluster spectroscopy; MS, NMR, and EPR spectroscopy | view journal scope | submit an article |
We wish to thank everyone who has supported the development of open access publishing. You are welcome to submit an application to the New Journal Committee (newjournal-committee@mdpi.com) if you would like to create more new journals.
7 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues
We are delighted to share some highly cited papers that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer”
by Se-Young Park, Byeong-Oh Hwang, Mihwa Lim, Seung-Ho Ok, Sun-Kyoung Lee, Kyung-Soo Chun, Kwang-Kyun Park, Yinling Hu, Won-Yoon Chung and Na-Young Song
Cancers 2021, 13(9), 2124; https://doi.org/10.3390/cancers13092124
Available online: https://www.mdpi.com/2072-6694/13/9/2124
“Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness”
by Elena Arance, Viviana Ramírez, Alejandro Rubio-Roldan, Francisco M. Ocaña-Peinado, Catalina Romero-Cachinero, Ana Belén Jódar-Reyes, Fernando Vazquez-Alonso, Luis Javier Martinez-Gonzalez and Maria Jesus Alvarez-Cubero
Cancers 2022, 14(1), 199; https://www.mdpi.com/2072-6694/14/1/199
Available online: https://www.mdpi.com/2072-6694/14/1/199
“Classification of Breast Cancer Nottingham Prognostic Index Using High-Dimensional Embedding and Residual Neural Network”
by Li Zhou, Maria Rueda and Abedalrhman Alkhateeb
Cancers 2022, 14(4), 934; https://doi.org/10.3390/cancers14040934
Available online: https://www.mdpi.com/2072-6694/14/4/934
“The Evolution of Ovarian Carcinoma Subclassification”
by Martin Köbel and Eun Young Kang
Cancers 2022, 14(2), 416; https://doi.org/10.3390/cancers14020416
Available online: https://www.mdpi.com/2072-6694/14/2/416
“The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis”
by Giorgio Ivan Russo, Nicolò Musso, Alessandra Romano, Giuseppe Caruso, Salvatore Petralia, Luca Lanzanò, Giuseppe Broggi and Massimo Camarda
Cancers 2022, 14(1), 198; https://doi.org/10.3390/cancers14010198
Available online: https://www.mdpi.com/2072-6694/14/1/198
“Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany”
by Louis Jacob, Sven H. Loosen, Matthias Kalder, Tom Luedde, Christoph Roderburg and Karel Kostev
Cancers 2021, 13(3), 408; https://doi.org/10.3390/cancers13030408
Available online: https://www.mdpi.com/2072-6694/13/3/408
“Chemotherapy Side-Effects: Not All DNA Damage Is Equal”
by Winnie M. C. van den Boogaard, Daphne S. J. Komninos and Wilbert P. Vermeij
Cancers 2022, 14(3), 627; https://doi.org/10.3390/cancers14030627
Available online: https://www.mdpi.com/2072-6694/14/3/627
“Timely Palliative Care: Personalizing the Process of Referral”
by David Hui, Yvonne Heung and Eduardo Bruera
Cancers 2022, 14(4), 1047; https://doi.org/10.3390/cancers14041047
Available online: https://www.mdpi.com/2072-6694/14/4/1047
|
“Advances in Ovarian Cancer Research and Treatment” Edited by: Dr. Maria Barbolina
|
“Advances in Brachytherapy in the Treatment of Tumors” Edited by: Dr. Hideya Yamazaki |
|
“Molecular Biology of Colorectal Cancers” Edited by: Dr. María Jesús Fernández-Aceñero, Dr. Rodrigo Barderas-Manchado, Dr. Javier Martinez Useros and Dr. Cristina Díaz del Arco
|
“Palliative Care in Cancer: Recent Advances and Upcoming Trends” Edited by: Prof. Dr. Philipp Lenz and Dr. Mitra Tewes
|
We hope this announcement will provide useful information for this field.
5 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Breast Cancer Research
We are delighted to share some highly cited papers on breast cancer research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will be of interest to you.
“Breast Tumour Classification Using Ultrasound Elastography with Machine Learning: A Systematic Scoping Review”
by Ye-Jiao Mao, Hyo-Jung Lim, Ming Ni, Wai-Hin Yan, Duo Wai-Chi Wong and James Chung-Wai Cheung
Cancers 2022, 14(2), 367; https://doi.org/10.3390/cancers14020367
Available online: https://www.mdpi.com/2072-6694/14/2/367
“Exosomes as Emerging Drug Delivery and Diagnostic Modality for Breast Cancer: Recent Advances in Isolation and Application”
by Dulla Naveen Kumar, Aiswarya Chaudhuri, Farrukh Aqil, Deepa Dehari, Radha Munagala, Sanjay Singh, Ramesh C. Gupta and Ashish Kumar Agrawal
Cancers 2022, 14(6), 1435; https://doi.org/10.3390/cancers14061435
Available online: https://www.mdpi.com/2072-6694/14/6/1435
“Role of ctDNA in Breast Cancer”
by Marta Sant, Adrià Bernat-Peguera, Eudald Felip and Mireia Margelí
Cancers 2022, 14(2), 310; https://doi.org/10.3390/cancers14020310
Available online: https://www.mdpi.com/2072-6694/14/2/310
“Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021”
by Maroun Bou Zerdan, Tala Ghorayeb, Fares Saliba, Sabine Allam, Morgan Bou Zerdan, Marita Yaghi, Nadeem Bilani, Rola Jaafar and Zeina Nahleh
Cancers 2022, 14(5), 1253; https://doi.org/10.3390/cancers14051253
Available online: https://www.mdpi.com/2072-6694/14/5/1253
“HER2-Low Breast Cancer: Molecular Characteristics and Prognosis”
by Elisa Agostinetto, Mattia Rediti, Danai Fimereli, Véronique Debien, Martine Piccart, Philippe Aftimos, Christos Sotiriou and Evandro de Azambuja
Cancers 2021, 13(11), 2824; https://doi.org/10.3390/cancers13112824
Available online: https://www.mdpi.com/2072-6694/13/11/2824
“Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?”
by Emma E. Newton, Lauren E. Mueller, Scout M. Treadwell, Cindy A. Morris and Heather L. Machado
Cancers 2022, 14(3), 482; https://doi.org/10.3390/cancers14030482
Available online: https://www.mdpi.com/2072-6694/14/3/482
|
“Comprehensive Genomic Profiling for Metastatic Breast Cancer: Current Status and Future Perspectives” Edited by: Dr. Hiroshi Tada and Dr. Hiroko Masuda
|
“Single Cell RNA Sequencing in Breast Cancer” Edited by: Dr. Yu-Chih Chen |
|
“Molecular Mechanisms in Breast Cancer Therapy and Resistance” Edited by: Dr. Lei Duan
|
“BRCA-Associated Breast Cancer” Edited by: Dr. Matilde Pensabene, Dr. Carmine De Angelis and Prof. Dr. Matteo Lambertini
|
We hope this announcement will provide useful information for this field.
4 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Resistance Research
We are delighted to share some highly cited papers on cancer resistance research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you. The list of relevant papers can be seen below:
“Mechanisms of Resistance to KRASG12C Inhibitors”
by Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall and Colin Lindsay
Cancers 2021, 13(1), 151; https://doi.org/10.3390/cancers13010151
Available online: https://www.mdpi.com/2072-6694/13/1/151
“Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance”
by Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin and Panagiotis Papageorgis
Cancers 2021, 13(17), 4363; https://doi.org/10.3390/cancers13174363
Available online: https://www.mdpi.com/2072-6694/13/17/4363
“Mechanisms of Resistance to Conventional Therapies for Osteosarcoma”
by Louise Marchandet, Morgane Lallier, Céline Charrier, Marc Baud’huin, Benjamin Ory and François Lamoureux
Cancers 2021, 13(4), 683; https://doi.org/10.3390/cancers13040683
Available online: https://www.mdpi.com/2072-6694/13/4/683
“Immune Resistance in Lung Adenocarcinoma”
by Magda Spella and Georgios T. Stathopoulos
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
Available online: https://www.mdpi.com/2072-6694/13/3/384
“Recent Insights into Therapy Resistance in Osteosarcoma”
by Zachary D. Prudowsky and Jason T. Yustein
Cancers 2021, 13(1), 83; https://doi.org/10.3390/cancers13010083
Available online: https://www.mdpi.com/2072-6694/13/1/83
“EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance”
by Mary Luz Uribe, Ilaria Marrocco and Yosef Yarden
Cancers 2021, 13(11), 2748; https://doi.org/10.3390/cancers13112748
Available online: https://www.mdpi.com/2072-6694/13/11/2748
Special Issues:
|
“The Role of Epithelial-Mesenchymal Transition in Therapies Resistance and Cancer Metastasis” Edited by: Dr. Pierre Savagner
|
“State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers” Edited by: Dr. Yan Li |
|
“Drug Resistance in Gastrointestinal Cancer” Edited by: Dr. Rosalba D’Alessandro and Dr. Carmelo Ferrai
|
“Triple Negative Breast Cancer Therapy Resistance and Metastasis” Edited by: Dr. Daniela Sousa
|
4 July 2023
Cancers Receives an Updated Impact Factor of 5.2
3 July 2023
MDPI Insights: The CEO’s Letter #1 - Open Access and Impactful Research
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
The Future is Open, and MDPI is Leading the Way
I strongly believe in a future that embraces openness, where open source, open information, and open access (OA) take center stage. This belief that led me to join MDPI in 2020, and I am honored to have recently been appointed as Chief Executive Officer (CEO). In this capacity, and operating in close liaison with Dr. Lin and MDPI’s senior management, I shall work to build on Dr. Lin’s achievements of the past quarter-century. In this role, I will focus on communication initiatives to promote MDPI's remarkable work and continue to build our company as a trusted leader in OA publishing. For over two decades, MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020. This trajectory is deeply rooted in our history and reflects our unwavering commitment and vision for an open future.
1 Million Published Articles
2023 began with a remarkable achievement for MDPI, as we became the first OA publisher to reach the milestone of 1 million published articles. This represents 2.7 million unique authors who have trusted us with their work, or about a third of all researchers worldwide. As the world's most cited OA publisher, we are proud in sharing these significant milestones.
Our mission remains unchanged: to make science open and accessible to all. We understand the importance of knowledge access, empowering researchers to stay at the forefront of a rapidly changing world. Our diverse range of journals covers a wide spectrum of disciplines, offering cutting-edge insights, trusted tools, and crucial knowledge to address global challenges.
Liberating Science
As the world’s leading OA publisher, MDPI is actively liberating science. We are committed to eliminating the frustrations researchers and the general public face when accessing information, ensuring it is not locked behind paywalls. We firmly believe that everyone has a right to information, and our commitment to open access publishing drives our work.
In this inaugural edition of Insights: The CEO's Letter, I draw inspiration from the upcoming 20th anniversary of the Berlin Declaration on Open Access. Its stated mission reminds us that true impact is achieved when knowledge is widely and readily available to society:
"Our mission of disseminating knowledge is only half complete if the information is not made widely and readily available to society”
Impactful Research
MDPI Publishes Impactful Research: Recognized by Leading Indexing Databases
MDPI journals are indexed in every single top database in the world.
As of June 2023, we have 214 journals indexed within Web of Science, 223 indexed within Scopus, 87 indexed within PubMed and PMC, and 17 indexed within MEDLINE, and these numbers increase every month. We constantly strive to expand the coverage of our journals within leading multi-disciplinary and scope-specific databases, resulting in an incredibly broad range of journals that are indexed within a variety of databases. MDPI has active relationships with approximately 65 well-known databases around the world, and we continue to expand our portfolio every year so that your work can be found, cited, and referenced with ease.
Continued Growth of MDPI Journals
The 2022 Scopus and Web of Science journal citation metrics were officially released in June, and I am pleased to report that 31 MDPI journals received their first CiteScore, taking the total number of journals with a CiteScore to 216. The number of MDPI journals receiving an Impact Factor (IF) also continues to grow with 111 receiving their first, by being covered in the ESCI, bringing our total number of journals with an IF to 208 of which 41 journals received an IF above 4.0. Looking at 2022 CiteScores in the Scopus database, 80% of MDPI journals have a score that ranks them in Q1 or Q2 in at least one subject category.
Publishing impactful science would not be possible without all of our authors, editors and reviewers. Thank you for your contribution and continued support! Together we share the latest scientific insights faster and ensure that your work is accessible to all.
Read more
Inside MDPI
Preprints.org: Clarivate adds the Preprint Citation Index to the Web of Science
At MDPI, we are dedicated to driving the advancement of science. Through our initiative, Preprints.org, researchers can publish their work and gain valuable feedback from the broader research community, ensuring rapid progress in their respective fields. This is particularly crucial during times of health and climate challenges, where timely dissemination of findings is essential.
Increased Visibility for Preprints
I am pleased to share that Clarivate recognizes the significance of preprints and has taken a crucial step to enhance their visibility. Clarivate has added the Preprint Citation Index to the Web of Science, encompassing preprints published not only on Preprints.org but also on other reputable repositories.
Looking ahead, the future of preprints appears promising, bolstered by the recent indexing announcement from the Web of Science. As a result, preprints will receive increased visibility, serving as a valuable resource for staying informed about the latest research developments.
Read more
What are Preprints?
The Pros and Cons of Preprints
Preprints and COVID-19
Preprints—The Future of Open Access Publishing?
Coming Together for Science
The First International Conference on Antioxidants: Sources, Methods, Health Benefits and Industrial Applications
In this edition of ‘Coming Together for Science,’ I am pleased to highlight the First International Conference on Antioxidants organized by our conference team in the beautiful city of Barcelona, Spain. The conference attracted over 130 attendees, who engaged in 42 talks, and 89 poster presentations spread across several sessions.
Working Together
Under the leadership of Prof. Dr. Alessandra Napolitano (Department of Chemical Sciences, University of Naples ‘Federico II’, Naples, Italy) and Prof. Dr. Rosa M. Lamuela Raventos (Department of Nutrition, Food Sciences and Gastronomy, University of Barcelona, Spain) as chairs, and supported by the committee members, 10 invited keynote speakers, poster presenters, and all the attendees, this dedicated group of academics came together to discuss the natural sources, methodologies, health benefits, and industrial applications of antioxidants.
Especially noteworthy is the positive feedback received from attendees, with 94% rating the overall organization of the conference as good or excellent. I particularly love the picture above, capturing the gathering of some of the participants. You can browse through more photos in the event gallery located here.
Managing Events With Sciforum
If you are considering hosting your own academic event, I highly recommend checking out Sciforum, MDPI's event management platform. Sciforum simplifies the entire process, making it easy to host your own event by allowing you to focus on what really matters: Science!
Read more
Closing Thoughts
Stefan Tochev, Dr. Shu-Kun Lin, Dr. Eric O. Freed, Peter Roth, Wynne Wang, Allison Yang
Viruses and Editorial Quality: Acknowledging the Dedication of our Viruses Journal Team
During a June meeting with Dr. Eric O. Freed, the founding and current Editor-in-Chief of our journal Viruses, I was reminded of the exceptional dedication of our editorial board. Meeting with Eric is a pleasure, as he has a strong commitment and clear vision for the journal. Over the course of two days, we gained a deep understanding of the journal’s expectations and focus on strategic growth, editorial board representation, and engagement.
I am pleased to share that Viruses holds a CiteScore of 7.1 (an increase of 7.57% versus the 2021 metric) and an Impact Factor of 4.7. You can view the journal statistics here. Viruses publishes highly cited papers, and is indexed in renowned databases such as Scopus, SCIE (Web of Science), PubMed, and others, and maintains affiliations with prestigious societies. Moreover, the Viruses team has recently announced an exciting upcoming event titled ‘Viruses 2024 – A World of Viruses,’ scheduled to take place in Barcelona, Spain, from 14–16 February 2024.
Testimonials
If you notice my enthusiasm regarding our editorial service, it’s because the surveys and testimonials we receive speak volumes about the experiences of our authors, reviewers, and guest editors who collaborate with MDPI. The purpose of these letters is to highlight the exceptional work that we do and the experiences we create for the scholars – thus, let me end with this testimonial from an author:
“It was a great pleasure to publish in Viruses Special Issue [Emerging Viruses in Aquaculture]. The submission process was easy. Guest editors were very helpful and provided all the guidance and support as needed. The handling of the manuscript by the Editorial Team was very fast, efficient, and professional. The reviewer’s comments were insightful, and the publication processes were remarkably rapid.”
– Ms. Magdalena Stachnik, Państwowy Instytut Weterynaryjny | PIWet
Article in Viruses: Emerging Viral Pathogens in Sturgeon Aquaculture in Poland: Focus on Herpesviruses and Mimivirus Detection
Chief Executive Officer
MDPI AG
29 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Epidemiology and Prevention
We are delighted to share some highly cited papers on cancer epidemiology and prevention that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission.
“Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies”
by Md. Sanower Hossain, Hidayah Karuniawati, Ammar Abdulrahman Jairoun, Zannat Urbi, Der Jiun Ooi, Akbar John, Ya Chee Lim, K. M. Kaderi Kibria, A. K. M. Mohiuddin, Long Chiau Ming et al.
Cancers 2022, 14(7), 1732; https://doi.org/10.3390/cancers14071732
Available online: https://www.mdpi.com/2072-6694/14/7/1732
“A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis”
by Tomasz Sawicki, Monika Ruszkowska, Anna Danielewicz, Ewa Niedźwiedzka, Tomasz Arłukowicz and Katarzyna E. Przybyłowicz
Cancers 2021, 13(9), 2025; https://doi.org/10.3390/cancers13092025
Available online: https://www.mdpi.com/2072-6694/13/9/2025
“Epidemiology of Glioblastoma Multiforme–Literature Review”
by Szymon Grochans, Anna Maria Cybulska, Donata Simińska, Jan Korbecki, Klaudyna Kojder, Dariusz Chlubek and Irena Baranowska-Bosiacka
Cancers 2022, 14(10), 2412; https://doi.org/10.3390/cancers14102412
Available online: https://www.mdpi.com/2072-6694/14/10/2412
“Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review”
by Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, Jacek Baj, Robert Sitarz and Andrzej Stanisławek
Cancers 2021, 13(17), 4287; https://doi.org/10.3390/cancers13174287
Available online: https://www.mdpi.com/2072-6694/13/17/4287
“Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries”
by Junjie Huang, Anastasios Koulaouzidis, Wojciech Marlicz, Veeleah Lok, Cedric Chu, Chun Ho Ngai, Lin Zhang, Ping Chen, Shanjuan Wang, Jinqiu Yuan et al.
Cancers 2021, 13(1), 141; https://doi.org/10.3390/cancers13010141
Available online: https://www.mdpi.com/2072-6694/13/1/141
|
“Feature Paper in Section “Cancer Epidemiology and Prevention” in 2022–2023“ |
“How COVID-19 Affects Cancer Patients“ |
|
“Colorectal Cancer: Epidemiology and Prevention“ |
“Inherited Breast Cancer Risk: BRCA Mutations and Beyond“ |
We hope this announcement will provide useful information for this field.
29 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Therapy
We are delighted to share some highly cited papers on cancer therapy research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
"STING Agonists as Cancer Therapeutics"
by Afsaneh Amouzegar, Manoj Chelvanambi, Jessica N. Filderman, Walter J. Storkus and Jason J. Luke
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695
"MMP9: A Tough Target for Targeted Therapy for Cancer"
by Katarzyna Augoff, Anita Hryniewicz-Jankowska, Renata Tabola and Kamilla Stach
Cancers 2022, 14(7), 1847; https://doi.org/10.3390/cancers14071847
Available online: https://www.mdpi.com/2072-6694/14/7/1847
"Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives"
by Nora Berois, Alvaro Pittini and Eduardo Osinaga
Cancers 2022, 14(3), 645; https://doi.org/10.3390/cancers14030645
Available online: https://www.mdpi.com/2072-6694/14/3/645
"The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment"
by Keiko Taguchi and Masayuki Yamamoto
Cancers 2021, 13(1), 46; https://doi.org/10.3390/cancers13010046
Available online: https://www.mdpi.com/2072-6694/13/1/46
"Photodynamic Therapy: A Compendium of Latest Reviews"
by José Francisco Algorri, Mario Ochoa, Pablo Roldán-Varona, Luís Rodríguez-Cobo and José Miguel López-Higuera
Cancers 2021, 13(17), 4447; https://doi.org/10.3390/cancers13174447
Available online: https://www.mdpi.com/2072-6694/13/17/4447
"Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives"
by Cristina Birzu, Pim French, Mario Caccese, Giulia Cerretti, Ahmed Idbaih, Vittorina Zagonel and Giuseppe Lombardi
Cancers 2021, 13(1), 47; https://doi.org/10.3390/cancers13010047
Available online: https://www.mdpi.com/2072-6694/13/1/47
"Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives"
by Shirin Hafezi and Mohamed Rahmani
Cancers 2021, 13(6), 1292; https://doi.org/10.3390/cancers13061292
Available online: https://www.mdpi.com/2072-6694/13/6/1292
|
“Feature Review for Cancer Therapy”
|
“Novel Therapeutic Strategies in Salivary Gland Tumor” |
|
“State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers” |
“New Strategies in Diagnosis and Treatments for Brain Tumors (Volume II)” |
We hope this announcement will provide useful information for this field.
29 June 2023
Meet Us at the ESMO Congress 2023, 20–24 October 2023, Madrid, Spain
28 June 2023
2022 Impact Factors for MDPI Journals
The 2022 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:
We are thrilled to announce that 90% of our ranked MDPI journals, specifically 86 out of 96 (captured in the table below), are performing above average in Q1 or Q2. This year, Clarivate has expanded its Impact Factor (IF) awards to include journals in the Emerging Sources Citation Index (ESCI) and the Arts and Humanities Citation Index (AHCI), providing greater transparency for the full set of journals indexed in the Web of Science Core Collection. As a result, 111 of MDPI journals have received their first IF in 2023, with 37 journals surpassing an IF of 3.0. In total, 208 MDPI journals have been honored with an IF.
Clarivate explains that by "expanding the coverage but holding to highly selective standards, the [Impact Factor] is now a reliable indicator of trustworthiness, as well as a measure of scholarly impact, at the journal level."
Please visit our blog post where we discuss the release of the latest citation metrics with our Indexing Manager, Dr. Constanze Schelhorn, to find out what's different this time around and how to make use of different metrics available.
| Journal | Impact Factor | Rank Quartile | Category |
| Vaccines | 7.8 | Q1 | Immunology |
| Medicine, Research & Experimental | |||
| Antioxidants | 7.0 | Q1 | Food Science & Technology |
| Biochemistry & Molecular Biology | |||
| Chemistry, Medicinal | |||
| Cells | 6.0 | Q2 | Cell Biology |
| Nutrients | 5.9 | Q1 | Nutrition & Dietetics |
| International Journal of Molecular Sciences | 5.6 | Q1 | Biochemistry & Molecular Biology |
| Q2 | Chemistry, Multidisciplinary | ||
| Journal of Theoretical and Applied Electronic Commerce Research | 5.6 | Q2 | Business |
| Biomolecules | 5.5 | Q1 | Biochemistry & Molecular Biology |
| Biosensors | 5.4 | Q1 | Chemistry, Analytical |
| Instruments & Instrumentation | |||
| Q2 | Nanoscience & Nanotechnology | ||
| Fractal and Fractional | 5.4 | Q1 | Mathematics, Interdisciplinary Applications |
| Marine Drugs | 5.4 | Q1 | Chemistry, Medicinal |
| Pharmacology & Pharmacy | |||
| Pharmaceutics | 5.4 | Q1 | Pharmacology & Pharmacy |
| Nanomaterials | 5.3 | Q1 | Physics, Applied |
| Q2 | Chemistry, Multidisciplinary | ||
| Materials Science, Multidisciplinary | |||
| Nanoscience & Nanotechnology | |||
| Cancers | 5.2 | Q2 | Oncology |
| Foods | 5.2 | Q1 | Food Science & Technology |
| Polymers | 5.0 | Q1 | Polymer Science |
| Remote Sensing | 5.0 | Q1 | Geosciences, Multidisciplinary |
| Q2 | Remote Sensing | ||
| Imaging Science & Photographic Technology | |||
| Environmental Sciences | |||
| Antibiotics | 4.8 | Q1 | Pharmacology & Pharmacy |
| Q2 | Infectious Diseases | ||
| Drones | 4.8 | Q2 | Remote Sensing |
| Journal of Functional Biomaterials | 4.8 | Q2 | Engineering, Biomedical |
| Materials Science, Biomaterials | |||
| Biomedicines | 4.7 | Q1 | Pharmacology & Pharmacy |
| Q2 | Biochemistry & Molecular Biology | ||
| Medicine, Research & Experimental | |||
| Journal of Fungi | 4.7 | Q2 | Mycology |
| Microbiology | |||
| Viruses | 4.7 | Q2 | Virology |
| Bioengineering | 4.6 | Q2 | Engineering, Biomedical |
| Gels | 4.6 | Q1 | Polymer Science |
| Molecules | 4.6 | Q2 | Chemistry, Multidisciplinary |
| Biochemistry & Molecular Biology | |||
| Pharmaceuticals | 4.6 | Q2 | Pharmacology & Pharmacy |
| Chemistry, Medicinal | |||
| Toxics | 4.6 | Q1 | Toxicology |
| Q2 | Environmental Sciences | ||
| Biomimetics | 4.5 | Q1 | Engineering, Multidisciplinary |
| Q2 | Materials Science, Biomaterials | ||
| Microorganisms | 4.5 | Q2 | Microbiology |
| Plants | 4.5 | Q1 | Plant Sciences |
| Biology | 4.2 | Q2 | Biology |
| Chemosensors | 4.2 | Q2 | Instruments & Instrumentation |
| Chemistry, Analytical | |||
| Electrochemistry | |||
| Membranes | 4.2 | Q2 | Engineering, Chemical |
| Materials Science, Multidisciplinary | |||
| Chemistry, Physical | |||
| Polymer Science | |||
| Toxins | 4.2 | Q1 | Toxicology |
| Q2 | Food Science & Technology | ||
| Metabolites | 4.2 | Q2 | Biochemistry & Molecular Biology |
| Batteries | 4.0 | Q2 | Electrochemistry |
| Materials Science, Multidisciplinary | |||
| Q3 | Energy & Fuels | ||
| Catalysts | 3.9 | Q2 | Chemistry, Physical |
| Journal of Clinical Medicine | 3.9 | Q2 | Medicine, General & Internal |
| Land | 3.9 | Q2 | Environmental Studies |
| Sensors | 3.9 | Q2 | Instruments & Instrumentation |
| Chemistry, Analytical | |||
| Engineering, Electrical & Electronic | |||
| Sustainability | 3.9 | Q2 | Environmental Sciences (SCIE) |
| Environmental Studies (SSCI) | |||
| Q3 | Green & Sustainable Science & Technology (SCIE) | ||
| Green & Sustainable Science & Technology (SSCI) | |||
| Buildings | 3.8 | Q2 | Construction & Building Technology |
| Engineering, Civil | |||
| Agronomy | 3.7 | Q1 | Agronomy |
| Q2 | Plant Sciences | ||
| Fermentation | 3.7 | Q2 | Biotechnology & Applied Microbiology |
| Pathogens | 3.7 | Q2 | Microbiology |
| Agriculture | 3.6 | Q1 | Agronomy |
| Diagnostics | 3.6 | Q2 | Medicine, General & Internal |
| Genes | 3.5 | Q2 | Genetics & Heredity |
| Journal of Intelligence | 3.5 | Q2 | Psychology, Multidisciplinary |
| Lubricants | 3.5 | Q2 | Engineering, Mechanical |
| Processes | 3.5 | Q2 | Engineering, Chemical |
| Coatings | 3.4 | Q2 | Materials Science, Coatings & Films |
| Physics, Applied | |||
| Q3 | Materials Science, Multidisciplinary | ||
| ISPRS International Journal of Geo-Information | 3.4 | Q2 | Geography, Physical |
| Q3 | Computer Science, Information Systems | ||
| Remote Sensing | |||
| Materials | 3.4 | Q2 | Metallurgy & Metallurgical Engineering |
| Physics, Applied | |||
| Physics, Condensed Matter | |||
| Q3 | Materials Science, Multidisciplinary | ||
| Chemistry, Physical | |||
| Micromachines | 3.4 | Q2 | Instruments & Instrumentation |
| Physics, Applied | |||
| Chemistry, Analytical | |||
| Q3 | Nanoscience & Nanotechnology | ||
| Water | 3.4 | Q2 | Water Resources |
| Environmental Sciences | |||
| Brain Sciences | 3.3 | Q3 | Neurosciences |
| Energies | 3.2 | Q3 | Energy & Fuels |
| Fire | 3.2 | Q1 | Forestry |
| Q2 | Ecology | ||
| Life | 3.2 | Q2 | Biology |
| Current Issues in Molecular Biology | 3.1 | Q3 | Biochemistry & Molecular Biology |
| Horticulturae | 3.1 | Q1 | Horticulture |
| Animals | 3.0 | Q1 | Agriculture, Dairy & Animal Science |
| Veterinary Sciences | |||
| Insects | 3.0 | Q1 | Entomology |
| Atmosphere | 2.9 | Q3 | Meteorology & Atmospheric Sciences |
| Environmental Sciences | |||
| Electronics | 2.9 | Q2 | Engineering, Electrical & Electronic |
| Physics, Applied | |||
| Q3 | Computer Science, Information Systems | ||
| Forests | 2.9 | Q1 | Forestry |
| Inorganics | 2.9 | Q2 | Chemistry, Inorganic & Nuclear |
| Journal of Marine Science and Engineering | 2.9 | Q1 | Engineering, Marine |
| Q2 | Oceanography | ||
| Engineering, Ocean | |||
| Metals | 2.9 | Q2 | Metallurgy & Metallurgical Engineering |
| Q3 | Materials Science, Multidisciplinary | ||
| Tropical Medicine and Infectious Disease | 2.9 | Q2 | Tropical Medicine |
| Parasitology | |||
| Q3 | Infectious Diseases | ||
| Universe | 2.9 | Q2 | Astronomy & Astrophysics |
| Physics, Particles & Fields | |||
| Healthcare | 2.8 | Q2 | Health Policy & Services (SSCI) |
| Q3 | Health Care Sciences & Services (SCIE) | ||
| Applied Sciences | 2.7 | Q2 | Engineering, Multidisciplinary |
| Physics, Applied | |||
| Q3 | Chemistry, Multidisciplinary | ||
| Materials Science, Multidisciplinary | |||
| Crystals | 2.7 | Q2 | Crystallography |
| Q3 | Materials Science, Multidisciplinary | ||
| Entropy | 2.7 | Q2 | Physics, Multidisciplinary |
| Magnetochemistry | 2.7 | Q2 | Chemistry, Inorganic & Nuclear |
| Q3 | Chemistry, Physical | ||
| Materials Science, Multidisciplinary | |||
| Symmetry | 2.7 | Q2 | Multidisciplinary Sciences |
| Actuators | 2.6 | Q2 | Instruments & Instrumentation |
| Engineering, Mechanical | |||
| Aerospace | 2.6 | Q1 | Engineering, Aerospace |
| Behavioral Sciences | 2.6 | Q2 | Psychology, Multidisciplinary |
| Current Oncology | 2.6 | Q3 | Oncology |
| Machines | 2.6 | Q2 | Engineering, Mechanical |
| Q3 | Engineering, Electrical & Electronic | ||
| Medicina | 2.6 | Q3 | Medicine, General & Internal |
| Separations | 2.6 | Q3 | Chemistry, Analytical |
| Minerals | 2.5 | Q2 | Mining & Mineral Processing |
| Mineralogy | |||
| Geochemistry & Geophysics | |||
| Children | 2.4 | Q2 | Pediatrics |
| Diversity | 2.4 | Q2 | Biodiversity Conservation |
| Q3 | Ecology | ||
| Journal of Cardiovascular Development and Disease | 2.4 | Q3 | Cardiac & Cardiovascular Systems |
| Mathematics | 2.4 | Q1 | Mathematics |
| Photonics | 2.4 | Q3 | Optics |
| Veterinary Sciences | 2.4 | Q1 | Veterinary Sciences |
| Fishes | 2.3 | Q2 | Marine & Freshwater Biology |
| Fisheries | |||
| Axioms | 2.0 | Q2 | Mathematics, Applied |
| Systems | 1.9 | Q2 | Social Sciences, Interdisciplinary |
| Tomography | 1.9 | Q3 | Radiology, Nuclear Medicine & Medical Imaging |
Note: The Journal of Personalized Medicine's Impact Factor was omitted in the original release and will be assigned separately. Please find the data on the journal webpage in due course.
Source: 2022 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2023)
25 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Clinical Cancer Research
We are delighted to share some highly cited papers on clinical cancer research that were published in the journal Cancers (ISSN: 2072-6694) in 2021-2022. In addition, some Special Issues on this topic are open for submission.
“Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?”
by Saikat Mitra, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, Kuldeep Dhama, M. Yasmin Begum, Afaf Aldahish et al.
Cancers 2022, 14(3), 759; https://doi.org/10.3390/cancers14030759
Available online: https://www.mdpi.com/2072-6694/14/3/759
“Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives”
by Fidan Seker-Polat, Nareg Pinarbasi Degirmenci, Ihsan Solaroglu and Tugba Bagci-Onder
Cancers 2022, 14(2), 443; https://doi.org/10.3390/cancers14020443
Available online: https://www.mdpi.com/2072-6694/14/2/443
“Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer”
by Kamya Sankar, Alex K. Bryant, Garth W. Strohbehn, Lili Zhao, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath and Michael D. Green
Cancers 2022, 14(3), 614; https://doi.org/10.3390/cancers14030614
Available online: https://www.mdpi.com/2072-6694/14/3/614
“Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic”
by Ana Isabel Fraguas-Sánchez, Irene Lozza and Ana Isabel Torres-Suárez
Cancers 2022, 14(5), 1198; https://doi.org/10.3390/cancers14051198
Available online: https://www.mdpi.com/2072-6694/14/5/1198
“New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines”
by Angela Santoro, Giuseppe Angelico, Antonio Travaglino, Frediano Inzani, Damiano Arciuolo, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Vincenzo Fiorentino, Antonio Raffone et al.
Cancers 2021, 13(11), 2623; https://doi.org/10.3390/cancers13112623
Available online: https://www.mdpi.com/2072-6694/13/11/2623
“The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications”
by John Charles Rotondo, Chiara Mazziotta, Carmen Lanzillotti, Chiara Stefani, Giada Badiale, Giulia Campione, Fernanda Martini and Mauro Tognon
Cancers 2022, 14(5), 1116; https://doi.org/10.3390/cancers14051116
Available online: https://www.mdpi.com/2072-6694/14/5/1116
|
“Clinical Trials for Pancreatic Cancer Diagnosis and Treatment” Edited by: Dr. Takuji Okusaka
|
“Advances in Clinical Trials of Hematological Malignancies” Edited by: Dr. Lajos Gergely |
|
“Steps towards the Clinics in Spatially Fractionated Radiation Therapy” Edited by: Dr. Stefan Bartzsch
|
“Strategies for Clinical Cancer Chemoprevention: From Bench to Bedside” Edited by: Dr. Nagi B. Kumar
|
We hope this announcement will provide useful information for this field.
21 June 2023
Cancers Receives an Increased CiteScore of 7.4
15 June 2023
Cancers | Highly Cited Papers on Cancer Progression, Development, Metastasis Research and Hot Topic Special Issues Recommendation
We are delighted to share some highly cited papers on cancer progression, development, metastasis research and hot topic Special Issues that were published in Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission.
“Trends in Research on Exosomes in Cancer Progression and Anticancer Therapy”
by Dona Sinha, Sraddhya Roy, Priyanka Saha, Nabanita Chatterjee and Anupam Bishayee
Cancers 2021, 13(2), 326; https://doi.org/10.3390/cancers13020326
Available online: https://www.mdpi.com/2072-6694/13/2/326
“Exosomal Proteins and Lipids as Potential Biomarkers for Lung Cancer Diagnosis, Prognosis, and Treatment”
by Ming-Tsung Hsu, Yu-Ke Wang and Yufeng Jane Tseng
Cancers 2022, 14(3), 732; https://doi.org/10.3390/cancers14030732
Available online: https://www.mdpi.com/2072-6694/14/3/732
“The Role of Macrophages in Cancer Development and Therapy”
by Ewa Cendrowicz, Zuzanna Sas, Edwin Bremer and Tomasz P. Rygiel
Cancers 2021, 13(8), 1946; https://doi.org/10.3390/cancers13081946
Available online: https://www.mdpi.com/2072-6694/13/8/1946
“The Functional Role of Extracellular Matrix Proteins in Cancer”
by Nadezhda V. Popova and Manfred Jücker
Cancers 2022, 14(1), 238; https://doi.org/10.3390/cancers14010238
Available online: https://www.mdpi.com/2072-6694/14/1/238
“Matrix Stiffness Contributes to Cancer Progression by Regulating Transcription Factors”
by Seiichiro Ishihara and Hisashi Haga
Cancers 2022, 14(4), 1049; https://doi.org/10.3390/cancers14041049
Available online: https://www.mdpi.com/2072-6694/14/4/1049
“Claudins and Gastric Cancer: An Overview”
by Itaru Hashimoto and Takashi Oshima
Cancers 2022, 14(2), 290; https://doi.org/10.3390/cancers14020290
Available online: https://www.mdpi.com/2072-6694/14/2/290
“Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis”
by Saima Usman, Naushin H. Waseem, Thuan Khanh Ngoc Nguyen, Sahar Mohsin, Ahmad Jamal, Muy-Teck Teh and Ahmad Waseem
Cancers 2021, 13(9), 4985; https://doi.org/10.3390/cancers13194985
Available online: https://www.mdpi.com/2072-6694/13/19/4985
|
“The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II)” Edited by: Dr. Huey-Jen Lin
|
“The Role of Autophagy in Brain Tumors (Volume II)” Edited by: Dr. Gabriella D'Orazi |
|
“Lung Cancer—Molecular Insights and Targeted Therapies (Volume II)” Edited by: Dr. Sonia Molina-Pinelo
|
“Advanced Research in Pancreatic Ductal Adenocarcinoma” Edited by: Prof. Dr. Stephan Kersting, Prof. Dr. Robert Grützmann and Prof. Dr. Tobias Keck
|
13 June 2023
Welcoming New Editorial Board Members of Cancers
12 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Radiation Research
We are delighted to share some highly cited papers on cancer radiation research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice”
by Shannon Cunningham, Shelby McCauley, Kanimozhi Vairamani, Joseph Speth, Swati Girdhani, Eric Abel, Ricky A. Sharma, John P. Perentesis, Susanne I. Wells, Anthony Mascia et al.
Cancers 2021, 13(5), 1012; https://doi.org/10.3390/cancers13051012.
Available online: https://www.mdpi.com/2072-6694/13/5/1012.
“EOB-MR Based Radiomics Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases”
by Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Sergio Venanzio Setola, Federica Dell’Aversana, Alessandro Ottaiano, Guglielmo Nasti, Roberta Grassi, Vincenzo Pilone et al.
Cancers 2022, 14(5), 1239; https://doi.org/10.3390/cancers14051239.
Available online: https://www.mdpi.com/2072-6694/14/5/1239.
“Contrast MR-Based Radiomics and Machine Learning Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases: A Preliminary Study”
by Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Sergio Venanzio Setola, Federica dell’ Aversana, Alessandro Ottaiano, Antonio Avallone, Guglielmo Nasti, Francesca Grassi et al.
Cancers 2022, 14(5), 1110; https://doi.org/10.3390/cancers14051110.
Available online: https://www.mdpi.com/2072-6694/14/5/1110.
“Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases”
by Vincenza Granata, Roberta Fusco, Antonio Avallone, Alfonso De Stefano, Alessandro Ottaiano, Carolina Sbordone, Luca Brunese, Francesco Izzo and Antonella Petrillo
Cancers 2021, 13(3), 453; https://doi.org/10.3390/cancers13030453.
Available online: https://www.mdpi.com/2072-6694/13/3/453.
“CT-Based Radiomics Analysis to Predict Histopathological Outcomes Following Liver Resection in Colorectal Liver Metastases”
by Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Federica De Muzio, Federica Dell’ Aversana, Carmen Cutolo, Lorenzo Faggioni, Vittorio Miele, Francesco Izzo and Antonella Petrillo
Cancers 2022, 14(7), 1648; https://doi.org/10.3390/cancers14071648.
Available online: https://www.mdpi.com/2072-6694/14/7/1648.
“Review of the Geant4-DNA Simulation Toolkit for Radiobiological Applications at the Cellular and DNA Level”
by Ioanna Kyriakou, Dousatsu Sakata, Hoang Ngoc Tran, Yann Perrot, Wook-Geun Shin, Nathanael Lampe, Sara Zein, Marie Claude Bordage, Susanna Guatelli, Carmen Villagrasa et al.
Cancers 2022, 14(1), 35; https://doi.org/10.3390/cancers14010035.
Available online: https://www.mdpi.com/2072-6694/14/1/35.
|
“Stereotactic Body Radiation and Stereotactic Ablative Radiotherapy Therapy for Cancers“
|
“Recent Perspectives on Mechanisms of Radiation-Mediated DNA Damage Induction and Response in Cancers“
|
|
“The Future of Radiation Research in Cancers“
|
“Steps towards the Clinics in Spatially Fractionated Radiation Therapy“
|
We hope this announcement will provide useful information for this field.
5 June 2023
Cancers | Cancer Immunotherapy Awareness Month
June is designated as “Cancer Immunotherapy Awareness Month”, with various global activities to celebrate in this important month. Immunotherapy is a type of cancer treatment and can be used alone or in combination with chemotherapy and/or other cancer treatments. Taking this opportunity, we would like to extend our appreciation to all the researchers who have contributed to the fight against cancer.
In particular, we would like to share some of the high-quality and innovative research findings in the field of cancer immunotherapy, published in Cancers (ISSN: 2072-6694).
We hope this announcement will provide useful information for this field.
“Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer”
by Antonio Lopez-Beltran, Alessia Cimadamore, Ana Blanca, Francesco Massari, Nuno Vau, Marina Scarpelli, Liang Cheng and Rodolfo Montironi
Cancers 2021, 13(1), 131; https://doi.org/10.3390/cancers13010131
“STING Agonists as Cancer Therapeutics”
by Afsaneh Amouzegar, Manoj Chelvanambi, Jessica N. Filderman, Walter J. Storkus and Jason J. Luke
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
“IL-12 Family Cytokines in Cancer and Immunotherapy”
by Bhalchandra Mirlekar and Yuliya Pylayeva-Gupta
Cancers 2021, 13(2), 167; https://doi.org/10.3390/cancers13020167
“Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma”
by Pier Francesco Ferrucci, Laura Pala, Fabio Conforti and Emilia Cocorocchio
Cancers 2021, 13(6), 1383; https://doi.org/10.3390/cancers13061383
“The Role of Macrophages in Cancer Development and Therapy”
by Ewa Cendrowicz, Zuzanna Sas, Edwin Bremer and Tomasz P. Rygiel
Cancers 2021, 13(8), 1946; https://doi.org/10.3390/cancers13081946
“CTLA-4 in Regulatory T Cells for Cancer Immunotherapy”
by Navid Sobhani, Dana Rae Tardiel-Cyril, Aram Davtyan, Daniele Generali, Raheleh Roudi and Yong Li
Cancers 2021, 13(6), 1440; https://doi.org/10.3390/cancers13061440
“The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment”
by Maximilian Haist, Henner Stege, Stephan Grabbe and Matthias Bros
Cancers 2021, 13(2), 210; https://doi.org/10.3390/cancers13020210
“Neutrophil Extracellular Traps (NETs) in Cancer Invasion, Evasion and Metastasis”
by Urszula Demkow
Cancers 2021, 13(17), 4495; https://doi.org/10.3390/cancers13174495
“The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy”
by Anastasia Mpakali and Efstratios Stratikos
Cancers 2021, 13(1), 134; https://doi.org/10.3390/cancers13010134
“Immune Resistance in Lung Adenocarcinoma”
by Magda Spella and Georgios T. Stathopoulos
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
“Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors”
by Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman and Thorbald van Hall
Cancers 2021, 13(2), 287; https://doi.org/10.3390/cancers13020287
“Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy”
by Rikke Sick Andersen, Atul Anand, Dylan Scott Lykke Harwood and Bjarne Winther Kristensen
Cancers 2021, 13(17), 4255; https://doi.org/10.3390/cancers13174255
“LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia”
by Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. González-Rodríguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto and Segundo Gonzalez
Cancers 2021, 13(9), 2112; https://doi.org/10.3390/cancers13092112
“Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy”
by Nader El-Sayes, Alyssa Vito and Karen Mossman
Cancers 2021, 13(4), 806; https://doi.org/10.3390/cancers13040806
“Role of Methylation in Pro- and Anti-Cancer Immunity”
by Ali Mehdi and Shafaat A. Rabbani
Cancers 2021, 13(3), 545; https://doi.org/10.3390/cancers13030545
“Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review”
by Walid Shalata, Amjad Abu-salman, Rachel Steckbeck, Binil Mathew Jacob, Ismaell Massalha and Alexander Yakobson
Cancers 2021, 13(20), 5218; https://doi.org/10.3390/cancers13205218
“Measles Virus as an Oncolytic Immunotherapy”
by Christine E. Engeland and Guy Ungerechts
Cancers 2021, 13(3), 544; https://doi.org/10.3390/cancers13030544
“Agonistic CD40 Antibodies in Cancer Treatment”
by Dijana Djureinovic, Meina Wang and Harriet M. Kluger
Cancers 2021, 13(6), 1302; https://doi.org/10.3390/cancers13061302
“Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy”
by Masmudur M. Rahman and Grant McFadden
Cancers 2021, 13(21), 5452; https://doi.org/10.3390/cancers13215452
“Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors”
by Agnese Paderi, Roberta Giorgione, Elisa Giommoni, Marinella Micol Mela, Virginia Rossi, Laura Doni, Andrea Minervini, Marco Carini, Serena Pillozzi and Lorenzo Antonuzzo
Cancers 2021, 13(4), 860; https://doi.org/10.3390/cancers13040860
“TAM Receptor Inhibition–Implications for Cancer and the Immune System”
by Pia Aehnlich, Richard Morgan Powell, Marlies J. W. Peeters, Anne Rahbech and Per thor Straten
Cancers 2021, 13(6),1195; https://doi.org/10.3390/cancers13061195
“Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives”
by Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Domenica Lorusso and Evaristo Maiello
Cancers 2021, 13(17), 4438; https://doi.org/10.3390/cancers13174438
“The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead”
by Adam Nelson, Jordan D. Lukacs and Brent Johnston
Cancers 2021, 13(20), 5174; https://doi.org/10.3390/cancers13205174
| “Inflammation, Immunity, and Cancer Progression” Edited by: Dr. Deepak Parashar, Dr. Vivek K. Kashyap and Dr. Subhash Tripathi Submission deadline: 15 September 2023 |
“Immune Checkpoint Therapy and Biomarker in Cancer” Edited by: Dr. Hashem O. Alsaab Submission deadline: 31 December 2023 |
 |
 |
| “Unnatural Killers for Immunotherapy: Harnessing NK Cells and Their Diversity in the Tumor Microenvironment” Edited by: Dr. Massimo Vitale, Prof. Dr. Claudia Cantoni, Prof. Dr. Simona Sivori and Prof. Dr. Daniel A. Vallera Submission deadline: 31 October 2023 |
“Targeted Treatment and Immunotherapy for Hepato-Biliary Tumors” Edited by: Dr. Girolamo Ranieri and Dr. Carmelo Laface Submission deadline: 30 November 2023 |
 |
 |
25 May 2023
Cancers Webinar | Bone Metastasis in Breast Cancer, Held on 28 June 2023
25 May 2023
Meet Us at the 64th Annual Spring Meeting of the Japanese Society of Clinical Cytology, 9–11 June 2023, Nagoya, Japan
19 May 2023
Cancers 2021 Best Paper Award—Winners Announced
16 May 2023
Meet Us at the 19th Annual International Conference of the Metabolomics Society, 18–22 June 2023, Niagara Falls, Ontario, Canada
10 May 2023
Meet Us at the ATS (American Thoracic Society) Conference 2023, 21–23 May 2023, Washington DC, USA
5 May 2023
Cancers | Bladder Cancer Awareness Month
May is designated as “Bladder Cancer Awareness Month”, with various global activities that highlight and increase awareness of bladder cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of bladder cancer, published in Cancers (ISSN: 2072-6694).
We hope this announcement will provide useful information for this field.
“Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review”
by Biagio Barone, Armando Calogero, Luca Scafuri, Matteo Ferro, Giuseppe Lucarelli, Erika Di Zazzo, Enrico Sicignano, Alfonso Falcone, Lorenzo Romano, Luigi De Luca et al.
Cancers 2022, 14(10), 2545; https://doi.org/10.3390/cancers14102545
“Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis”
by Francesco Del Giudice, Rocco Simone Flammia, Benjamin I. Chung, Marco Moschini, Benjamin Pradere, Andrea Mari, Francesco Soria, Simone Albisinni, Wojciech Krajewski, Tomasz Szydełko et al.
Cancers 2022, 14(4), 887; https://doi.org/10.3390/cancers14040887
“Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy”
by Jianya Huan, Petros Grivas, Jasmine Birch and Donna E. Hansel
Cancers 2022, 14(6),1555; https://doi.org/10.3390/cancers14061555
“Long Noncoding RNA LINC02470 Sponges MicroRNA-143-3p and Enhances SMAD3-Mediated Epithelial-to-Mesenchymal Transition to Promote the Aggressive Properties of Bladder Cancer”
by Cheng-Shuo Huang, Chen-Hua Tsai, Cheng-Ping Yu, Ying-Si Wu, Ming-Fong Yee, Jar-Yi Ho and Dah-Shyong Yu
Cancers 2022, 14(4), 968; https://doi.org/10.3390/cancers14040968
“BCG in Bladder Cancer Immunotherapy”
by Song Jiang and Gil Redelman-Sidi
Cancers 2022, 14(13), 3073; https://doi.org/10.3390/cancers14133073
“The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy”
by Gad Singer, Venkat M. Ramakrishnan, Uwe Rogel, Andreas Schötzau, Daniel Disteldorf, Philipp Maletzki, Jean-Pascal Adank, Marc Hofmann, Tilo Niemann, Sylvia Stadlmann et al.
Cancers 2022, 14(3), 618; https://doi.org/10.3390/cancers14030618
“Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer”
by Stephanie N. Shishido, Salmaan Sayeed, George Courcoubetis, Hooman Djaladat, Gus Miranda, Kenneth J. Pienta, Jorge Nieva, Donna E. Hansel, Mihir Desai, Inderbir S. Gill et al.
Cancers 2022, 14(3), 758; https://doi.org/10.3390/cancers14030758
“Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy”
by Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, Gabriele Sorce, Francesco Chierigo, Andrea Panunzio, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti et al.
Cancers 2022, 14(5), 1222; https://doi.org/10.3390/cancers14051222
“Advances in Diagnosis and Therapy for Bladder Cancer”
by Xinzi Hu, Guangzhi Li and Song Wu
Cancers 2022, 14(13), 3181; https://doi.org/10.3390/cancers14133181
“The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk?”
by Achille Aveta, Crescenzo Cacciapuoti, Biagio Barone, Erika Di Zazzo, Francesco Del Giudice, Martina Maggi, Matteo Ferro, Daniela Terracciano, Gian Maria Busetto, Giuseppe Lucarelli et al.
Cancers 2022, 14(19), 4775; https://doi.org/10.3390/cancers14194775
“From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)”
by Susanne Deininger, Peter Törzsök, Michael Mitterberger, Maximilian Pallauf, David Oswald, Christian Deininger and Lukas Lusuardi
Cancers 2022, 14(3), 694; https://doi.org/10.3390/cancers14030694
“Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis”
by Julia Jacyna, Marta Kordalewska, Małgorzata Artymowicz, Marcin Markuszewski, Marcin Matuszewski and Michał J. Markuszewski
Cancers 2022, 14(5), 1210; https://doi.org/10.3390/cancers14051210
“Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review”
by Gottfrid Sjödahl, Johan Abrahamsson, Carina Bernardo, Pontus Eriksson, Mattias Höglund and Fredrik Liedberg
Cancers 2022, 14(7), 1692; https://doi.org/10.3390/cancers14071692
4 April 2023
Cancers | Testicular Cancer Awareness Month
3 April 2023
Cancers | Esophageal Cancer Awareness Month
30 March 2023
Meet Us at the 29th Congress of the European Association for Cancer Research, 12–15 June 2023, Torino, Italy
29 March 2023
Meet Us at the 112th Annual Meeting of the Japanese Society of Pathology, 13–15 April 2023, Shimonoseki, Japan
16 March 2023
Cancers 2022 Best Ph.D. Thesis Award—Winner Announced
16 March 2023
Cancers 2022 Best Ph.D. Thesis Award—Winner Announced
16 March 2023
Meet Us at the Chinese Academic Conference on Tumor Biomarker, 7–9 April 2023, Shanghai, China
16 March 2023
Cancers 2022 Young Investigator Award—Winners Announced
14 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Biomarkers”
13 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Pediatric Oncology”
13 March 2023
MDPI’s Newly Launched Journals in December 2022
As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.
In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.
|
Journal |
Founding Editor-in-Chief |
Journal Topics (Selected) |
|
|
Prof. Dr. Fabio Gresta, University of Messina, Italy| Editorial | view inaugural issue |
grass/forage/turf production; grassland management; pasture monitoring; grazing and livestock; grass agro-ecosystems| view journal scope | submit an article |
|
|
Prof. Dr. Christos G. Athanassiou, University of Thessaly, Greece| Editorial | view inaugural issue |
pesticides; fungicides; herbicides; fertilizers; soil conditioners| view journal scope | submit an article |
|
|
Prof. Dr. Stephen H. Safe, Texas A&M University, USA| Editorial | view inaugural issue |
receptor structure; receptor function; receptor signaling; receptor expression and regulation; receptor interactions with drugs| view journal scope | submit an article |
|
|
Dr. Jean Jacques Vanden Eynde, University of Mons-UMONS, Belgium| Editorial | view inaugural issue |
drug discovery; medicinal chemistry; preclinical and clinical research; marketed drugs; intellectual property and regulatory affairs| view journal scope | submit an article |
|
|
Prof. Dr. Heather Kanuka, University of Alberta, Canada| Editorial | view inaugural issue |
higher education; tertiary education; policy and practice in higher education; educational leadership in higher education; educational administration and management in higher education| view journal scope | submit an article |
If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to newjournal-committee@mdpi.com.
9 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Tumor Microenvironment”
7 March 2023
Displaying Co-Authors’ Email Addresses on the Webpage of Published Papers
7 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Causes, Screening and Diagnosis”
7 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Infectious Agents and Cancer”
7 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Methods and Technologies Development”
6 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section "Transplant Oncology and Cancer Nursing Care"
1 March 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Immunology and Immunotherapy”
27 February 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Molecular Cancer Biology”
27 February 2023
Cancers | Top 10 Cited Papers in 2022 in the Section "Clinical Trials of Cancer"
16 February 2023
Increasing Visibility for Preprints.org – Clarivate adds the Preprint Citation Index to the Web of Science
15 February 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Pathophysiology”
15 February 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Therapy”
15 February 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Informatics and Big Data”
15 February 2023
Cancers | Top 10 Cited Papers in 2022 in the Section “Cancer Epidemiology and Prevention”
7 February 2023
Prof. Dr. Sanjay K. Srivastava Appointed Section Editor-in-Chief of Section “Cancer Metastasis” in Cancers
We are delighted to announce that Prof. Dr. Sanjay K. Srivastava, M.S., Ph.D., FAAAS, has become the new Section Editor-in-Chief of the Section “Cancer Metastasis” in Cancers (ISSN: 2072-6694).
|
|
Name: Prof. Dr. Sanjay K. Srivastava Affiliation: Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA Interests: determining the mechanism of drug resistance in various cancer models; understanding the tumor microenvironment; angiogenesis and metastasis; repurposing non-cancer drugs for cancer therapy; phytochemicals for cancer prevention and therapeutics; targeting STAT-3, NF-kB, HER2, MCL-1, AKT/FOXO, GLI1/2, and related oncogenic signaling pathways. |
Prof. Dr. Sanjay K. Srivastava is a University Distinguished Professor, the Chairman of the Department of Immunotherapeutics and Biotechnology, and the Associate Dean for Graduate Programs at the Texas Tech University Health Sciences Center (TTUHSC). He is also a James ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology and Oncology. Prof. Dr. Srivastava also served as the Associate Dean for Research for six years at TTUHSC. He recently received the honor to be elected as the Fellow of the American Association for the Advancement of Science (AAAS), which is a very prestigious scientific organization.
Prof. Dr. Srivastava has extensive research experience in the field of cancer chemoprevention and therapeutics. He is a serial innovator with several patents to his credit. His inventive contributions are supported by excellence in research. Named in the World’s Top 2% Scientists list for 2020 and 2021, Prof. Dr. Srivastava has a track record of being a productive scientist, authoring more than 160 research articles in high-impact journals with more than 10,000 citations and holding an H-index of 57, demonstrating just how impactful his research contributions have been over the years. His research has been funded by the National Cancer Institute, NIH, and other agencies and he has received numerous prestigious awards. The major focus of his laboratory is on delineating the signaling mechanisms responsible for tumor growth, angiogenesis, and metastasis in different cancer models including pancreatic, ovarian, breast, melanoma, and glioblastoma. His recent research focuses on understanding the mechanism of chemotherapeutic drug resistance in melanoma, breast, and glioblastoma. For the last 10+ years, he has also been repurposing existing non-cancer drugs for cancer therapy. For example, his group has demonstrated the anticancer effects of a few anti-psychotic drugs for breast cancer, brain cancer, and pancreatic cancer therapy. He also outlined the anti-tumor effects of anti-malarial and anti-helminthic drugs for drug-resistant breast cancer.
Prof. Dr. Srivastava has mentored numerous trainees (undergraduate students, post-doctoral fellows, and graduate students) who are now established researchers/faculty at different places. His research has been highlighted by media and news agencies. Prof. Dr. Srivastava is on the editorial board of several prestigious journals and is a member of societies including AACR, SOT, AAAS, and AAPS. He serves on the grant review panels of the National Institute of Health (NIH), the Department of Defense, and other agencies.
The following is a short Q&A with Prof. Dr. Srivastava, who shared his vision for the journal with us, as well as his views of the research area and Open Access publishing:
1. What appealed to you about the journal that made you want to take the role as its Editor-in-Chief?
I am a well-established cancer researcher and have published a few articles in Cancers. I realized that Cancers was lacking one of the key hallmarks of cancer, metastasis, so I decided to establish a separate Section for “Cancer Metastasis”. With my 30 years of research experience in the field of cancer and over 160 publications, I can contribute significantly to this Section.
2. What is your vision for the Section?I would like to expand this Section and would like to see it become one of the top-rated journal Sections on cancer metastasis.
3. What does the future of this field of research look like?Although a lot of groundbreaking discoveries have been made, there is still a lot to know about cancer and appropriate drugs to be found for therapy, especially for metastatic tumors.
4. What do you think of the development of Open Access in the publishing field?The benefit of Open Access journals is that they are easily accessible to people across the globe.
We warmly welcome Prof. Dr. Sanjay K. Srivastava as the new Section Editor-in-Chief and we look forward to him leading Cancers to reach many more milestones.
23 December 2022
Editorial Board Members from Cancers Featured in the 2022 Highly Cited Researchers List Published by Clarivate
22 December 2022
Special Issue Mentor Program
14 December 2022
"Thanks a Million!" – One Million Articles Published in MDPI Journals
MDPI has just become the first open access (OA) publisher to reach the milestone of one million articles published. That is one million articles freely available to all, to circulate and build upon! We are proud to share this special moment with the global scientific community.
This landmark has been reached thanks to the immeasurable support of more than 600,000 expert reviewers, 66,000 editorial board members and 6700 hard-working colleagues across MDPI’s global offices.
Within more than 25 years of publishing, our journals received 2.1 million manuscripts and generated 4.6 million peer review reports to get to one million papers published.
Reaching the milestone of one million articles published reinforces our mission to remove any existing barriers and to make scientific research accessible to all. Since its inception, MDPI’s goal has been to create reliable processes to make science open. This is a path towards facilitating the dissemination of novel insights in scientific communities.
Regular feedback from authors and reviewers shows that our service is greatly appreciated and needed. At the same time, the feedback helps us identify areas for further improvement.
As it stands, a significant share of published research findings remain closed access. More than half of the content published with the most well-known legacy publishers stays behind a paywall, and that is not including articles published in hybrid OA journals, or made available months or years after publication.
A new policy announced by the US administration in August 2022 requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. While the new policy does not mandate articles be published under an open access license, it is aligned with the open access movement in removing all barriers to research. Similarly, some of the most advanced research institutions in the world intend to have all funded research articles published in open access by 2025.
MDPI is proud to be the leading agent of the transition to open access.
"Thanks a Million" to all the contributors!
12 December 2022
Dr. Maen Abdelrahim Appointed Section Editor-in-Chief of Section “Transplant Oncology and Cancer Nursing Care” in Cancers
We are delighted to announce that Dr. Maen Abdelrahim, MD, Ph.D., Pharm B, Associate Professor of Medicine, Weill Cornell Medical College, Associate Clinical Member, Houston Methodist Research Institute, Director, Cockrell Center for Advanced Therapeutics, Research Institute, has taken over as Section Editor-in-Chief of the Section “Transplant Oncology and Cancer Nursing Care” in Cancers (ISSN: 2072-6694).
Dr. Maen Abdelrahim is a gastrointestinal medical oncologist and transplant oncologist attending to patients with upper and lower GI malignancies in addition to malignancies treated by liver transplantation. He is the section chief of GI medical oncology leading GI cancer care at Houston Methodist Neal Cancer Center with a focus on clinical trial Phase II/III in GI malignancies. Dr. Abdelrahim serves as the medical director of the Cockrell Center for Advanced Therapeutics where he oversees the Phase I program at Houston Methodist Hospital and Neal Cancer Center. He is a principal investigator on multiple clinical trials with a focus on chemotherapy, targeted therapy, and immunotherapy in GI malignancies. His translational research is focused on developing new mechanism-based drugs for the treatment of gastrointestinal cancers. He has identified for the first time a new structural class of compounds that can target selective transcription factors that is now recognized as a candidate for the development of new anticancer drugs. The lead compound of this class reached Phase I clinical trial to treat patients with GI cancers.
Dr. Maen Abdelrahim's research has pinpointed a number of compounds that inhibit tumor growth and angiogenesis, in part by inducing proteasome-dependent degradation of selected Sp proteins in cancer cells and tumors. The lead compound of this class (Tolfenamic acid) has reached Phase I clinical trial to treat patients with advanced and metastatic pancreatic cancer in combination with gemcitabine and radiation therapy. Dr. Abdelrahim has a patent application submitted for the new use of these compounds in GI cancers. In prior research, he was the first to discover that Sp4 protein is overexpressed in GI cancers, including pancreatic cancer, and that the role of Sp4 can be equally as important as Sp1 in some types of GI cancers.
Researchers in cancer have the ultimate responsibility of taking their findings to the clinic, which is described as translational research. By seeing GI cancer patients in his practice, collaborating with translational scientists in the lab and conducting and directing clinical trials, Dr. Maen Abdelrahim hopes to continue to fuel the translational research cycle from lab to clinic and back to the lab. Dr. Abdelrahim has published more than 220 original research articles, abstracts, review articles, and book chapters in prestigious journals and publishing groups. He is a member of the American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Cholangiocarcinoma Foundation, European Society for Medical Oncology, and International Liver Transplant Society. He is the site principal investigator for the Southwest Oncology Cooperative Group at Houston Methodist Neal Cancer Center.
Dr. Maen Abdelrahim completed his pharmacy degree followed by a Ph.D. and graduate work in the field of pharmacology and toxicology from Texas A&M University, College Station, Texas. He obtained his medical degree from Texas A&M University, completed his residency at Baylor College of Medicine, and a fellowship in medical oncology at Duke University.
The following is a short Q&A with Dr. Maen Abdelrahim, who shared his vision for the journal with us, as well as his views of the research area:
1. What appealed to you about Cancers that made you want to take the role as its Section Editor-in-Chief?
What drew me to Cancers is its emphasis on openness and novelty in research by publishing studies on clinical translations, and basic science topics associated with cancer research. As an Editorial Board Member, reviewer, and contributor to Cancers, I have found it to be the best resource for information on the problems that affect oncology. One of those platforms that aid in guiding research in the right direction is Cancers; as well as guiding research in the right direction, Cancers’ emphasis on publishing results from around the world with the same enthusiasm strikes me as being the aspect that most closely aligns with my way of thinking. Publishing meaningful negative results with the same enthusiasm as positive results is another aspect of Cancers.
2. What is your vision for Cancers?
In the years to come, I hope to see Cancers serve as a forum for researchers and oncologists to share their knowledge and research findings. My goal is to make a difference in the field of cancer research by opening doors for fresh ideas and giving them the chance to present their work without just focusing on experiments' positive and negative outcomes. I would see this as a chance to inspire and encourage researchers to explain the reasoning behind their research and will make sure to add my expertise to every research or study I undertake.
3. What does the future of this field of research look like?
It is a well-known fact that the number of cancer patients has been increasing over the years; deaths from this disease are very visible, and these numbers are expected to rise further in the coming years. According to statistics, implementing cancer prevention strategies can prevent half to two-thirds of all cancer cases. Once the potential of this field is realized, the battle against cancer will be half won, and lethal exposure to existing cancer therapies will be eliminated. As a result, it is critical to prioritize cancer research and expand its reach.
4. What do you think of the development of Open Access in the publishing field?
In my opinion, there should be no obstacles between science and readers. It should be open to all with no restrictions. Furthermore, as this research field gains traction, it would benefit a larger population if the progress was transparent and accessible to all newcomers in this field.
We warmly welcome Dr. Maen Abdelrahim to his new role as Section Editor-in-Chief, and we look forward to him leading Cancers to many more milestones.
8 December 2022
MDPI Sustainability Foundation: New Look and Nominations for the 2023 Sustainability Awards Now Open
We are pleased to announce that the website of the MDPI Sustainability Foundation has been revamped! For the past couple of months, our UX UI team and front-end developers have been working hard to launch the website in time for the opening of the Sustainability Awards nominations.
The website is not the only thing that has had a remodeling. Indeed, the format of the Emerging Sustainability Leader Award (ESLA) has been updated. ESLA is now a competition open to individual researchers or start-ups founded by researchers under the age of 35. Nominee applications will go through 2 rounds of selection until the final 3 are decided. The finalists will then be invited to give pitch presentations during the Award Ceremony to win either first place (10,000 USD) or runner-up (2 x 5000 USD).
The World Sustainability Award, on the other hand, remains the same: a total prize money of 100,000 USD is up for grabs by senior individual researchers or groups of researchers from the international research community.
Nominations for both the World Sustainability Award and the Emerging Sustainability Leader award are now open! Check out our new website for more information on how to nominate.
1 December 2022
Cancers | Recruiting Section Editorial Board Members for Section “Cancer Drug Development”
24 November 2022
Cancers | Recruiting Section Editorial Board Members for the Section “Cancer Metastasis”
21 November 2022
Meet Us at the 15th Annual Meeting of Chinese Society for Immunology, 27–30 December 2022, Chongqing, China
18 November 2022
World Lung Cancer Awareness Month | A Message from the Editorial Board of Cancers
9 November 2022
Editorial Board Members from Cancers Featured in Stanford’s List of the World’s Top 2% Scientists
9 November 2022
Cancers | Recruiting Section Editorial Board Members for Section “Pediatric Oncology”
7 November 2022
Cancers | Recruiting Section Editorial Board Members for Section “Cancer Informatics and Big Data”
4 November 2022
Meet Us at the 27th Congress of the Chinese Pediatric Society, 15–18 December 2022, Changsha, China
MDPI will be attending the 27th Congress of the Chinese Pediatric Society, held in Changsha, China, from 15–18 December 2022.
The following MDPI journals will be represented:
- Children (leading journal);
- JPM;
- Medicina;
- Audiology Research;
- JCM;
- Healthcare;
- Diagnostics;
- Metabolites;
- Cancers;
- Nutrients.
If you plan on attending this conference, feel free to stop by our booth: #B67. Our delegates look forward to meeting you in person to answer any questions that you may have.
For more information about the conference, please see the following link: https://nccps2022.tiemeeting.com/CN.
3 November 2022
Cancers | Recruiting Section Editorial Board Members for Section “Infectious Agents and Cancer”
18 October 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Systematic Review or Meta-Analysis in Cancer Research”
18 October 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Informatics and Big Data”
17 October 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Causes, Screening and Diagnosis”
12 October 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Tumor Microenvironment”
12 October 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Pathophysiology”
12 October 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Immunology and Immunotherapy”
29 September 2022
Meet Us at the 2022 BMES Annual Meeting, 12–15 October 2022, San Antonio, Texas, USA
28 September 2022
Peer Review Week 2022 – Research Integrity: Creating and Supporting Trust in Research
21 September 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Methods and Technologies Development”
21 September 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Therapy”
13 September 2022
Meet Us at the 34th Annual Conference of the International Society for Environmental Epidemiology (ISEE 2022), 18–21 September 2022, Athens, Greece
8 September 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Epidemiology and Prevention”
8 September 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Pediatric Oncology”
8 September 2022
Meet Us at the 2022 CAGPO ACMOO 19th Annual Conference, 15–18 September 2022, Toronto, Canada
7 September 2022
Meet Us at the ASHG Annual Meeting 2022 (ASHG 2022), 25–29 October 2022, Los Angeles, USA
1 September 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Transplant Oncology and Cancer Nursing Care”
1 September 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Molecular Cancer Biology”
31 August 2022
Meet Us at the ESMO Congress 2022, 9–13 September 2022, Paris, France
24 August 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Clinical Trials of Cancer”
24 August 2022
Cancers | Top 10 Cited Papers in 2021 in the Section “Cancer Biomarkers”
18 August 2022
Cancers | National Immunization Awareness Month
11 July 2022
Sarcoma and Bone Cancer Awareness Month | A Message from the Editorial Board of Cancers
28 June 2022
2021 Impact Factors - Released
The 2021 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:
| Journal | Impact Factor | Rank | Category |
| Antioxidants | 7.675 | Q1 | Food Science & Technology |
| Biochemistry & Molecular Biology | |||
| Chemistry, Medicinal | |||
| Cells | 7.666 | Q2 | Cell Biology |
| Nutrients | 6.706 | Q1 | Nutrition & Dietetics |
| Cancers | 6.575 | Q1 | Oncology |
| Pharmaceutics | 6.525 | Q1 | Pharmacology & Pharmacy |
| International Journal of Molecular Sciences | 6.208 | Q1 | Biochemistry & Molecular Biology |
| Q2 | Chemistry, Multidisciplinary | ||
| Marine Drugs | 6.085 | Q1 | Chemistry, Medicinal |
| Pharmacology & Pharmacy | |||
| Biomolecules | 6.064 | Q2 | Biochemistry & Molecular Biology |
| Batteries * | 5.938 | Q2 | Electrochemistry |
| Energy & Fuels | |||
| Materials Science, Multidisciplinary | |||
| Viruses | 5.818 | Q2 | Virology |
| Biosensors | 5.743 | Q1 | Chemistry, Analytical |
| Instruments & Instrumentation | |||
| Q2 | Nanoscience & Nanotechnology | ||
| Journal of Fungi | 5.724 | Q1 | Mycology |
| Q2 | Microbiology | ||
| Nanomaterials | 5.719 | Q1 | Physics, Applied |
| Q2 | Chemistry, Multidisciplinary | ||
| Materials Science, Multidisciplinary | |||
| Nanoscience & Nanotechnology | |||
| Metabolites | 5.581 | Q2 | Biochemistry & Molecular Biology |
| Foods | 5.561 | Q1 | Food Science & Technology |
| Drones * | 5.532 | Q2 | Remote Sensing |
| Remote Sensing | 5.349 | Q1 | Geosciences, Multidisciplinary |
| Imaging Science & Photographic Technology | |||
| Q2 | Remote Sensing | ||
| Environmental Sciences | |||
| Journal of Theoretical and Applied Electronic Commerce Research | 5.318 | Q2 | Business |
| Antibiotics | 5.222 | Q1 | Pharmacology & Pharmacy |
| Q2 | Infectious Diseases | ||
| Pharmaceuticals | 5.215 | Q1 | Pharmacology & Pharmacy |
| Q2 | Chemistry, Medicinal | ||
| Biology | 5.168 | Q1 | Biology |
| Fermentation | 5.123 | Q2 | Biotechnology & Applied Microbiology |
| Toxins | 5.075 | Q1 | Toxicology |
| Q2 | Food Science & Technology | ||
| Bioengineering * | 5.046 | Q2 | Engineering, Biomedical |
| Polymers | 4.967 | Q1 | Polymer Science |
| Journal of Clinical Medicine | 4.964 | Q2 | Medicine, General & Internal |
| Vaccines | 4.961 | Q2 | Immunology |
| Medicine, Research & Experimental | |||
| Molecules | 4.927 | Q2 | Chemistry, Multidisciplinary |
| Biochemistry & Molecular Biology | |||
| Microorganisms | 4.926 | Q2 | Microbiology |
| Journal of Functional Biomaterials * | 4.901 | Q2 | Engineering, Biomedical |
| Materials Science, Biomaterials | |||
| Biomedicines | 4.757 | Q2 | Medicine, Research & Experimental |
| Pharmacology & Pharmacy | |||
| Biochemistry & Molecular Biology | |||
| Plants | 4.658 | Q1 | Plant Sciences |
| International Journal of Environmental Research and Public Health | 4.614 | Q1 | Public, Environmental & Occupational Health (SSCI) |
| Q2 | Public, Environmental & Occupational Health (SCIE) | ||
| Environmental Sciences (SCIE) | |||
| Membranes | 4.562 | Q1 | Polymer Science |
| Q2 | Engineering, Chemical | ||
| Materials Science, Multidisciplinary | |||
| Chemistry, Physical | |||
| Pathogens | 4.531 | Q2 | Microbiology |
| Catalysts | 4.501 | Q2 | Chemistry, Physical |
| Toxics | 4.472 | Q2 | Toxicology |
| Environmental Sciences | |||
| Gels | 4.432 | Q1 | Polymer Science |
| Journal of Cardiovascular Development and Disease | 4.415 | Q2 | Cardiac & Cardiovascular Systems |
| Chemosensors | 4.229 | Q1 | Instruments & Instrumentation |
| Q2 | Chemistry, Analytical | ||
| Q3 | Electrochemistry | ||
| Genes | 4.141 | Q2 | Genetics & Heredity |
| Diagnostics | 3.992 | Q2 | Medicine, General & Internal |
| Agronomy | 3.949 | Q1 | Agronomy |
| Plant Sciences | |||
| Land | 3.905 | Q2 | Environmental Studies |
| Sustainability | 3.889 | Q2 | Environmental Sciences (SCIE) |
| Environmental Studies (SSCI) | |||
| Q3 | Green & Sustainable Science & Technology (SCIE) | ||
| Q4 | Green & Sustainable Science & Technology (SSCI) | ||
| Sensors | 3.847 | Q2 | Instruments & Instrumentation |
| Chemistry, Analytical | |||
| Engineering, Electrical & Electronic | |||
| Materials | 3.748 | Q1 | Metallurgy & Metallurgical Engineering |
| Q2 | Physics, Applied | ||
| Physics, Condensed Matter | |||
| Q3 | Materials Science, Multidisciplinary | ||
| Chemistry, Physical | |||
| Biomimetics * | 3.743 | Q2 | Engineering, Multidisciplinary |
| Q3 | Materials Science, Biomaterials | ||
| Tropical Medicine and Infectious Disease * | 3.711 | Q1 | Tropical Medicine |
| Q2 | Parasitology | ||
| Q3 | Infectious Diseases | ||
| Lubricants * | 3.584 | Q2 | Engineering, Mechanical |
| Fractal and Fractional | 3.577 | Q1 | Mathematics, Interdisciplinary Applications |
| Water | 3.530 | Q2 | Water Resources |
| Q3 | Environmental Sciences | ||
| Micromachines | 3.523 | Q2 | Instruments & Instrumentation |
| Physics, Applied | |||
| Chemistry, Analytical | |||
| Q3 | Nanoscience & Nanotechnology | ||
| Journal of Personalized Medicine | 3.508 | Q2 | Medicine, General & Internal |
| Health Care Sciences & Services | |||
| Agriculture | 3.408 | Q1 | Agronomy |
| Processes | 3.352 | Q2 | Engineering, Chemical |
| Separations | 3.344 | Q2 | Chemistry, Analytical |
| Magnetochemistry | 3.336 | Q2 | Chemistry, Inorganic & Nuclear |
| Q3 | Chemistry, Physical | ||
| Materials Science, Multidisciplinary | |||
| Brain Sciences | 3.333 | Q3 | Neurosciences |
| Buildings | 3.324 | Q2 | Construction & Building Technology |
| Engineering, Civil | |||
| Forests | 3.282 | Q1 | Forestry |
| Energies | 3.252 | Q3 | Energy & Fuels |
| Life | 3.251 | Q2 | Biology |
| Coatings | 3.236 | Q2 | Materials Science, Coatings & Films |
| Physics, Applied | |||
| Q3 | Materials Science, Multidisciplinary | ||
| Animals | 3.231 | Q1 | Agriculture, Dairy & Animal Science |
| Veterinary Sciences | |||
| Journal of Intelligence * | 3.176 | Q2 | Psychology, Multidisciplinary |
| Fishes | 3.170 | Q1 | Marine & Freshwater Biology |
| Q2 | Fisheries | ||
| Healthcare | 3.160 | Q2 | Health Policy & Services (SSCI) |
| Health Care Sciences & Services (SCIE) | |||
| Inorganics * | 3.149 | Q2 | Chemistry, Inorganic & Nuclear |
| Insects | 3.139 | Q1 | Entomology |
| Atmosphere | 3.110 | Q3 | Meteorology & Atmospheric Sciences |
| Environmental Sciences | |||
| Current Oncology | 3.109 | Q3 | Oncology |
| ISPRS International Journal of Geo-Information | 3.099 | Q2 | Geography, Physical |
| Q3 | Computer Science, Information Systems | ||
| Remote Sensing | |||
| Diversity | 3.029 | Q2 | Biodiversity Conservation |
| Ecology | |||
| Tomography | 3.000 | Q3 | Radiology, Nuclear Medicine & Medical Imaging |
| Current Issues in Molecular Biology | 2.976 | Q3 | Biochemistry & Molecular Biology |
| Medicina | 2.948 | Q3 | Medicine, General & Internal |
| Symmetry | 2.940 | Q2 | Multidisciplinary Sciences |
| Horticulturae | 2.923 | Q1 | Horticulture |
| Machines | 2.899 | Q2 | Engineering, Mechanical |
| Engineering, Electrical & Electronic | |||
| Systems * | 2.895 | Q2 | Social Sciences, Interdisciplinary |
| Applied Sciences | 2.838 | Q2 | Engineering, Multidisciplinary |
| Physics, Applied | |||
| Q3 | Chemistry, Multidisciplinary | ||
| Materials Science, Multidisciplinary | |||
| Children | 2.835 | Q2 | Pediatrics |
| Minerals | 2.818 | Q2 | Mining & Mineral Processing |
| Mineralogy | |||
| Geochemistry & Geophysics | |||
| Universe | 2.813 | Q2 | Astronomy & Astrophysics |
| Q3 | Physics, Particles & Fields | ||
| Journal of Marine Science and Engineering | 2.744 | Q1 | Engineering, Marine |
| Q2 | Oceanography | ||
| Engineering, Ocean | |||
| Entropy | 2.738 | Q2 | Physics, Multidisciplinary |
| Fire * | 2.726 | Q2 | Forestry |
| Q3 | Ecology | ||
| Metals | 2.695 | Q2 | Metallurgy & Metallurgical Engineering |
| Q3 | Materials Science, Multidisciplinary | ||
| Electronics | 2.690 | Q3 | Engineering, Electrical & Electronic |
| Computer Science, Information Systems | |||
| Physics, Applied | |||
| Crystals | 2.670 | Q2 | Crystallography |
| Q3 | Materials Science, Multidisciplinary | ||
| Aerospace | 2.660 | Q1 | Engineering, Aerospace |
| Mathematics | 2.592 | Q1 | Mathematics |
| Photonics | 2.536 | Q3 | Optics |
| Actuators | 2.523 | Q2 | Instruments & Instrumentation |
| Q3 | Engineering, Mechanical | ||
| Veterinary Sciences | 2.518 | Q2 | Veterinary Sciences |
| Behavioral Sciences * | 2.286 | Q3 | Psychology, Multidisciplinary |
| Axioms * | 1.824 | Q2 | Mathematics, Applied |
For more information on Impact Factors and what it means to index academic journals, please visit our related blog posts.
* Journals given their first Impact Factor in 2022
Source: 2021 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2022)
20 June 2022
MDPI’s 2021 Young Investigator Awards in “Medicine & Pharmacology”—Winners Announced
20 June 2022
MDPI’s 2021 Travel Awards in “Medicine & Pharmacology”—Winners Announced
20 June 2022
MDPI’s 2021 Outstanding Reviewer Awards in “Medicine & Pharmacology”—Winners Announced
20 June 2022
MDPI’s 2021 Best Paper Awards in “Medicine & Pharmacology”—Winners Announced
9 June 2022
2021 CiteScores - Released
13 May 2022
National Cancer Research Month | A Message from the Editors-in-Chief of Cancers
30 March 2022
Dr. Farrukh Aqil Appointed Section Editor-in-Chief of Section “Cancer Epidemiology and Prevention” in Cancers
We are delighted to announce that Dr. Farrukh Aqil, Assistant Professor of Medicine at the University of Louisville, has just taken over as Section Editor-in-Chief of Section “Cancer Epidemiology and Prevention” in Cancers (ISSN: 2072-6694).
Dr. Aqil attended the Aligarh Muslim University to earn his doctorate in Microbiology in 2006. He then moved to the United States to complete his post-doctoral training in the Cancer Chemoprevention and Control Program of Brown Cancer Center, Louisville. After his post-doctorate, he served as an Instructor at the Department of Medicine, University of Louisville, Louisville for two years. Along with his faculty position as an Assistant Professor at the University of Louisville, he has been meticulously involved with the James Graham Brown Cancer Center as an integral member.
Dr. Aqil has been involved in cancer prevention research for over 12 years and has received several awards, including the Faculty Excellence Award of the University of Louisville. Dr. Aqil has published over 80 articles in peer-reviewed journals, 13 book chapters, and has edited 4 books. He has participated in many conferences and presented his work as 80 abstracts/oral presentations/invited talks. He aims to keep up with his contributions to expand outreach in cancer research.
The following is a short Q&A with Dr. Farrukh Aqil, who shared his vision for the journal with us, as well as his views of the research area:
1. What appealed to you about Cancers that made you want to take the role as its Section Editor-in-Chief?
The fact that Cancers emphasizes the importance of transparency and reproducibility in research by publishing research on both clinical and basic science issues related to cancer research is what attracted me to the journal. I have been associated with this journal as an author, reviewer, and editorial board member and always found that it is the leading source of information on the issues that shape oncology. A question that often arises in cancer research is how we can make better progress in prevention and early detection. Cancers is one of those platforms that helps to move research in the right direction. The aspect that I think is the closest to my thought process is the importance the journal places on publishing results from all over the world with the same enthusiasm. Another aspect of Cancers is publishing meaningful negative results with the same interest as positive results. I feel that the negative results help research grow faster because we know what to avoid, so we move closer to positive outcomes.
2. What is your vision for Cancers?
My vision is to create a difference in the field of cancer research and open doors for new minds and provide them with a chance to put forth their research while not just confining experiments to positive and negative results; in the coming years, I would like to see this journal to be a platform for researchers to dissipate their knowledge and research outcomes. I would consider this as an opportunity to motivate and encourage researchers to communicate their research rationale, and I would make sure to add my expertise to every bit of research I go through.
3. What does the future of this field of research look like?
It is a well-known fact that the number of cancer patients has been increasing over the years; the deaths due to this disease are very much evident, and these numbers will continue to grow in the coming years. According to statistics, one-half to two-thirds of all cancer cases can be prevented upon the implementation of cancer prevention strategies. In my opinion, research and development in the field of cancer epidemiology and prevention is the need of the hour. Once the potential of this field is realized, the battle with cancer would be half won and would eliminate lethal exposure to existing cancer therapies. As such, it is necessary to place importance on cancer epidemiology and prevention and to increase its outreach.
4. What do you think of the development of Open Access in the publishing field?
I believe that there should be no barriers between science and readers. It should be accessible to all without any restrictions. Additionally, as this research field is taking grip, it would benefit larger masses if the progress was transparent and reachable to all of the beginners in this field.
We warmly welcome Dr. Farrukh Aqil to his new role as Section Editor-in-Chief, and we look forward to his leading Cancers to many more milestones.
22 November 2021
722 MDPI Editorial Board Members Receiving "2021 Highly Cited Researchers" Distinction
16 November 2021
Topical Advisory Panel Established to Support Editorial Board
25 October 2021
Open Access Week 2021 | It Matters How We Open Knowledge: Building Structural Equity, 25–31 October
Founded in 1996, MDPI was one of the first fully Open Access publisher. Over 25 years MDPI has grown to become the largest Open Access publisher globally, publishing over 160,000 articles across more than 350 journals in 2020. At the core, MDPI was founded in response to a pressing need of fast publication and inclusion. The scholar was set at the centre of the publication process for the first time. Acting as a service provider, rather than a product provider, MDPI exists to help scientists achive their objective to disseminate research results. At MDPI, we believe scientists deserve a better service from the publishing world.
The International Open Access Week (Open Access Week), founded by the SPARC (the Scholarly Publishing and Academic Resources Coalition) Alliance and student partners in 2008, has been successfully running for 13 years. As an advocate and pioneer of open access publishing, MDPI actively responds to the call of International Open Access Week. This year’s theme of “It Matters How We Open Knowledge: Building Structural Equity” highlights the Recommendation’s call for equitable participation from all authors and readers.
For the last 25 years, MDPI has been committed to disseminating open research. Here is a video showing MDPI’s Commitment to Equity, Inclusion and Diversity for More than 25 Years.
International Open Access Week is an important opportunity to catalyze new conversations, create connections across and between communities that can facilitate this co-design, and advance progress in the building of more equitable foundations for opening knowledge—discussions and actions that need to be continued, year in and year out. MDPI has always aimed to provide professional and efficient publishing services to scholars around the world.
Our mission is to make scientific research accessible to everyone; this year, we interview and hold discussions with open science ambassadors on how to build an equal and inclusive environment for open science. Academic editors help us collaborate with more institutions to advocate for open access ideas.
Besides this, our scientific community is a key driver of our success and MDPI’s remarkable growth. Despite the pandemic, we have prepared online conferences and workshops to gather scholars from different communities.
The Basel Sustainable Publishing online forum provides an equal opportunity for stakeholders and researchers from multi-cultural environments to exchange ideas and eliminate barriers to participation.
Conference date: 25 October 2021, online
Conference website: https://bspf2021.sciforum.net/
Main topics: MDPI discusses the current dilemma of open access science from various perspectives such as governments, libraries, and publishers, and related measures on how to change the status quo of discrimination from a global perspective.
We aim to support equality, inclusion, diversity, and accessibility in scholarly communications. We collaborate with universities and key laboratories and have scholarly communications with researchers, teachers, and students on open access workshops.
- 25 October 2021
Energies journal and Institute of Mechanics, Chinese Academy of Sciences
- 28 October 2021
Machines journal and State Key Laboratory of Traction Power, Southwest Jiaotong University
- 29 October 2021
Processes journal and Beijing Institute of Technology
- 29 October 2021
Coatings journal and Wuhan University of Technology
MDPI is committed to providing open access and high-quality publishing services for scholars and promoting rapid dissemination of academic achievements. We hope to promote the practices and policies of open access publishing and diversify the dissemination of academic achievements.
23 September 2021
2020 MDPI Top Reviewer Award—Winners Announced
22 September 2021
MDPI Joins SDG Publishers Compact
UN's 17 Sustainable Development Goals (SDGs) are the blueprint to achieve a better and more sustainable future for all. In 2020 the SDG Publishers Compact was launched, aimed to inspire publishers and accelerate progress to achieve the 17 goals by 2030. Members of the programme are committed to support the publication of materials that will promote and inspire actions towards SDGs.
MDPI is an eager advocate of SDGs and has already been supporting the programme by creating Special Issues and publishing a series of books on SDGs prior to joining the Compact in 2021. MDPI's Sustainability Foundation initiated the World Sustainability Awards in 2016. We fully support UN's goals to promote sustainable actions that make the world a better place for all and, as part of its commitment, we will focus our actions on SDG10: Reduced Inequalities whilst promoting all 17 SDGs. For more details, please visit the programme’s website: https://www.un.org/sustainabledevelopment/sdg-publishers-compact/.
Joining this initiative was a unanimous decision. MDPI has in its core values the dissemination of science for all, breaking the wall between research access and under-represented members of the scientific community and the general population. To support this initiative further and continue to support under-represented scientists, MDPI will take a series of actions that will be announced once ready.
The first action MDPI takes is to nominate Dr. Liliane Auwerter as the coordinator of the programme. Dr. Auwerter studied Environmental Process Technology (UTFPR, Brazil), obtained her MSc degree in Water and Environmental Engineering (University of Surrey, UK) and in 2020 completed her PhD in self-healing low-friction materials for water transport (Imperial College London, UK), always focusing on diverse scientific projects that would potentially bring sustainability to industrial processes. As a student in Brazil, she engaged in volunteering activities focused on environmental education and took part in the Millennial Development Goals meetings held at the university.
For more information, please contact:
Dr. Liliane Auwerter
Scientific Officer
liliane.auwerter@mdpi.com
3 August 2021
Announcement on Japanese Consumption Tax (JCT)
30 June 2021
2020 Impact Factors - Released
28 April 2021
Book Builder—Compile a Customized E-Book from Your Favorite MDPI Open Access Content
MDPI Books recently released Book Builder, a new online tool to conveniently arrange, design and produce an eBook from any content published in MDPI journals. Book Builder offers two functions: on the one hand (1) Selections, available to every registered user of MDPI; on the other hand (2) Special Issue Reprints, which can be used exclusively by Guest Editors of Special Issues.
Selections
In just a matter of a few clicks, all users are now able to assemble books from MDPI articles and receive instantaneous feedback in the form of a fully produced and compiled book (PDF), which can be downloaded or ordered as print copy. Selections can include any paper published with MDPI, picking and combining content from different journals and special issues.
This way, the user may for example choose to compile an ebook focusing around a particular topic, or assemble articles from a group of others.
We invite you to make yourself familiar with the new tool! The Book Builder can be found here: https://www.mdpi.com/books/book_builder.
Special Issue Reprints
The Book Builder allows Guest Editors of MDPI journals to create a reprint from a successfully completed Special Issue or Topical Collection in book format. If you are a Guest Editor for an MDPI journal, you can use the new tool to create an PDF document which includes all articles published in the Special Issue as well as a book cover and table of contents.
For Special Issues containing a minimum of 5 articles, the Guest Editor can request its publication on the MDPI Book platform. Published reprints are assigned an ISBN and DOI.
In addition to the PDF copy of the Reprint Book, as a token of our gratitude, MDPI offers every Guest Editor one (1) complimentary print copy (via print-on-demand). All contributors benefit from a discount on orders of any additional print copies, to share with colleagues or libraries or others.
Why choose MDPI Books?
In line with our organization's values, MDPI Books publishes all content in open access, promoting the exchange of ideas and knowledge in a globalized world. MDPI Books encompasses all the benefits of open access—high availability and visibility, as well as wide and rapid dissemination. MDPI Books are distributed under the terms and conditions of the Creative Commons Attribution License, meaning as an author you retain the copyright for your work. In addition, with MDPI Books you can complement the digital version of your work with a high-quality printed counterpart.
If you are interested in editing a book volume or series, or have a monograph manuscript to be considered for publication, please submit your proposal online and look at our Information for Authors.
Contact: Laura Wagner, MDPI Books Manager (email)
15 April 2021
MDPI Celebrates Company Milestone With 25th Anniversary Page
"We exist to help scientists achieve their own objectives"
10 March 2021
Journal Selector: Helping to Find the Right MDPI Journal for Your Article
15 December 2020
MDPI adopts C4DISC principles to improve diversity and inclusion in scholarly communications
MDPI is proud to adopt the principles of the Coalition for Diversity & Inclusion in Scholarly Communications (C4DISC) to support building equity, inclusion, diversity, and accessibility in scholarly communications.
The C4DISC represents organizations and individuals working in scholarly communications and is focused on addressing issues of diversity and inclusion within the publishing industry.
MDPI’s Managing Editors encourage the Editors-in-Chief and Associate Editors to appoint diverse expert Editorial Boards. This is also reflective in our multi-national and inclusive workplace. We are proud to create equal opportunities without regard to gender, ethnicity, geographic location, sexual orientation, age, disability, political beliefs, religion, or socio-economic status. There is no place for discrimination in our workplace and editors of MDPI journals are to uphold these principles in high regard.
Representatives from C4DISC meet monthly, and have started to implement initiatives to shed light and improve on the lack of diversity in scholarly communications. Some of the initiatives include developing a joint statement of principles; conducting market research; providing training resources, best practices, toolkits, and documentation for our collective memberships; and establishing outreach programs, curricula, events, and publications.
The Coalition is committed to:
- eliminating barriers to participation, extending equitable opportunities across all stakeholders, and ensuring that our practices and policies promote equitable treatment and do not allow, condone, or result in discrimination;
- creating and maintaining an environment that respects diverse traditions, heritages, and experiences;
- promoting diversity in all staff, volunteers, and audiences, including full participation in programs, policy formulation, and decision-making;
- raising awareness about career opportunities in our industries to groups who are currently underrepresented in the workforce;
- supporting our members in achieving diversity and inclusion within their organizations.
14 December 2020
Article Layout and Templates Revised for Future Volumes
At MDPI we have slightly revised the layout for articles to be published in the 2021 Volume, starting at the end of December 2020. As of today, the article templates available for download on ‘Instructions for Authors’ pages have been updated.
The most noticeable change can be found on the first page of the article, where a left-hand column has been created to include the following front matter elements: (i) the recommended citation style for the article, (ii) the publishing history, (iii) as well as the Creative Commons Attribution license used (iv) a standard note regarding affiliations. At the same time, the extra spacing on the left means the authors’ affiliations are now more clearly set apart than before. Other front matter key elements such as journal logo, article type, article title, authors, abstract and keywords remain unchanged.
The blank column on the left runs through all pages in an article; as a result, the main text is slightly more condensed, which improve reader friendliness for smaller screens. Small figures/tables are aligned on the left with standard indenture, while large figures/tables are centered and covering the full width of the page. The revised layout was applied in the article pictured below, to serve as an example:
1) Information is displayed in the left information bar.
2) In the main text, there is a blank column on the left.
3) Small tables/figures are aligned on the left, large tables/figures are centered.
11 December 2020
2020 "Highly Cited Researchers" on MDPI Journal's Editorial Boards
2 November 2020
Current Oncology, Canada's Premier Oncology Journal, Published with MDPI from 2021
MDPI acquired Current Oncology (ISSN 1718-7729) in October 2020 from Multimed Publications Inc., who launched the title in 1994, as Canada’s first peer-reviewed journal in oncology.
Current Oncology features papers in all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. It continues to be a trusted source for all members of the oncology community in Canada and abroad.
Coverage in indexing services includes MEDLINE (PubMed/National Library of Medicine), the Science Citation Index Expanded (Web of Science), Journal Citation Reports, Scopus (Elsevier), EMBASE (Elsevier), and more. Current Oncology's 2019 Impact Factor is 2.257, ranked 185/244 in the 'Oncology' category.
Previously published six times annually, normally with one or two additional supplements, MDPI will continue the schedule of bimonthly publications. The current volume of Current Oncology (v. 27) will be concluded at the end of 2020, at which point MDPI will take over publication of the journal, starting with Volume 28, at the beginning of 2021.
The goal is to greatly expand the journal's global reach, alongside MDPI's flagship Cancers journal, in order to become one of the world’s leading oncology journals.
Website: https://www.mdpi.com/journal/curroncol
Contact: Danica Jevtic, Marko Ristic
Current Oncology Editorial Office
10 July 2020
Meet Us at the Society for Neurosciences’ 50th Annual Meeting (Neuroscience 2020), Washington, USA, 24–28 October 2020
9 July 2020
Open Access Agreement Between Jisc Collections and MDPI
We are delighted to announce the establishment of our Open Access agreement with Jisc Collections, which will allow UK institutions to benefit from access to article processing charge (APC) discounts and streamlined payment workflows.
All institutions participating in the agreement will also gain access to the MDPI online submission system where they can find full article metadata and pricing information for easy identification and additional transparency.
Eligible authors affiliated with the participating institutions are prompted to choose the corresponding Institutional Open Access Program (IOAP) when they submit an article via our online submission system.
About Jisc
Jisc's vision is for the UK to be the most digitally advanced education and research nation in the world. At its heart is the super-fast national research and education network, Janet, with built-in cyber security protection. Jisc also provides technology solutions for its members (colleges, universities and research centres) and customers (public sector bodies), helps members save time and money by negotiating sector-wide deals and provides advice and practical assistance on digital technology. Jisc is funded by the UK higher and further education and research funding bodies and member institutions.
For more information, contact helen.dobson@jisc.ac.uk.
About MDPI
MDPI is a publisher of fully peer-reviewed, Open Access journals with a focus on thorough and rapid editorial processing. Its aim is to ensure that high-quality research is verified and made available to the research community as quickly as possible. MDPI stands at the forefront of the Open Access movement, having launched its first online journal Molecules in 1996. Today, MDPI is a leader in Open Access publishing with over 250 journals across all research disciplines, and all content published under a Creative Commons Attribution License (CC BY).
For any questions about this agreement, please contact the MDPI IOAP team at ioap@mdpi.com.
29 June 2020
Updated Impact Factors Released in the Journal Citation Reports (Clarivate)
The updated citation metrics have been released in the Journal Citation Reports (JCR), published by Clarivate. The recent release of the JCR includes seventy-one MDPI titles. Out of these, 18 titles are newcomers, receiving a first Journal Impact Factor which is based on citation activity in 2019: Actuators, Agriculture, Biology, Biomedicines, Biosensors, Chemosensors, Children, Healthcare, Journal of Fungi, Journal of Personalized Medicine (JPM), Land, Life, Magnetochemistry, Membranes, Pharmaceuticals, Photonics, Separations and Toxics.
- Out of the previously listed journals, a total of 72 percent boast an increased Impact Factor.
- 25 journals are ranked among the top 25% of journals in at least one of the categories they are ranked for.
- Articles published in 2019 in MDPI journals account for approximately 17 percent of of articles published in gold Open Access journals covered in the Science Citation Index Expanded (SCIE) and Social Sciences Citation Index (SSCI).
First Impact Factors
| Journal | Impact Factor | Rank | Category | Details |
| Actuators | 1.957 | 31/64 (Q2) | • Instruments & Instrumentation | Link |
| Agriculture | 2.072 | 25/91 (Q2) | • Agronomy | Link |
| Biology | 3.796 | 19/93 (Q1) | • Biology | Link |
| Biomedicines | 4.717 | 30/138 (Q1) 36/270 (Q1) |
• Medicine, Research & Experimental • Pharmacology & Pharmacy |
Link |
| Biosensors | 3.240 | 24/86 (Q2) | • Chemistry, Analytical | Link |
| Chemosensors | 3.108 | 16/64 (Q1) 27/86 (Q2) 13/27 (Q2) |
• Instruments & Instrumentation • Chemistry, Analytical • Electrochemistry |
Link |
| Children | 2.078 | 50/128 (Q2) | • Pediatrics | Link |
| Healthcare | 1.916 | 62/102 (Q3) 45/87 (Q3) |
• Health Care Sciences & Services (SCIE) • Health Policy & Services (SSCI) |
Link |
| Journal of Fungi | 4.621 | 5/29 (Q1) 31/135 (Q1) |
• Mycology • Microbiology |
Link |
| Journal of Personalized Medicine | 4.433 | 24/165 (Q1) 10/102 (Q1) |
• Medicine, General & Internal • Health Care Sciences & Services |
Link |
| Land | 2.429 | 58/123 (Q2) | • Environmental Studies (SSCI) | Link |
| Life | 2.991 | 26/93 (Q2) 109/267 (Q2) |
• Biology • Microbiology |
Link |
| Magnetochemistry | 1.947 | 22/45 (Q2) 109/159 (Q3) 201/314 (Q3) |
• Chemistry, Inorganic & Nuclear • Chemistry, Physical • Materials Science, Multidisciplinary |
Link |
| Membranes | 3.094 | 53/143 (Q2) 129/314 (Q2) 23/89 (Q2) |
• Engineering, Chemical • Materials Science, Multidisciplinary • Polymer Science |
Link |
| Pharmaceuticals | 4.286 | 49/270 (Q1) | • Pharmacology & Pharmacy | Link |
| Photonics | 2.140 | 48/97 (Q2) | • Optics | Link |
| Separations | 1.900 | 53/86 (Q3) | • Chemistry, Analytical | Link |
| Toxics | 3.271 | 32/92 (Q2) 92/265 (Q2) |
• Toxicology • Environmental Sciences |
Link |
Updated Impact Factors
| Journal | Impact Factor | Rank | Category | Details |
| Agronomy | 2.603 | 18/91 (Q1) 65/234 (Q2) |
• Agronomy • Plant Sciences |
Link |
| Animals | 2.323 | 10/63 (Q1) 14/142 (Q1) |
• Agriculture, Dairy & Animal Science • Veterinary Sciences |
Link |
| Antibiotics | 3.893 | 23/93 (Q1) 64/270 (Q1) |
• Infectious Diseases • Pharmacology & Pharmacy |
Link |
| Antioxidants | 5.014 | 10/139 (Q1) 56/297 (Q1) 7/61 (Q1) |
• Food Science & Technology • Biochemistry & Molecular Biology • Chemistry, Medicinal |
Link |
| Applied Sciences | 2.474 | 161/314 (Q3) 32/91 (Q2) 88/177 (Q2) 62/154 (Q2) |
• Materials Science, Multidisciplinary • Engineering, Multidisciplinary • Chemistry, Multidisciplinary • Physics, Applied |
Link |
| Atmosphere | 2.397 | 48/93 (Q3) | • Meteorology & Atmospheric Sciences | Link |
| Biomolecules | 4.082 | 98/297 (Q2) | • Biochemistry & Molecular Biology | Link |
| Brain Sciences | 3.332 | 113/271 (Q2) | • Neurosciences | Link |
| Cancers | 6.126 | 37/244 (Q1) | • Oncology | Link |
| Catalysts | 3.520 | 65/159 (Q2) | • Chemistry, Physical | Link |
| Cells | 4.366 | 70/195 (Q2) | • Cell Biology | Link |
| Coatings | 2.436 | 10/21 (Q2) | • Materials Science, Coatings & Films | Link |
| Crystals | 2.404 | 10/26 (Q2) 165/314 (Q3) |
• Crystallography • Materials Science, Multidisciplinary |
Link |
| Diagnostics | 3.110 | 39/165 (Q1) | • Medicine, General & Internal | Link |
| Diversity | 1.402 | 119/168 (Q3) | • Ecology | Link |
| Electronics | 2.412 | 125/266 (Q2) | • Engineering, Electrical & Electronic | Link |
| Energies | 2.702 | 63/112 (Q3) | • Energy & Fuels | Link |
| Entropy | 2.494 | 33/85 (Q2) | • Physics, Multidisciplinary | Link |
| Foods | 4.092 | 27/139 (Q1) | • Food Science & Technology | Link |
| Forests | 2.221 | 17/68 (Q1) | • Forestry | Link |
| Genes | 3.759 | 53/177 (Q2) | • Genetics & Heredity | Link |
| Insects | 2.220 | 18/101 (Q1) | • Entomology | Link |
| International Journal of Environmental Research and Public Health (IJERPH) | 2.849 | 58/193 (Q2) 32/170 (Q1) 105/265 (Q2) |
• Public, Environmental & Occupational Health (SCIE) • Public, Environmental & Occupational Health (SSCI) • Environmental Sciences (SCIE) |
Link |
| International Journal of Molecular Sciences (IJMS) | 4.556 | 74/297 (Q1) 48/177 (Q2) |
• Biochemistry & Molecular Biology • Chemistry, Multidisciplinary |
Link |
| ISPRS International Journal of Geo-Information (IJGI) | 2.239 | 31/50 (Q3) 18/30 (Q3) |
• Geography, Physical • Remote Sensing |
Link |
| Journal of Clinical Medicine | 3.303 | 36/165 (Q1) | • Medicine, General & Internal | Link |
| Journal of Marine Science and Engineering | 2.033 | 31/66 (Q2) | • Oceanography | Link |
| Marine Drugs | 4.073 | 16/61 (Q2) | • Chemistry, Medicinal | Link |
| Materials | 3.057 | 132/314 (Q2) | • Materials Science, Multidisciplinary | Link |
| Mathematics | 1.747 | 28/324 (Q1) | • Mathematics | Link |
| Medicina | 1.205 | 107/165 (Q3) | • Medicine, General & Internal | Link |
| Metabolites | 4.097 | 95/297 (Q2) | • Biochemistry & Molecular Biology | Link |
| Metals | 2.117 | 18/79 (Q1) 185/314 (Q3) |
• Metallurgy & Metallurgical Engineering • Materials Science, Multidisciplinary |
Link |
| Micromachines | 2.523 | 56/92 (Q3) 23/64 (Q2) |
• Nanoscience & Nanotechnology • Instruments & Instrumentation |
Link |
| Microorganisms | 4.152 | 37/135 (Q2) | • Microbiology | Link |
| Minerals | 2.380 | 6/21 (Q2) 11/30 (Q2) |
• Mining & Mineral Processing • Mineralogy |
Link |
| Molecules | 3.267 | 70/177 (Q2) 141/297 (Q2) |
• Chemistry, Multidisciplinary • Biochemistry & Molecular Biology |
Link |
| Nanomaterials | 4.324 | 89/314 (Q2) 42/103 (Q2) |
• Materials Science, Multidisciplinary • Nanoscience & Nanotechnology |
Link |
| Nutrients | 4.546 | 17/89 (Q1) | • Nutrition & Dietetics | Link |
| Pathogens | 3.018 | 65/135 (Q2) | • Microbiology | Link |
| Pharmaceutics | 4.421 | 44/270 (Q1) | • Pharmacology & Pharmacy | Link |
| Plants | 2.762 | 58/234 (Q1) | • Plant Sciences | Link |
| Polymers | 3.426 | 16/89 (Q1) | • Polymer Science | Link |
| Processes | 2.753 | 59/143 (Q2) | • Engineering, Chemical | Link |
| Remote Sensing | 4.509 | 9/30 (Q2) | • Remote Sensing | Link |
| Sensors | 3.275 | 22/86 (Q2) 77/266 (Q2) 15/64 (Q1) |
• Chemistry, Analytical • Engineering, Electrical & Electronic • Instruments & Instrumentation |
Link |
| Sustainability | 2.576 | 120/265 (Q2) 26/41 (Q3) 53/123 (Q2) 6/8 (Q3) |
• Environmental Sciences (SCIE) • Green & Sustainable Science & Technology (SCIE) • Environmental Studies (SSCI) • Green & Sustainable Science & Technology (SSCI) |
Link |
| Symmetry | 2.645 | 29/71 (Q2) | • Multidisciplinary Sciences | Link |
| Toxins | 3.531 | 21/92 (Q1) 34/139 (Q1) |
• Toxicology • Food Science & Technology |
Link |
| Universe | 1.752 | 18/29 (Q3) 42/68 (Q3) |
• Physics, Particles & Fields • Astronomy & Astrophysics |
Link |
| Vaccines | 4.086 | 57/158 (Q2) 50/138 (Q2) |
• Immunology • Medicine, Research & Experimental |
Link |
| Viruses | 3.816 | 12/37 (Q2) | • Virology | Link |
| Water | 2.544 | 31/94 (Q2) | • Water Resources | Link |
Source: Clarivate 2020, InCites Journal Citation Reports®.
13 May 2020
COVID-19 Academic Resources Center
9 April 2020
Free Open Platforms to Support Academics During the COVID-19 Pandemic
25 March 2020
MDPI Comment on the COVID-19 Virus
20 March 2020
MDPI Backs Open Pharma Statement on Open Access
20 March 2020
Meet us at the 43rd Annual Meeting of the Spanish Society of Biochemistry & Molecular Biology (SEBBM 2020) in Barcelona, Spain, 20–23 July 2020
18 March 2020
MDPI Co-Signed Position Statement on Transformative Agreements
16 March 2020
Encyclopedia Outstanding Contributor Awards 2020 - Open for Application
We are pleased to announce that Encyclopedia will be awarding five Outstanding Contributor Awards for researchers in 2020. The nominations and applications will be assessed by an Evaluation Committee consisting of senior scholars from the Encyclopedia Editorial Board.
Prize for Winners
- An official certificate;
- A cash award of 500 CHF or an MDPI discount voucher of 800 CHF.
Application Deadline
31 December, 2020 (Please send your application email with a list of all entries you contributed to our office before the deadline: office@encyclopedia.pub)
Candidate Requirements
- Have a Ph.D. degree;
- Have more than three qualified entries published in Encyclopedia in 2020.
Evaluation Standards
- Number of entries published in Encyclopedia in 2020;
- Quality of entries online (including length, figure quality, and novelty);
- Impact of entries (including the number of likes, discussion contents, views, and downloads).
If you are a researcher and have not yet contribute entries to Encyclopedia, please do not miss this chance to highlight your research results.
21 February 2020
Registered Report: New Article Type Accepted For Submission
19 February 2020
Meet Us at American Thoracic Society (ATS) 2020 Congress in Philadelphia, PA, USA, 15–20 May 2020
14 February 2020
Meet Us at the Allied Genetics Conference (TAGC 2020) in Washington, DC, USA, 22–26 April 2020
28 January 2020
Attending the 2020 ACSO Annual Meeting in Chicago, IL, USA, from 29 May–1 June 2020
11 December 2019
Meet Us at Precision Medicine World Conference 2020 in Silicon Valley, CA, USA, 21-24 January, 2020
11 October 2019
Introducing SciProfiles, an Academic Social Network
MDPI is pleased to announce the release of SciProfiles, its social network platform for researchers and scholars.
The purpose of SciProfiles is aligned with MDPI’s broad mission to accelerate discovery and innovation by facilitating immediate access to research results and to serve scholars and communities by providing opportunities for academic networking.
SciProfiles also ambitions to serve as a sustainable, transparent and community-driven research evaluation system aligned with the DORA principles (https://sfdora.org/). Through their scientific profiles, academics can highlight their contribution to research communities, and measure their impact on their field, beyond publication numbers and impact factors. SciProfiles is currently a beta version and will enrich to give researchers the possibility to highlight all of their contributions to science and their scientific communities as authors, reviewers, editors, conference organizers, conference panelists, conference keynote speakers, or even as lecturers or student mentors at their University.
The classic components of popular community social networks, including follower/following, classical metrics, endorsements and recommendations (https://www.mdpi.com/about/announcements/1690), comments (https://www.mdpi.com/about/announcements/1397) are or will be very soon highlighted in SciProfiles as open science contributions.
To help increase the impact and visibility of articles and their authors to an appropriate audience, the platform offers a NewsFeed that includes recommendations of relevant content based on interests, publication history, saved searches or colleagues’ recommendations.
SciProfiles’ avatars are now being integrated on several MDPI platforms, meaning that you will directly access researchers’ profiles from any of the MDPI platforms:
MDPI's journal publishing website: www.mdpi.com
MDPI's conference hosting and management website: www.sciforum.net
MDPI's pre-print website : www.preprints.org
MDPI's knowledge sharing website : www.encyclopedia.pub
MDPI's books store: www.mdpi.com/books
MDPI's literature database : www.scilit.net
SciProfiles aims to serve scientific communities at large. It can be embedded into third-party websites and also welcomes integration of data from third-parties.
Dr. Shu-Kun Lin: https://sciprofiles.com/profile/2
Dr. Franck Vazquez: https://sciprofiles.com/profile/FranckVazquez
Dr. Martyn Rittman: https://sciprofiles.com/profile/martynrittman
2 October 2019
Winners of the 2019 MDPI Writing Prize
We are delighted to announce the winners of the 2019 MDPI Writing Prize. Entrants were asked to write on the theme "Judging research: How should research and researchers be evaluated and rewarded?" We received a large number of excellent essays from PhD students and postdocs, and the process of shortlisting and choosing winners was not an easy one. The winners demonstrated excellent writing skills alongside interesting and thought-provoking ideas.
As last year, we will begin the process of collating all entries into a book that will be available in open access format. Alongside promoting good writing skills, we see the prize as a way to promote the voices of early career researchers within broader debates and policy discussions.
Congratulations to all of the participants and especially the winners. The winners are:
1st Prize (500 CHF):
Albin Nilsson (National Centre for Nuclear Research, Warsaw, Poland)
[Read here]
2nd Prize (250 CHF):
Qi Zhang (Shandong University, Jinan, China)
[Read here]
Igor Ogashawara (Indiana University, Indianapolis, US)
[Read here]
3rd Prize (100 CHF):
Margaret Sivapragasam (Universiti Teknologi Petronas, Perak, Malaysia)
[Read here]
Arvind Sharma (The University of Queensland, Gatton, Australia)
[Read here]
Jose Flores-Guerrero (University Medical Center Groningen, Groningen, The Netherlands)
[Read here]
The MDPI Writing Prize is an annual award supported by MDPI Author Services, which provides services including language editing, reformatting, plagiarism checks, and image editing.
20 September 2019
MDPI Now Gives Scholars the Possibility to Endorse and Recommend Articles
MDPI is pleased to announce the release of a new functionality giving the possibility for researchers and scholars to endorse, and formally recommend articles to their colleagues.
MDPI was an early signatory of the San Francisco Declaration on Research Assessment (https://sfdora.org/read/) which calls for improvement in how quality and impact of scholarly research outputs are evaluated, especially in moving beyond journal-based citation metrics (journal Impact Factor, Scopus Citescore, etc.).
MDPI supports the establishment of article-level impact metrics, including citations, views, downloads, and Altmetric scores. These measures serve as an impact indicator for research articles on a case–by-case basis, assessing paper on its own merit. However, these metrics are also subjective and can give a biased picture of the article impact: they do not directly reflect the quality or the intrinsic scientific value of the article.
In our view, community engagement with publications based on community-driven metrics can help to overcome this limitation. We have therefore launched an option for scholars to endorse articles, indicating their own assessment of its content and making a recommendation to their community. This follows our implementation of the open source Hypothesis commenting tool, which has been available for all articles published by MDPI for over a year (https://www.mdpi.com/about/announcements/1397). Both endorsement and commenting are available for all previously published and forthcoming MDPI articles.
In addition to potentially serving as a sustainable solution to article assessment, endorsements will help scientific communities to identify the most relevant articles, independently of the journal in which it was published.
The code for the endorsing functionality, which relies on DOIs and ORCIDs, will be made available on GitHub with an open source license.
Dr. Shu-Kun Lin, President and Founder
Dr. Franck Vazquez, Chief Scientific Officer
Dr. Martyn Rittman, Publishing Director
11 September 2019
Meet Us at ASCB|EMBO 2019 in Washington DC, 7–11 December 2019
11 September 2019
Create an Entry in Encyclopedia to Get a 100 CHF Voucher in Publishing in MDPI Journals
Encyclopedia is a free online reference created and curated by active scholars. It aims to highlight the latest research results as well as provide a comprehensive record of scientific development. If you have any suggestions or questions, please feel free to contact us via office@encyclopedia.pub.
6 August 2019
Preprints Reaches 10,000 Posted Articles Milestone
We are pleased to announce that Preprints has passed the milestone of 10,000 posted preprints. We are delighted to have reached this after just over three years of operation. Our congratulations and thanks go to our authors and advisory board who have supported growth of the platform and been crucial to its operation.
You can find further details at https://www.preprints.org/announcement/show/37.
2 August 2019
DeepGreen Partnering with Publishers and Universities in Distributing Open Access Content to Institutional Repositories
Last week, the DeepGreen initiative in Germany started into an advanced test phase with the publishing partners S. Karger AG, SAGE Publishing, MDPI, Frontiers and De Gruyter, as well as 27 universities from all over Germany, from Hamburg University of Applied Sciences to University of Konstanz.
DeepGreen aims at lowering the barriers for open access publishing by automatically delivering metadata and full text publications from participating publishers to authorized repositories at German universities.
In preparation for a later live operation, the advanced test phase serves to gain experience with extensive data deliveries from publishers and also handling different repository software (including OPUS4, DSpace, EPrints, MyCoRe). DeepGreen thereby acts as a sophisticated platform, receiving articles published by authors affiliated with German universities and depositing these articles to respective university repositories, based on the affiliation metadata. For more information about DeepGreen: https://deepgreen.kobv.de
Karger AG has been a close cooperation partner of the DeepGreen consortium since 2016. S. Karger has more than 80 subscription-based and around 20 open access journals covering a wide spectrum in health science. DeepGreen will assign S. Karger articles to authorized institutions on the legal basis of German alliance and national licenses.
SAGE Publishing was founded by Sara Miller McCune in 1965 to support the dissemination of usable knowledge and educate a global community. SAGE publishes more than 1,000 journals and over 600 new books each year, spanning a wide range of subject areas. Our growing selection of library products includes archives, data, case studies and video. SAGE remains majority owned by our founder and after her lifetime will become owned by a charitable trust that secures the company’s continued independence. Principal offices are located in Los Angeles, London, New Delhi, Singapore, Washington DC and Melbourne. SAGE Publishing has been a close cooperation partner of DeepGreen since 2016.
MDPI is a scientific open access publisher and has been a partner of DeepGreen since 2017. MDPI comprises 205 peer-reviewed journals of various disciplines. All articles are published under a CC-BY license and are freely available without embargo period.
Frontiers is a scientific open access publisher with 61 journals of over 600 academic disciplines. All articles are peer-reviewed and published freely available under CC-BY license.
De Gruyter is an academic publisher with more than 700 subscription-based and open access journals of 29 disciplines. Articles provided by De Gruyter will be assigned to institutions with German alliance and national licenses.
There is promising communication with other publishers.
DeepGreen is funded by the German Research Foundation (DFG) and the consortium comprises six institutions: the Cooperative Library Network Berlin-Brandenburg, Bavarian State Library, Bavarian Library Network, University Library of the Technische Universität Berlin, University Library of Erlangen-Nuremberg and the Helmholtz Open Science Coordination Office at the GFZ German Research Centre for Geosciences.
If you would like to know in more detail which institutions take part in the advanced test phase of DeepGreen, you can find more information here.
30 July 2019
Meet Us at the 2019 APHA Annual Meeting and Expo
25 July 2019
Meet Us at the 12th European Public Health Conference
17 July 2019
First Basel Sustainable Publishing Forum
The University of Basel and the MDPI Sustainability Foundation are organizing the First Basel Sustainable Publishing Forum on 9th September 2019.
The aim of this event is to provide background and perspectives on Plan S to Learned Societies, which have to make well-informed decisions to transition their journals to Open Access (OA).
The BSPF will bring together several representatives of Learned societies, Plan S architects as well as representatives from various publishers and publishing platforms. After getting the big picture from cOAlition S, panel discussions will allow to better understand the diverse challenges that Learned societies are facing to transition their journals to OA as well as to identify sustainable, implementable and scalable solutions for successful Open Access transition.
For program details and registration, please follow the link below:
https://sciforum.net/conference/SustainableSolutionsToOpenAccess
28 June 2019
Meet Us at the 2019 ISV Annual Congress in Ghent, Belgium, 27–29 October 2019
20 June 2019
Cancers Receiving 2018 Updated Impact Factor of 6.162
19 June 2019
Meet Us at Neuroscience 2019 in Chicago, IL, USA, 19–23 October 2019
18 June 2019
Meet Us at the 42nd Congress of the Spanish Society of Biochemistry and Molecular Biology in Madrid, Spain, 16–19 July 2019
6 June 2019
Meet Us at European Society of Cardiology Congress 2019 in Paris, France, 31 August – 4 September 2019
20 May 2019
Meet Us at the European Human Genetics Conference in Gothenburg, Sweden, 15–18 June 2019
8 May 2019
Meet Us at the ESMO Congress 2019
20 March 2019
Fostering Open Access Publishing Worldwide: New IOAP Participants in February and March 2019
We are pleased to welcome more universities from Poland, Italy, Germany, Brazil and other parts of the world to MDPI's Institutional Open Access Program (IOAP). A warm welcome to the institutions listed below, who have joined the Program in February and March this year.
Authors affiliated with these institutions can now enjoy a discount on the APC for papers accepted for publication in any MDPI journal. If you would like to learn more about our program, please visit: https://www.mdpi.com/about/ioap or email us at ioap@mdpi.com.
5 March 2019
MDPI Joins Jisc’s Publications Router Service
1 February 2019
2018 MDPI Top Reviewer Award—Winners Announced
Rigorous peer-review is the cornerstone of high quality academic publishing. Over 97,000 scholars served as reviewers for MDPI journals in 2018. We are extremely appreciative of all those who made a contribution to the editorial process in this capacity. At the beginning of every year, journal editorial offices publish a list all reviewers’ names to express our gratitude. In addition, this year the “MDPI Top Reviewer Awards” are announced, to recognize the very best reviewers for their expertise, dedication, high quality, and timely review reports. We are pleased to announce the following winners of the 2018 MDPI Top Reviewer Awards:
- Ali Behnood
- Andrea Pezzuolo
- Angela Gorgoglione
- Anna D'Auria
- Antonio D'Andrea
- Azhar Abbas
- Bogdan Zagajewski
- Chunhui Chen
- Dominika Głąbska
- Dominika Guzek
- Dragan Pamucar
- Francisco J. G. Silva
- Frank Li
- Gianluca Serafini
- Gyorgy Szekely
- Haozhi Pan
- Helvi Heinonen-Tanski
- José Manuel Gómez-Soberón
- Kathy Lewis
- Klara Kosova
- Luis N. López De Lacalle
- M. Z. Naser
- Malwina Tytła
- Masoume Amirkhani
- Matteo Ghidelli
- Moretti Laura
- Petra Schneider
- Roberto Cerchione
- Spyros Papaefthymiou
- Ştefan Cristian Gherghina
24 January 2019
JAMS Journals: A Low-Cost Publishing Platform
24 January 2019
Popularity of Preprints Continues to Grow
2018 was a great year for preprints, with increasing numbers of authors looking to make their papers available online before peer review. Along with other preprint servers, our platform Preprints.org saw an increase in the uptake from authors, and more than double the number of announced papers compared to 2017. In fact, we recently passed two important milestones: 8000 preprints online and 30,000 authors.
We believe that the whole research community has the opportunity to benefit from work being available online as early as possible. We thank and congratulate our authors for supporting us to make this goal a reality.
In 2019, we will be looking carefully at how to provide better value for authors, maintain efficiency while growing in size, and make sure we remain well-connected with the research community.
If you want to participate, you can consider screening preprints or joining our advisory board. And, of course, posting your own work.
9 January 2019
Open Access Agreement between the Austrian Academic Library Consortium (KEMÖ), the Austrian Science Fund (FWF), and MDPI
We are delighted to announce the establishment of our national Open Access agreement with the Austrian Academic Library Consortium (KEMÖ) and the Austrian Science Fund (FWF). Through this national agreement, the Austrian institutions listed below as well as FWF will cover the Article Processing Charges (APC) of manuscripts published by eligible corresponding or funded authors in MDPI journals as long as central funds are available.
All participating institutions have gained access to the MDPI online submission system where they can find full article metadata and pricing information as well as Funder and Grant ID details for easy identification and additional transparency. At the same time eligible authors are benefited from an APC discount which comes at no cost for the institutions.
Eligible corresponding authors affiliated with the participating institutions are prompted to choose the corresponding Institutional Open Access Program (IOAP) when they submit an article via our online submission system. The program will be selected automatically if authors submit their papers using their institutional email address. To claim their discount, FWF funded authors should choose the particular funder and add their Grant ID upon online submission of their manuscript. The institutions will then crosscheck the information and confirm the APC funding.
Eligible authors that have their APC covered by their institution or funder are advised to include the following sentence in their acknowledgments: "Open Access Funding by the [name of the institution/funder]".
The full text of the agreement is openly available online at: http://doi.org/10.5281/zenodo.2536007
For any questions about the agreement, please contact the KEMÖ Consortium at emedien@obvsg.at, FWF at Katharina.Rieck@fwf.ac.at, or the MDPI IOAP team at ioap@mdpi.com.
The Austrian institutions participating in this agreement are:
- Austrian Science Fund (FWF)
- University for Continuing Education Krems
- University of Applied Sciences BFI Vienna
- University of Applied Sciences Upper Austria
- University of Applied Sciences Technikum Wien
- Vorarlberg University of Applied Sciences
- International Institute for Applied Systems Analysis (IIASA)
- Institute of Science and Technology Austria
- MCI Management Center Innsbruck
- University of Graz
- University of Linz
- University of Salzburg
- Graz University of Technology
- TU Wien
- University of Veterinary Medicine Vienna
- University of Vienna
This is our first collective agreement with a national library consortium, while the individual institutions around the world participating in our IOAP are now more than 500 - see details here: https://www.mdpi.com/about/ioap. We would be mostly interested in discussing about possible collaborations with other consortia, funders, and institutions in our mutual efforts to accelerate Open Access.
2 January 2019
Encyclopedia—the Scholarly Community Encyclopedia
5 November 2018
Blog │ Funders Push for a Full Transition to Open Access: Plan S
30 October 2018
Institutional Open Access Agreement between Bill and Melinda Gates Foundation and MDPI
3 October 2018
2018 Nobel Prize in medicine awarded for pioneering research on immune checkpoints
This week, James P. Allison and Tasuku Honjo were awarded the 2018 Nobel prize in physiology or medicine "for their discovery of cancer therapy by inhibition of negative immune regulation." As early as the 1990s, both immunologists discovered proteins that act as brakes on the T cells, ensuring the regulation that keeps autoreactive T cells in check.
Subsequent research found that blocking these so-called immune checkpoints through the use of checkpoint inhibitors shows promising results for cancer treatment, by ramping up the body's immune system and causing a stronger attack against tumor cells. In immunotherapy, doctors now have a viable alternative to chemotherapy and radiotherapy in treating some types of cancer, especially at advanced stages of infestation and including metastasis, even though instances of autoimmune reaction in immunotherapy are not yet fully understood.
Recent research has been looking into the potential of inhibitors blocking PD-1, the T cell protein discovered by Tasuku Honjo in 1992. A group at University of Calgary "investigated the ability for immune checkpoint blockade to enhance the efficacy of oncolytic reovirus (RV) for the treatment of breast cancer" (article published by Ahmed A. Mostafa et al. in Cancers). Simona De Rosa et al. investigated PD-L1/PD-1 expression in gastric cancer cells (article here). One group in Nice, France, studied the characteristics of lung adenocarcinomas in elderly patients in another article published in Cancers.
Diagram depicting the anticancer mechanism of PD-1/PD-L1 inhibitors
(Source: Figure 1 in S.M. Abdin et al., Cancers 2018,
doi:10.3390/cancers10020032).
In an article published in the International Journal of Molecular Sciences (IJMS), Xin Sun et al. give "some structural guidance" for the design of an antibody effective in blocking the PD-L1 immune suppressor. Shifaa M. Abdin et al. provide an overview of checkpoint inhibitors in their review paper entitled "Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors" (Figure 1 to the right).
In order to improve response rates in patients, targeting additional checkpoints such as LAG-3, BTLA or TIM-3 may prove effective, as discussed in an IJMS review paper by Robert J. Torphy et al. Other studies are looking into resistance mechanisms in tumor cells. Once these mechanisms are better understood, adjuvant treatments can help "improve the efficacy of immunotherapy and [...] expand its scope" (review paper by J. Rieth and S. Subramanian: "Mechanisms of Intrinsic Tumor Resistance to Immunotherapy").
One more recent review paper entitled "Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses" (Teresa Nguyen et al.) lays out different strands of use of oncolytic viruses in cancer treatment, one of them being their combined use with checkpoint inhibitors.
A number of papers published in last year's Special Issue on "Targeting Immune Checkpoints and Immunotherapy" (guest-edited by Dr. William Chi-shing Cho) dealt with aspects of immunotherapy as well:
➤ "Targeting Immune Cell Checkpoints during Sepsis" (Naeem K. Patil et al.)
➤ "Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality" (Andreas Pircher et al.)
➤ "PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression"
(Michal Šmahel)
➤ "Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways" (Kai Li et al.)
If you are interested to publish your research on related topics, we welcome your submission to the Special Issue on "Signaling Pathways and Immune Checkpoint Regulation in Cancer" (guest-edited by Prof. Dr. Georgios Rassidakis) in our oncology journal Cancers.
2 October 2018
MDPI Welcomes Plan S
Recently, it was announced that a group of European funders supported 10 principles that will help to expand open access, known as Plan S. MDPI warmly welcomes this move as a step towards achieving more open and accessible communication of research across all disciplines. Some aspects remain to be clarified, however the details given so far match the aims and values that MDPI has held over the past two decades.
We believe that open access publishers should be active participants in discussions around Plan S, particularly regarding potential new business models and practical aspects of implementation. MDPI supports APCs as a transparent unit of payment for article publishing, however we are committed to exploring other measures and recently signed the Jussieu Call. Sustainability is a key value for MDPI, and future funding models should have at their heart the sustainability of knowledge and research dissemination. Plan S provides an opportunity for funders and publishers to directly discuss funding of open access journals in ways that are beneficial to all parties involved.
3 September 2018
Meet Us at the 77th Annual Meeting of the Japanese Cancer Association in Osaka, Japan (27–29 September 2018)
30 August 2018
MDPI establishes Open Access agreement with Qatar National Library
We are happy to announce the establishment of an Open Access (OA) agreement with Qatar National Library (QNL). QNL is committed to supporting and helping Qatar authors publish OA at no cost. Through this national agreement, QNL will cover the Article Processing Charges (APC) of manuscripts published by Qatar-based corresponding authors in MDPI journals.
Eligible corresponding authors affiliated with Qatar research centers and universities are prompted to choose QNL as part of our Institutional Open Access Program (IOAP) when they submit an article via our online submission system. The program will be selected automatically if authors submit their papers using their institutional email and/or a computer registered with the institution’s IP range. QNL will then crosscheck the information and confirm the APC funding.
Qatar authors that have their APC covered by QNL are advised to include the following sentence in their acknowledgments: "The publication of this article was funded by Qatar National Library".
For more information, please visit Open Access at QNL or email the QNL Open Access team at openaccess@qnl.qa.
3 July 2018
Meet Us at the ESMO 2018 Congress (19–23 October 2018) in Munich, Germany
26 June 2018
Cancers (ISSN 2072-6694) receives first Journal Impact Factor: 5.326
We are pleased to announce that Cancers has received a first Impact Factor in the latest edition of the Journal Citation Reports®, published by Clarivate Analytics in June 2018.
Cancers is covered in the Science Citation Index Expanded (SCIE) in Web of Science and received a first Impact Factor of 5.326. The journal ranks 44/222 (Q1) in the 'Oncology' category.
The Journal Citation Reports®, 2018 release, is a Clarivate Analytics product.
6 June 2018
Meet Us at the 18th World Congress of Basic and Clinical Pharmacology in Kyoto
31 May 2018
Cancers 2017 CiteScore™ Announced - 5.82
We are pleased to report Cancers received a CiteScore of 5.82 for 2017. The metric reflects citation activity in 2017 in Scopus for papers published in the period 2014‒2016.
Cancers ranks among the Top 10% of journals in the 'Oncology' category.
For the full details in the current CiteScore release, please see the journal's Source profile. To check the full list of MDPI journals receiving CiteScores, please see here.
31 May 2018
2017 CiteScore™ Metrics Released
30 April 2018
Winners of the First MDPI Writing Prize
23 March 2018
Check for Updates: A New Function in the Article PDF Version
At MDPI, we always want to keep you up to date. Even for already published articles, some corrections or minor changes may occur. To prevent you from missing any updates, from now on you will be able to access the latest version of any manuscript by clicking on the “check for updates” logo that you can find in the PDF file, even if you have saved the file on your computer.
15 March 2018
Congratulations to Eleven Journals for Publishing the Tenth Volume in 2018
Congratulations to the journals Cancers, Diversity, Future Internet, Nutrients, Polymers, Pharmaceutics, Remote Sensing, Sustainability, Symmetry, Toxins and Water for publishing their 10th volume in 2018!
We would like to send warm wishes from the Editors-in-Chief of these journals and look to the future. Acknowledgement of our past achievements provides the strongest stimulus for future endeavor.
To date, the journal Cancers has published more than 1000 papers and will receive its first impact factor in June. This milestone could not be achieved without our readers, authors, peer reviewers, editors, and all the people working for the journal who, for years, have contributed their tremendous efforts.
— Prof. Dr. Samuel Mok
Editor-in-Chief of Cancers
Ten years is a long time but a short period for a new journal. When we started Diversity 10 years ago, we had hoped that a journal with such a broad coverage of topics would attract potential authors and good contributions. We are very satisfied that our vision became reality.
Today, Diversity is home to interesting studies on different aspects of diversity mainly in biology, ranging from systematics, phylogeny and evolution, to ecology, biodiversity and conservation issues. I am confident that the next 10 years will witness the further growth of Diversity both in quality and quantity.
— Prof. Dr. Michael Wink
Editor-in-Chief of Diversity
Ten years have passed from the foundation of the “Future Internet” MDPI journal. We have witnessed the positive evolution of our journal, with ever-increasing interest from potential authors. The increasing fundamental eco-systemic importance of the journal’s subjects has also had positive effects. Therefore, the journal is currently evolving to cope with the increasing interdisciplinary and transdisciplinary views.
Past achievements and future prospects give us reason to celebrate ten years since the journal’s foundation. We will also set up a commemorative Special Issue.
— Prof. Dr. Dino Giuli
Editor-in-Chief of Future Internet
It is with great pride that Nutrients enters its 10th year of publication. Through the hard work and dedication of its Editorial Board, journal staff, and individuals who have unselfishly given their time to peer-review manuscripts, the journal has grown to become a leading publisher of nutrition research. During this 10th Anniversary year of Nutrients, I would like to take the opportunity to thank all who have contributed to the journal during its first decade.
— Prof. Dr. Jonathan Buckley
Editor-in-Chief of Nutrients
I am pleased and honored to celebrate the first decade of Pharmaceutics, as the founding Editor-in-Chief. This is also an opportunity for me to thank our authors, readers, reviewers, and editorial board members for their continuous support. We will receive our first impact factor in June 2018, in recognition of the great efforts made in the past ten years. We shall strive to improve the journal in the next ten years.
— Prof. Dr. Yvonnne Perrie
Editor-in-Chief of Pharmaceutics
Since its foundation in 2009, Polymers has evolved into an internationally renowned and successful Open Access journal. The core concept, namely that Open Access publishing can stand for high-quality publications, is working well. On a daily basis, ever since the journal’s foundation, the editorial team and the editorial board dedicate themselves to ensuring a high-quality rigorous peer-review process: only 30 to 50% of the submissions will be published in Polymers. This strategy been complemented by, among other features, the increasing impact factor of Polymers, the most recent one being 3.364. On the occasion of Polymers’ 10th anniversary, we would like to thank all authors who have contributed to the success of the journal by submitting their high-quality research papers. We look forward to your continuous support and the continued growth of the journal in the next decade.
— Prof. Dr. Alexander Böker
Editor-in-Chief of Polymers
MDPI’s Open Access journal Remote Sensing is now one of the top international scientific journal 's in remote sensing science. Well known scientists in the subject, from all over the world, publish in it on a regular basis. It has an outstanding and dedicated editorial team, editorial office, and reviewers. We pride ourselves on publishing high-quality original scientific articles. Our goal remains to become # 1 Journal in Remote Sensing Science.
— Dr. Prasad S. Thenkabail
Editor-in-Chief of Remote Sensing
The tenth anniversary of Sustainability is a momentous milestone, and it has been a privilege for me to be a part of it as Editor-in-Chief. This anniversary demonstrates the growing interest in and recognition of the importance of sustainability. The journal has been able to showcase the many advances made over the last decade in the thinking, methods and applications surrounding sustainability. Recently, the content of the journal has reflected the 17 Sustainable Development Goals of the 2030 Agenda for Sustainable Development that was adopted by the United Nations in September 2015. Sustainability has had a notable impact and expects to have an even greater impact over its next decade through publishing research on new advances in sustainability and fostering critical discussion.
— Prof. Dr. Marc A. Rosen
Editor-in-Chief of Sustainability
Our journal Symmetry celebrates its 10th anniversary in 2018. During the last 10 years, the journal has become one of the leading journals among all multi-science journals. This shows the fundamental role played by the symmetries of nature in natural science. This also reflects the huge number of researchers whose work relates to symmetry. We hope to achieve even better results in the coming years.
— Prof. Dr. Sergei D. Odintsov
Editor-in-Chief of Symmetry
It is my honor as Editor-in-Chief of Toxins to inaugurate the 10th anniversary of the journal’s inception. From the founding EIC, Professor Florian Lang and EIC Vernon Tesh and the many Section EICs and Editorial Board Members, the combined leadership of this effort to provide an outstanding vehicle for the dissemination of the results of high-quality scientific investigations and in-depth, insightful comprehensive reviews has resulted in the flagship journal of toxinology as we know it today. The publication metrics associated with Toxins support this claim by virtue of our increase in manuscript submissions and publications and annual citation rate of articles published in Toxins. Importantly, the impact factor for Toxins remains strong and representative of the significance of the science published in Toxins. As we progress in this anniversary year, we will celebrate the 10th anniversary with a continuation of our acclaimed travel award program for Post-Doctoral Fellows in the field of Toxinology as well as our soon to be announced “Toxins' 10th Anniversary Top Cited Researcher Award” program.
Thus, 2018 will be an exciting year, celebrating the 10th anniversary of Toxins, but also a year of looking forward for the best practices by which the journal can serve the toxinology community. With that in mind, please join us in celebrating the journal by submitting your work to Toxins and as always I welcome your suggestions for the improvement of “our” journal.
— Prof. Dr. Jay W. Fox
Editor-in-Chief of Toxins
Thank you to all the dedicated researchers, reviewers and editors who have made Water a success. The journal has become a popular outlet for cutting-edge research in the broad field of water science, technology, management and governance. The Open Access format has proven to be attractive, and authors highly value the quick handling of papers. After ten years, Water has become an established journal in the field.
— Prof. Dr. Arjen Y. Hoekstra
Editor-in-Chief of Water
To mark the anniversaries, we have established a Special Issue to look back over the previous decade of outstanding accomplishments and highlight innovative frontier research perspectives. We encourage you to keep an eye on the publications in this Special Issue and this journal, and hope you consider it as a venue for your future publications.
13 March 2018
MDPI Becoming a Member of UKSG
We are proud to announce that MDPI is now a member of UKSG, the UK´s largest scholarly communications community. Through UKSG, different stakeholders share their knowledge and experience in order to improve the knowledge and information environment for researchers. UKSG´s members include universities, publishers, content providers, intermediaries, and other similar organisations. Members participate in discussions and events on issues around scholarly communications.
The UKSG Annual Conference and Exhibition is a flagship initiative from the UKSG and one of the most stimulating events in the scholarly communications calendar. It is held annually and attracts a large number of delegates. More information is available at https://www.uksg.org/events/annualconference
MDPI is delighted to be a part of this active community and we look forward to making our own contribution. We will continue to support organisations and initiatives that boost collaboration and vision within scholarly communication.
More information about UKSG can be found at https://www.uksg.org/. The full membership list is available at: https://www.uksg.org/members.
8 March 2018
Meet Us at NANOTECH 2018 in Anaheim, CA, USA, 13–16 May 2018
1 February 2018
MDPI Signed the San Francisco Declaration on Research Assessment (DORA)
The DORA initiative addresses the need for advanced approaches in the evaluation and measurement of the quality of scientific research outputs. It is a worldwide initiative covering all scholarly disciplines. MDPI proudly joins a list of more than 400 organizations around the world which support DORA’s recommendations for improving the way the quality of research results is evaluated.
More info can be found at http://www.ascb.org/dora/
22 January 2018
Meet Us at the Experimental Biology 2018 (21–25 April 2018) in San Diego, CA, USA
3 January 2018
Expanding the Coverage in SCIE (Web of Science)
The collection of journals in the Science Citation Index Expanded (SCIE)—the most prestigious part of the Web of Science Core Collection—keeps expanding. Last year, nine MDPI open access journals were added in SCIE; they are due to receive first Journal Impact Factors in June 2018.
|
Journal |
Current Volume |
Scope |
|
|
Oncology | more | submit article |
|
|
|
Vol. 8 (2018) | articles |
Animal science; animal welfare | more | submit article |
|
|
Vol. 7 (2018) | articles |
Cell biology; cell structure; cell function and processes; molecular biology and biophysics | more | submit article |
|
|
Pharmacokinetics; pharmacodynamics; biopharmaceutics; molecular biology and biotechnology | more | submit article |
|
|
|
General and internal medicine; healthcare research and practice | more | submit article |
|
|
|
Entomology; physiology and ecology of insects; taxonomy of insects | more | submit article |
|
|
|
Chemistry applied to agronomy; agroecology; food science | more | submit article |
|
|
|
Vol. 7 (2018) | articles |
Electrical engineering; microelectronics; signal processing | more | submit article |
|
|
Vol. 6 (2018) | articles |
Chemical engineering and processing; biochemistry | more |
21 December 2017
Meet Us at the AACR Annual Meeting 2018 in Chicago, IL, USA
19 December 2017
Announcing the MDPI English Writing Prize
15 December 2017
UCL Press Adopts the MDPI Editorial Platform JAMS
23 November 2017
New Participants in the Institutional Open Access Program (IOAP)
10 November 2017
Available Journal Awards at MDPI
7 November 2017
MDPI has signed the Jussieu Call for Open Science and Bibliodiversity
The Jussieu Call aims to develop and implement alternative models to meet the aims of open science while promoting bibliodiversity. In particular it wishes to promote new business models for funding open access publication. It was drafted on the Jussieu campus in Paris by a group of French researchers and scientific publishing professionals.
MDPI supports scholarly communities and initiatives that innovate and further promote Open Access publishing. There is a need to explore different frameworks to fund open access in ways that ensure that excessive funds are not diverted from research towards publishing. Many fair funding models already exist, and they can be further developed and extended. These include institutional support, library contributions or subsidies, premium services, participatory funding, etc. For this reason, MDPI has signed up to the Jussieu call and welcomes its aims.
More information can be found at http://jussieucall.org/ (archived here)
10 October 2017
Cancers Reaches 1'000 Articles Milestone
Cancers, MDPI's open access oncology journal, has published more than 1'000 articles and reviews since its inception in 2009. Cancers is now covered in the Science Citation Index Expanded in Web of Science; the journal is expected to receive its first Impact Factor in the 2017 edition of the Journal Citation Reports, which is going to be published by Clarivate Analytics in June 2018.
Cancers' current CiteScore in Scopus is 5.02. The CiteScore is a ratio between the number of citations in 2016 to papers published 2013–2015 in the numerator and the number of papers published 2013–2015 in the denominator, drawn from Scopus data. Full-text article pages were accessed more than 7'000 times directly from PubMed in August and September 2017.
Our sincere thanks go to the Editors of Cancers, Prof. Dr. Samuel C. Mok and Prof. Dr. David Wong, as well as numerous Guest Editors of Special Issues, who ensure the continued significance of the journal.
6 October 2017
Dr. Franck Vazquez, MDPI CEO, Interviewed by Scholarly Kitchen
3 October 2017
Meet Us at the 2017 NCRI Cancer Conference in Liverpool
19 September 2017
A Warm Welcome to the New IOAP Participants
23 June 2017
Congratulations for Publishing the 100,000th Peer-Reviewed Article
6 June 2017
CiteScore™ Metrics Released for Scopus Journals
17 May 2017
Three New Institutional Memberships Established
We are pleased to announce that the Goethe University of Frankfurt, the Technical University of Hamburg (TU Hamburg-Harburg), as well as the Humboldt University of Berlin, in Germany, have joined MDPI's institutional membership program: Primary authors from these instititions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
4 May 2017
MDPI Supports the Initiative for Open Citations (I4OC)
2 May 2017
Publons Peer Review Academy Goes Live
24 April 2017
Two New Institutional Memberships Established
We are pleased to announce that the following universities have joined MDPI's institutional membership program: Trinity University, San Antonio, Texas, USA and the University of New South Wales (UNSW), Sydney, Australia. Primary authors from these instititions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
30 March 2017
Credit for Preprints Comments via Publons
Preprints.org is a platform run by MDPI that allows authors to make early versions of manuscripts available before peer review has been completed.
One of the major benefits of putting a preprint online is to get feedback before journal submission. Until now, however, the feedback has been on a voluntary basis. Preprints is delighted to be the first preprint server to collaborate with Publons to acknowledge substantial comments as reviews and give commentators the opportunity to receive credit for their efforts.
When you add a comment to any article, there is a check box to click for it to appear on Publons. If you have already linked your account it will be passed on automatically. If you don't already have a Publons account, you will be contacted soon afterwards with instructions on how to create one.
We appreciate the enthusiasm and cooperation of Publons in this project and expect it to be of great benefit to authors and commenters alike.
20 March 2017
MDPI 2016 Annual Report Released
15 March 2017
Our 100,000th Article Could be Yours!
After the 20th anniversary of MDPI in 2016, we will reach another milestone this year and will publish the 100,000th peer-reviewed article in one of our 170+ open access journals.
We would like you to be part of this great achievement and so are offering to publish the 100,000th accepted paper free of charge.
To be in with a chance, select a journal in one of our 10 scientific subject areas and submit your paper.
Access the live tracker on published articles here.
14 March 2017
Cancers (ISSN 2072-6694) Accepted for Coverage in Science Citation Index Expanded (Web of Science)
We are pleased to announce that Cancers (ISSN 2072-6694) has been accepted for indexing in the Science Citation Index Expanded (SCIE), as well as BIOSIS Previews and Biological Abstracts. The coverage starts with volume 6 (2014); the articles will be available in Web of Science soon.
Cancers is an international, peer-reviewed open access journal on oncology covering all strands of cancer research. The journal was founded by Prof. Dr. Robert H. Weiss from the University of California Davis in 2009. Since its inception over 900 review and research articles have since been published in the journal. From December 2015, Prof. Dr. Samuel C. Mok from the University of Texas MD Anderson Cancer Center has been serving as Editor-in-Chief. He has been joined by Prof. Dr. David Wong, who is an Associate Editor for Cancers.
The Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI) and Web of Science are Clarivate Analytics products.
3 March 2017
1000 Preprints Online
We are delighted that Preprints now has 1000 papers online since its launch on 3 May 2016.
For more information, see the editorial here.
9 February 2017
Minister and State Secretaries Visit MDPI Office at STP, Belgrade, Serbia
Earlier this week the Science Technology Park in Belgrade, Serbia was visited by Swiss Secretary of State Dr. Mauro Dell’Ambrogio, as well as Serbian Minister of Public Administration and Local Self-Government Ana Brnabic, State Secretary Dr. Vladimir Popovic and Mayor of Belgrade Mr. Siniša Mali.
During the visit to the STP they had a short presentation from MDPI’s CEO Dr. Franck Vazquez and IT Manager Mr. Miloš Čučulović, and further discussed important issues such as Open Access and Open education. Dr. Dell'Ambrogio said he was impressed with the potential for development and ideas for business.
For more information please see:
http://bit.ly/2kpIu7k and http://bit.ly/2kpUQfz
7 February 2017
The 6th World Sustainability Forum: Final Press Release
Basel, 29 January 2017
The 6th World Sustainability Forum #WSF2017SA: African universities critical to achieving the Sustainable Development Goals
Jeffrey and Sonia Sachs win first World Sustainability Award.
Universities need to take the lead in solving the greatest challenges the world faces today, particularly in Africa. They need to do this not only through education – teaching the next generation to think critically and creatively to find sustainable solutions – but also through research that cuts across a range of disciplines. To ensure these solutions are implemented, they need to partner with the private sector and with government.
This was the key message from the 6th World Sustainability Forum (WSF2017), which took place in Cape Town on 27 and 28 January 2017. Sponsored by MDPI and the journal Sustainability under the patronage of the Universities of the Western Cape (UWC), Cape Town (UCT), University of Basel and the National Research Foundation (NRF) of South Africa, the conference was attended by key national and international speakers, including world-leading economist Professor Jeffrey D. Sachs, senior United Nations (UN) advisor and director of the Earth Institute at Columbia University.
The WSF is an annual sustainability conference which addresses research in a range of areas related to sustainable development and sustainability globally. This was the first WSF to take place on the African continent. Discussions at the 2017 conference were driven by the 17 sustainable development goals (SDGs) adopted as part of the 2030 Agenda for Sustainable Development by the UN in September 2015.
Achieving the SDGs “is the moonshot for our generation,” said Sachs. “Like the moonshot [moon landing] of the 1960s, these are tough, bold and achievable objectives.”
“This is a nasty, tough world we live in, and our world agrees on very little. So when 193 governments agree on something, that is important. And when they agree on something as important as sustainable development, that is really something for us to grab hold of – that is a lifeline.”
There was agreement at the WSF that the SDGs are particularly important for Africa, and that African universities in particular have a role to play in achieving them.
Said Professor Tyrone Pretorius, vice-chancellor of UWC: “The quest for sustainable development can only be met through education. Universities today are the oil that fuels the knowledge economy.”
As part of the drive to develop academic capacity to provide the knowledge needed to meet the SDGs, WSF2017 was preceded by the 1st Postgraduate Forum on Sustainability. “A series of workshops for postgraduate education linked to WSF are important, in order to equip postgraduates with the skills necessary to promote sustainability,” said Professor Thandi Mgwebi, director for research at UWC. A second postgraduate forum will take place alongside the WSF2018 in Beijing.
This capacity development is particularly critical to Africa. Said Sachs: “African universities need to do research to find solutions to Africa’s development challenges, because no other university will.”
The UN set a target of achieving the SDGs by 2030: “I regard this as the breakthrough period to end extreme poverty on the continent,” said Sachs, “and for Africa to become one of the most dynamic centres of the world economy.”
It is a critical time for South African universities, said Professor Mamokgethi Phakeng, deputy vice-chancellor for research and internationalisation at UCT: “Higher education is at a crossroads, and there is much polarisation. We need to think carefully about how this sustainable development agenda is owned by all so that it is inclusionary.”
There was also strong emphasis on public–private partnerships – for universities, business and government to work together to achieve the goals.
Said Professor Francis Petersen, deputy vice-chancellor at UCT and vice-chancellor designate at the University of the Free State: “Business sustainability has become critical, because there is increasing demand and complexity of demand on business from the natural, social and economic environment. Sustainability cannot be a standalone issue, divorced from business as usual. Sustainability needs to be embedded into business.”
Environmental crises and climate change was also high on the WSF agenda. In his keynote address, Sachs noted the irreversibility of the climate- and environmental-related challenges.
“If we don’t get our act together, we lose the chance of safety,” he said.
Said Professor Mark New, pro vice-chancellor and director of the African Climate and Development Initiative at UCT: “We have a fundamental challenge in responding to climate change, and we must go further than just putting a plaster on a wound. We need to address the deep structural issues, to move from our current model of development into climate-compatible development.”
“This requires researchers to find the evidence for the correct development pathways to take, and then support the ability of policymakers at all levels to enable the shift to climate-compatible development planning.”
Said Dr. Aldo Stroebel, executive director of international relations and cooperation at the NRF, in closing: “We have seen over the past two days an urgency towards the next step of thinking, that critical type of framework that we all must engage with, not only from an academic perspective, but further up into the policy environment and into rural-based environments where one can clearly see the links and effectiveness of the work.”
World Sustainability Awards
The first World Sustainability Award and the first Emerging Sustainability Leader Awards were presented by Prof. Thandi Mgwebi, Director of Research at UWC, and Dr. Franck Vazquez, CEO of MDPI, during the ceremony on 27 January 2017 as part of the gala dinner of the 6th World Sustainability Forum in South Africa.after day one of proceedings of the 2017 World Sustainability Forum South Africa.
Professor Jeffrey D. Sachs and Dr. Sonia Ehrlich Sachs are the joint recipients of the first World Sustainability Award. Jeffrey Sachs is a world-renowned economist and senior United Nations (UN) advisor and director of the Earth Institute at Columbia University. Sonia Sachs is a paediatrician and public health specialist, and director of the Health Centre at the Centre for Sustainable Development, also at Columbia University.
The joint recipients of the first Emerging Sustainability Leader Award are Dr. Esther Ngumbi and Dr. Xiaosong Hu. Esther Ngumbi is a postdoctoral researcher at Auburn University in Alabama USA and serves as a 2015 Clinton Global University Mentor for agriculture. Xiaosong Hu is a professor at the Chongqing University in China and specialises in automotive control systems and mechanical engineering.
The World Sustainability Award and the Emerging Sustainability Leader Awards are funded to encourage new initiatives and developments in sustainability with the ultimate aim of fostering the transition to sustainable practices and societies.
The World Sustainability Award is funded by the MDPI Sustainability Foundation, and included a monetary prize of USD 100,000 to Jeffrey and Sonia Sachs. The Emerging Sustainability Leader Award is funded by the journal Sustainability, awarded to researchers under 40, and included a monetary prize of USD10,000.
Issued jointly by: UCT Global Strategy and Visibility, Research Office, UWC Communications & Media and MDPI AG
Conference photos are free available at: https://sciforum.net/conference/wsf-6/page/175 Photo credit: Matthias Burkhalter
|
Carla Bernardo |
Luthando Tyhalibongo |
Matthias Burkhalter |
31 January 2017
Three New Institutional Memberships Established
We are pleased to announce that the Chalmers University of Technology, Sweden, the University of Manitoba, Canada and the Technical University of Cartagena, Spain, have joined MDPI's institutional membership program: Primary authors from these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
27 January 2017
6th World Sustainability Forum under way in South Africa
The 6th World Sustainability Forum is currently being held at the Cape Sun Hotel until 28 January 2017.
The Forum will showcase the work of internationally renowned researchers and include more than 150 presentations. During the conference dinner, the World Sustainability Award, associated with a US$ 100,000 prize, will be announced, as well as the Emerging Sustainability Leader Award, associated with a US$ 10,000 prize. The prizes are sponsored by the MDPI Sustainability Foundation and Sustainability, an academic open access journal by MDPI.
Here are some pictures from the forum so far:
To see the full WSF2017 program and schedule, please see here: https://sciforum.net/conference/wsf-6/page/schedule
19 January 2017
Cape Town to Host the 6th World Sustainability Forum
Cape Town will host the 6th World Sustainability Forum at the Cape Sun Hotel on 27 and 28 January 2017. This prominent event, held for the first time in Africa, will include many illustrious South African and international experts, such as Her Excellency Graça Machel (Sustainable Development Advocate for the United Nations, Mozambique), Joyene Isaacs (HoD Agriculture Western Cape Government), Jeffrey Sachs (Columbia University, USA), Max Bergman (SRaM, University of Basel), Mark New (Pro Vice-Chancellor, University of Cape Town), Frans Swanepoel (FutureAfrica, University of Pretoria) and Francis Petersen (Vice-Chancellor-designate, University of the Free State). The Forum will provide a stage for national and international debates on sustainability in South Africa, the African continent, and about international perspectives on sustainability. It brings together researchers and representatives from government and the business sector to discuss a wide-ranging set of issues associated with sustainability, including food security, water and energy scarcity, mining, poverty reduction, climate change, and urbanisation.
The next few decades will be marked by profound changes in the relationships between global economics, national societies, and the environment. We have entered what some call the Anthropocene, an age in which human activity dominates the climate and the environment. These changes will have numerous consequences on societies around the globe. South Africa and Africa will play a central role, for better or worse, in creating opportunities and risks during these changing times as Africa is profoundly influencing and being influenced by global developments.
The adoption of the 17 United Nations Sustainable Development Goals and the 2030 Agenda for Sustainable Development in September 2015 was accompanied by what insiders considered an optimism they have not experienced in relation to UN resolutions before. The relative efficiency in the drafting, the lack of trenches between East and West, or between North and South, and the unanimity of support of the 193 countries speak volumes. In stark contrast, sustainability seems to go against a changing economic and political tide, where waves of nationalism and protectionism from some of the most powerful countries risk the wellbeing of the rest of the world. The 6th World Sustainability Forum will enable fruitful exchanges, which sensitise South African and international communities to the global urgency and specifics of sustainability.
The Forum will showcase the work of internationally renowned researchers and include more than 150 presentations. During the conference dinner, the World Sustainability Award, associated with a US$ 100 000 prize, will be announced, as well as the Emerging Sustainability Leader Award, associated with a US$ 10 000 prize. The prizes are sponsored by the MDPI Sustainability Foundation and Sustainability, an academic open access journal by MDPI. The World Sustainability Forum is preceded by the Postgraduate Forum on Sustainability, which will introduce more than 100 young scholars from South Africa and the African continent to sustainability research. Both events are organized and sponsored by the University of Cape Town, the University of the Western Cape, the University of Basel, MDPI, and by the National Research Foundation of South Africa.
Contacts:
Scientific Matters: Prof Manfred Max Bergman, Social Research and Methodology Group (SRaM), University of Basel, Switzerland; Email: max.bergman@unibas.ch
Press Accreditation and General Enquiries: Mr Matthias Burkhalter, MDPI AG, Basel, Switzerland; Email: burkhalter@mdpi.com; Tel. +41 61 683 77 34
Follow us on Twitter
#WSF2017SA
6 January 2017
MDPI Supports the OA2020 Initiative
MDPI is now a proud supporter of the OA2020 Initiative.
Open Access 2020 is an international initiative that aims to induce the swift, smooth and scholarly-oriented transformation of today’s scholarly journals from subscription to open access publishing.
MDPI is participating in the upcoming Berlin13 conference in March 2017, where we are contributing to the initiative by aiding in the design of the roadmap which will make OA the default publishing model.
For more information please see here.
5 January 2017
Three New Institutional Memberships Established
We are pleased to announce that the University of Texas at Arlington, USA, the Harbin Institute of Technology, China and TU Darmstadt, Germany, have joined MDPI's institutional membership program: Primary authors from these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
22 December 2016
Happy Festive Season!
Season's greetings from everyone at MDPI!
22 December 2016
Two New Institutional Memberships Established
We are pleased to announce that the Otto-von-Guericke-Universität Magdeburg, Germany and the University of California, Berkeley, USA, have joined MDPI's institutional membership program: Primary authors from these instititions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
19 December 2016
MDPI and Wellcome Trust Compliance
The Wellcome Trust has, for a number of years, required that the results of its funded projects are published in open access format. Recently it announced criteria that publishers must fulfil for publication fees to be paid by the Trust. MDPI is pleased to have been added to the list of compliant publishers.
Only publishers who have confirmed their compliance by 16 December 2016 will be eligible to receive payment of APCs by the Wellcome Trust as of 1 April 2017. For more information on the criteria and a full list of publishers that meet them, see here.
13 December 2016
Meet MDPI at the 2016 AGU Fall Meeting
MDPI is currently attending the 2016 AGU Fall Meeting (12–16 December, 2016)
If you are also attending the conference, please feel free to stop by our booth (Booth #1147) and meet the representative editors.
Conference details:
2016 AGU Fall Meeting
12–16 December 2016
Moscone Center
747 Howard St
San Francisco, CA 94103, USA
8 December 2016
Three New Institutional Memberships Established
We are pleased to announce that Purdue University, USA, the Universitat Politécnica de Valencia, Spain and the Queensland University of Technology, Australia, have joined MDPI's institutional membership program: Primary authors from these instititions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
16 November 2016
World Sustainability Award - Final Extension
The deadline for the World Sustainability Award has been extended for one last time! You now have one more month to nominate an individual researcher, group or project! The final deadline for nominations will be December 15, 2016.
For full details, please visit here.
11 November 2016
Three New Institutional Memberships Established
We are pleased to announce that the University of Minnesota, USA, the Universidad Politécnica de Madrid, Spain and Shanghai Jiao Tong University, China, have joined MDPI's institutional membership program: Primary authors from these instititions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
4 November 2016
MDPI Joins the United Nations Global Compact
MDPI has become a member of the United Nations Global Compact to support corporate sustainability and have committed ourselves to the ten principles associated with the Compact.
Sustainability has always been at the core of MDPI’s values, starting with the collection and preservation of rare chemical samples that started in 1996 and led to the first journal, Molecules. Sustainability has become one of our flagship journals and we have supported and organized several conferences and events based on Sustainability, including the upcoming 6th World Sustainability Forum. As a global enterprise, we see it as our duty to promote responsible practices that will ensure a bright future for our planet. Given this, the choice to join the Global Compact was an easy one and we will do our utmost to fully implement it.
3 November 2016
MDPI Now a Member of SPARC Europe
We are delighted to announce that MDPI has become a member of SPARC Europe, an organization that works for open scholarship in Europe, including support of open access publication.
As one of the few publishers to join SPARC Europe to date, MDPI looks forward to making a contribution that puts open scholarship on a positive and sustainable path. We fully support the goals of open scholarship that allow the largest number of people possible to benefit from work of researchers in all disciplines. We hope that our membership will enable us to work with other stakeholders to find the best possible solution.
2 November 2016
World Sustainability Award Deadline Extension
The deadline for the World Sustainability Award has been extended! You now have until November 15, 2016 to nominate an individual researcher, group or project!
For full details, please visit here.
.
26 October 2016
Four New Institutional Memberships Established
We are pleased to announce that the Wuppertal Institut, Germany, the University of Girona, Spain and Central South University and Huazhong University of Science and Technology, China, have joined MDPI's institutional membership program: Primary authors from these instititions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
24 October 2016
International Open Access Week 2016
Meet us during International Open Access Week 2016! We will be presenting at various locations in Europe and China.
To get involved and for full details see the complete list of events organised by MDPI here.
18 October 2016
Institutional Membership established with Universitat Pompeu Fabra, Spain and Aalto University, Finland
We are pleased to announce that the Universitat Pompeu Fabra, Spain and Aalto University, Finland, have joined MDPI's institutional membership program: Primary authors from these universities will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
12 October 2016
Institutional Membership Established with Iowa State University and the University of North Texas, USA
We are pleased to announce that the Iowa State University and the University of North Texas, USA, have joined MDPI's institutional membership program: Primary authors from these universities will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
7 October 2016
MDPI at Open Access Days in Munich, 10-11 October 2016
Meet MDPI during the Open Access Days held from 10-11 October 2016 at Ludwig Maximilian University of Munich, Germany.
The two-day event will feature experts from the open access sector, scientists from all disciplines, publishing representatives and supporters of scientific research and communication from libraries as well as research institutes and funding institutions. Join us!
For more information about the event and to see the program, visit the event webpage.
7 October 2016
Institutional Membership Established with the University of Sevilla and the University of Alicante, Spain
We are pleased to announce that the University of Sevilla and the University of Alicante, Spain have joined MDPI's institutional membership program: Primary authors from these universities will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
29 September 2016
Institutional Membership Established with the University of Delaware
We are pleased to announce that the University of Delaware, USA, has joined MDPI's institutional membership program: Primary authors from this university will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
19 September 2016
Peer Review Week 2016
As an open access publisher indebted to the work of our peer reviewers, we are proud to support Peer Review Week 2016. As part of the week's activities and to celebrate this year's theme "Recognition for Review", MDPI will host two webinars that anyone can join.
These webinars will explore the role and value of reviewers and the recognition they receive from a publishers perspective, with examples from MDPI's experience in publishing nearly 80,000 peer reviewed papers, along with evidence from reviewer surveys. It will also touch upon potential changes in how review is carried out and tips for early career researchers who want to be involved in the review process.
Details and links to join can be found below:
Wednesday September 21, 08:00 (CEST)
Friday September 23, 16:00 (CEST)
For more information about all the activites taking place, please visit the Peer Review Week website.
6 September 2016
Institutional Membership established with Kansas State University and Northwestern University, USA
We are pleased to announce that Kansas State University and Northwestern Universty, USE, have joined MDPI's institutional membership program: Primary authors from these universities will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
5 September 2016
Institutional Membership Established with University College Cork
We are pleased to announce that University College Cork, Ireland, has joined MDPI's institutional membership program: Primary authors from this university will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
22 August 2016
MDPI New Office Location
We are pleased to announce that MDPI has now moved to a new permanent address:
MDPI AG
St. Alban Anlage 66
CH-4052 Basel
Postfach, CH-4020 Basel
Switzerland
Telephone and fax numbers remain unchanged.
10 August 2016
Institutional Membership established with the University of Texas at Austin, USA, the Wroclaw University of Science and Technology, Poland and the University of Granada and the Compultense University of Madrid, Spain
We are pleased to announce that the following institutions have joined MDPI's institutional membership program in August 2016:
- University of Texas at Austin, USA
- Wroclaw University of Science and Technology, Poland
- University of Granada, Spain
- Compultense University of Madrid, Spain
Authors affiliated with these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
18 July 2016
Institutional Membership established with Louisiana State University and Florida State University, USA, Royal College of Surgeons, Ireland, University of Rostock, Germany, AGH University of Science and Technology, Poland and Southeast University, China
We are pleased to announce that the following institutions have joined MDPI's institutional membership program in July 2016:
- Louisiana State University, USA
- Florida State University, USA
- Royal College of Surgeons, Ireland
- University of Rostock, Germany
- AGH University of Science and Technology, Poland
- Southeast University, China
Authors affiliated with these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
12 July 2016
MDPI Moving to New Office Location in Basel (Switzerland) in August 2016
As of 20 August 2016, MDPI's new address in Basel will be:
MDPI AG
St. Alban-Anlage 66
CH-4052 Basel
Switzerland
Telephone and fax numbers remain unchanged.
St. Alban-Anlage 66 was built from 1947 to 1948 and initially the home of the "Bühler AG", a book printing business.
For more information about this building, see: https://www.mdpi.com/about/headquarters
21 June 2016
"Behind the Scenes of Academic Publishing—A Publisher's Perspective" - MDPI's Lecture at the University of Basel
From the 15-16 September, 2016, MDPI will run a course on Academic Publishing at the University of Basel.
In this two day workshop, MDPI will look in detail at the role performed by academic journal publishers and how they interact with academics. Ethical dimensions, what happens when problems occur and how the publisher coordinates all aspects of the submission process will also be covered.
For more detailed information about the program, trainers and registration please visit the course webpage.
14 June 2016
2015 Impact Factors Released
26 May 2016
Institutional Membership established with University of Bremen, Germany, Koç University, Turkey, IIASA, Austria and Jilin University and Kunming Institute of Botany, CAS, China
We are pleased to announce that the following institutions have joined MDPI's institutional membership program in May 2016:
- Unversity of Bremen, Germany
- Koç University, Turkey
- International Institute for Applied Systems Analysis (IIASA), Austria
- Jilin University, China
- Kunming Institute of Botany, Chinese Academy of Sciences, China
Authors affiliated with these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
23 May 2016
Institutional Membership Established with the KTH Royal Institute of Technology, Sweden and the South China University of Technology, Beijing University of Technology and Southern Medical University, China
We are pleased to announce that the following institutions have joined MDPI's institutional membership program in April and May 2016:
- KTH Royal Institute of Technology, Sweden
- South China University of Technology, China
- Beijing University of Technology, China
- Southern Medical University, China
Authors affiliated with these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
26 April 2016
New Section on www.mdpi.com - Latest Books
You may have noticed a new section that is now visible on our home page. This section is called "Latest Books" and showcases recent publications from MDPI Books, our book publishing service.
By clicking on the hyperlink "More Books" you will be taken to the MDPI Books Home Page. There you will find more information about the service, as well as the "Recent Publications" list.
Clicking on any of the book images in this list will take you to detailed information about that book (shown below). Here you can also download a PDF version of the book, or order a hardcover printed copy.
For further information about the MDPI Books service, please visit the webpage or contact books@mdpi.com.
31 March 2016
Axioms, Behavioral Sciences, Photonics, Separations and Toxics added to the Emerging Sources Citation Index in Web of Science
We are pleased to announce that the journals Axioms, Behavioral Sciences, Photonics, Separations and Toxics were recently accepted for inclusion in the newly launched Emerging Sources Citation Index (ESCI) in Web of Science.
ESCI serves to highlight promising journals which are still under consideration for the Science Citation Index Expanded (SCIE) or the Social Sciences Citation Index (SSCI).
The Emerging Sources Citation Index (ESCI), Science Citation Index Expanded (SCIE), Social Sciences Citation Index
(SSCI), and Web of Science™ (WoS) are Thomson Reuters products.
30 March 2016
Institutional Membership established with the University of Winchester, UK, Silesian University of Technology, Poland and Beijing Jiaotong University and Zhejiang University, China
We are pleased to announce that the University of Winchester, UK, the Silesian University of Technology, Poland and Beijing Jiaotong University and Zhejiang University, China, have joined our Institutional Membership program. Primary authors from these universities will benefit from a 10% discount on article processing charges.
Additional details can be found on our institutional membership page.
24 March 2016
New Editorial Office in Barcelona, Spain
We are excited to announce the opening of our new editorial office in Barcelona, Spain. The launch team is led by a Senior Editor and comprises further staff holding doctoral degrees with several years of research experience. The new editorial team will help us to get closer to European research communities and progress Sciforum, the platform to support the scientific community via conference hosting and other functions. They will also help spread the word about Open Access and meet academics at scientific events.
We are in the process of hiring more doctoral and masters graduates to join the editorial team and welcome applications via jobs@mdpi.com. For contact details about the office, see our contact page.
22 February 2016
Membership Established with the Max Planck Society
We are pleased to announce that the Max Planck Digital Library (MPDL) has signed an agreement with MDPI to support authors associated with the Max Planck Society (Max-Planck-Gesellschaft). As of 22 February 2016, corresponding authors will receive full funding from the MPDL for articles published in MDPI journals, with a 10% discount applied to the Article Processing Charges. Additional details can be found at our institutional membership page.
Founded in 1948, The Max Planck Society is one of Germany’s leading research organizations, and is currently made up of 83 institutes conducting basic research in natural sciences, life sciences, social sciences and humanities. 18 Nobel laureates have emerged from its ranks of scientists and the society has more than 15,000 publications in scientific journals each year.
5 February 2016
Institutional Membership Extension: Wageningen University, CSIC, University of Zürich, ETH Zürich, University of Tübingen and Osnabrück University
We are pleased to announce that Wageningen University, the Netherlands, the Spanish National Research Council (CSIC), Spain, the University of Zürich and ETH Zürich, Switzerland, and the University of Tübingen and Osnabrück University, Germany, have not only renewed their institutional memberships with MDPI after two years of successful cooperation, but have also increased the reduction of the article processing charges (APCs) for affiliated authors to 25%.
Additional details can be found on our institutional membership page.
5 February 2016
Institutional Membership established with Brock University, Canada and the University of Pisa, Italy
We are pleased to announce that Brock University, Cananda, and the University of Pisa, Italy, have joined MDPI's institutional membership program: Primary authors from these universities will benefit from a 10% discount on the article processing charges as of 01 February 2016.
Additional details can be found on our institutional membership page.
25 January 2016
MDPI Sponsors diss:kurs with the University of Basel
MDPI is pleased to announce its newly established sponsorship of diss:kurs, an event coordinated by the University of Basel to support their doctorate program. For more information about the event and how to register, please visit the diss:kurs webpage.
7 January 2016
New Institutional Memberships Established with Tsinghua University, the Chinese Society of Micro-Nano Technology, Ruhr University Bochum and the University of Ulm
We are pleased to announce that the following institutions have joined MDPI's institutional membership program as of 1 January 2016:
- Tsinghua University, China
- Chinese Society of Micro-Nano Technology (CSMNT)
- Ruhr University Bochum, Germany
- University of Ulm, Germany
Authors affiliated with these institutions will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
5 January 2016
Safety, Fermentation, C-Journal of Carbon Research, Magnetochemistry, Batteries and Horticulturae Released Their First Issue in December 2015
We are pleased to announce that MDPI's open access journals Safety, Journal of Imaging, Fermentation, C-Journal of Carbon Research, Magnetochemistry, Batteries and Horticulturae released their first issue at the end of December 2015.
23 December 2015
Happy Festive Season!
Season's greetings from everyone at MDPI!
17 December 2015
Institutional Membership Extension: University of Bern, Switzerland
We are pleased to announce that the University of Bern, Switzerland has not only renewed their institutional membership with MDPI after two years of successful cooperation, but also increased the reduction of the article processing charges (APCs) for affiliated authors to 25%.
17 December 2015
Institutional Membership with the University of Ulm and Helmholtz Zentrum Munich
We are pleased to announce that University of Ulm, Germany and Helmholtz Zentrum Munich, Germany has joined MDPI's institutional membership program:
Primary authors from the University of Ulm and Helmholtz Zentrum Munich will benefit from a 10% discount on the article processing charges as of 1 January 2016. Additional details can be found on our institutional membership page.
9 December 2015
Membership Established with the Virginia Polytechnic Institute and State University (Virginia Tech)
We are pleased to announce that Virginia Tech has joined MDPI's institutional membership program. Authors from Virginia Tech will benefit from a 10% discount on the article processing charges as of 1 December 2015. Additional details can be found on our institutional membership page.
1 December 2015
Membership Established with the Technical University of Denmark and the University of North Florida
We are pleased to announce that the following universities have joined MDPI's institutional membership program:
- Technical University of Denmark (as of 1 November 2015)
- University of North Florida, USA (as of 15 November 2015)
Primary authors from the Technical University of Denmark and the University of North Florida will benefit from a 10% discount on the article processing charges.
Additional details can be found on our institutional membership page.
2 October 2015
Membership Established with the University of Freiburg and the University of Regensburg
We are pleased to announce that the following universities have joined MDPI's institutional membership program:
University of Freiburg, Germany
University of Regensburg, Germany
Primary authors from the University of Freiburg and the University of Regensburg will benefit from a 10% discount on the article processing charges as of 1 October 2015 and 1 November 2015.
Additional details can be found on our institutional membership page.
